BioMedLib Search Engine
[ goto HOMEPAGE ]
Search the biomedical literature, for the most relevant articles.
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
adenocarcinoma of the kidney 2005:2010[pubdate] *count=100
8693 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
adenocarcinoma of the kidney
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 8693
1.
Alfieri A, Mazzoleni G, Schwarz A, Campello M, Broger M, Vitale M, Vigl EE:
Renal cell carcinoma and intradural spinal metastasis with cauda equina infiltration: case report--part II.
Spine (Phila Pa 1976)
; 2005 Jan 15;30(2):260-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Renal cell carcinoma
and intradural spinal metastasis with cauda equina infiltration: case report--part II.
OBJECTIVE: To describe the
diagnosis
, pathophysiology, and treatment of
a papillary renal cell carcinoma
that developed an intradural spinal mass with cauda equina infiltration.
SUMMARY OF BACKGROUND DATA:
Cancers
that metastasize intradurally to the spinal canal are uncommon, accounting for the 6% of all spinal metastases.
Those from
renal cell carcinoma
are especially unusual.
Only 3 reports that describe the spread of metastatic
renal cell carcinoma
to the cauda equina have been published to our knowledge.
METHODS: A female patient had undergone nephrectomy for the treatment of the
papillary renal cell carcinoma
2 years before, and only 1 localization (at the genital tract) was previously diagnosed.
CONCLUSIONS: The majority of cauda equina
tumors
are primary
tumors
, and metastases are very rare.
To our knowledge, this is the fourth case described of metastasis of
renal cell carcinoma
at the cauda equina and the first of
papillary
type.
[MeSH-major]
Carcinoma
,
Renal Cell
/ secondary. Cauda Equina / pathology. Dura Mater / pathology.
Kidney
Neoplasms / pathology. Spinal Cord Neoplasms / secondary
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15644767.001).
[ISSN]
1528-1159
[Journal-full-title]
Spine
[ISO-abbreviation]
Spine
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
2.
Leung RS, Biswas SV, Duncan M, Rankin S:
Imaging features of von Hippel-Lindau disease.
Radiographics
; 2008 Jan-Feb;28(1):65-79; quiz 323
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Imaging features of von Hippel-Lindau
disease
.
von Hippel-Lindau (VHL)
disease
is a rare, autosomal dominantly inherited multisystem
disorder
characterized by development of a variety of benign and
malignant tumors
.
The spectrum of clinical manifestations of the
disease
is broad and includes retinal and central nervous
system
hemangioblastomas, endolymphatic sac
tumors
,
renal
cysts and
tumors
, pancreatic cysts and
tumors
, pheochromocytomas, and epididymal cystadenomas.
The most
common
causes of death in VHL
disease
patients are
renal cell carcinoma
and neurologic complications from cerebellar hemangioblastomas.
Screening is important because the lesions in VHL
disease
are treatable; thus, early detection allows use of more conservative therapy and may enhance the patient's length and quality of life.
A multidisciplinary team approach is important in screening for VHL
disease
.
[MeSH-major]
Diagnostic Imaging / methods. Image Enhancement / methods. Neoplasms /
diagnosis
. von Hippel-Lindau
Disease
/
diagnosis
MedlinePlus Health Information.
consumer health - Diagnostic Imaging
.
MedlinePlus Health Information.
consumer health - Von Hippel-Lindau Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18203931.001).
[ISSN]
1527-1323
[Journal-full-title]
Radiographics : a review publication of the Radiological Society of North America, Inc
[ISO-abbreviation]
Radiographics
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
28
3.
McHugh K:
Renal and adrenal tumours in children.
Cancer Imaging
; 2007;7:41-51
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Renal
and adrenal
tumours
in children.
The differential
diagnosis
of
renal
and supra-
renal
masses firstly depends on the age of the child.
Neuroblastoma (NBL) may be seen antenatally or in the newborn period; this
tumour
has a good prognosis unlike NBL seen in older children (particularly NBL in those aged 2-4 years).
Benign
renal
masses predominate in early infancy but beyond the first year of life Wilms'
tumour
is the most
common renal
malignancy, until adolescence when
renal cell carcinoma
has similar or increased frequency as children get older.
Adrenal adenomas and
carcinomas
also occur in childhood; these
tumours
are indistinguishable on imaging but criteria for the
diagnosis
of adrenal
carcinoma
include size larger than 5 cm, a tendency to invade the inferior vena cava and to metastasise.
The most topical dilemmas in the
radiological
assessment of
renal
and adrenal
tumours
are presented.
Topics covered include a proposed revision to the staging of NBL, the problems inherent in distinguishing nephrogenic rests from Wilms'
tumour
and the current recently altered approach regarding small lung nodules in children with Wilms'
tumour
.
[MeSH-major]
Adrenal Gland Neoplasms /
diagnosis
. Diagnostic Imaging / methods.
Kidney
Neoplasms /
diagnosis
[MeSH-minor]
Adolescent. Age of Onset.
Carcinoma
,
Renal Cell
/
diagnosis
.
Carcinoma
,
Renal Cell
/ epidemiology. Child. Child, Preschool.
Diagnosis
, Differential. Ganglioneuroblastoma /
diagnosis
. Ganglioneuroblastoma / epidemiology. Ganglioneuroblastoma / pathology. Humans. Infant. Infant, Newborn. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Mass Screening. Neoplasm Staging. Neuroblastoma /
diagnosis
. Neuroblastoma / epidemiology. Neuroblastoma / pathology. Neuroblastoma / secondary. Neuroblastoma / therapy. Pheochromocytoma /
diagnosis
. Pheochromocytoma / epidemiology. Positron-Emission Tomography. Tomography, X-Ray Computed. Wilms
Tumor
/
diagnosis
. Wilms
Tumor
/ epidemiology. Wilms
Tumor
/ pathology. Wilms
Tumor
/ therapy
MedlinePlus Health Information.
consumer health - Adrenal Gland Cancer
.
MedlinePlus Health Information.
consumer health - Diagnostic Imaging
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 1999 Oct 14;341(16):1165-73
[
10519894.001
]
[Cites]
Curr Probl Cancer. 2005 Sep-Oct;29(5):221-60
[
16216623.001
]
[Cites]
Urology. 2005 Dec;66(6):1296-300
[
16360460.001
]
[Cites]
J Pediatr Endocrinol Metab. 2006 May;19(5):749-56
[
16789642.001
]
[Cites]
Eur J Radiol. 2001 Feb;37(2):72-8
[
11223474.001
]
[Cites]
Eur Radiol. 2001;11(10):2071-81
[
11702143.001
]
[Cites]
Radiographics. 2002 Jul-Aug;22(4):911-34
[
12110723.001
]
[Cites]
Med Pediatr Oncol. 2003 Jan;40(1):18-22
[
12426681.001
]
[Cites]
Radiographics. 2003 Jan-Feb;23(1):29-43
[
12533638.001
]
[Cites]
Am J Surg Pathol. 2003 Jul;27(7):1005-7
[
12826894.001
]
[Cites]
Eur J Pediatr. 2003 Sep;162(9):623-8
[
12811553.001
]
[Cites]
J Clin Oncol. 2004 Mar 1;22(5):838-45
[
14990639.001
]
[Cites]
Pediatr Surg Int. 2004 Jan;20(1):27-32
[
14689211.001
]
[Cites]
J Pediatr Surg. 2004 May;39(5):759-63
[
15137014.001
]
[Cites]
J Nucl Med. 2004 Jul;45(7):1172-88
[
15235064.001
]
[Cites]
Cancer. 2004 Oct 1;101(7):1575-83
[
15378495.001
]
[Cites]
Cancer. 1987 Jun 1;59(11):1853-9
[
3567848.001
]
[Cites]
J Clin Oncol. 1997 Mar;15(3):1171-82
[
9060561.001
]
[Cites]
Acta Radiol. 1999 Sep;40(5):534-42
[
10485244.001
]
(PMID = 17339140.001).
[ISSN]
1470-7330
[Journal-full-title]
Cancer imaging : the official publication of the International Cancer Imaging Society
[ISO-abbreviation]
Cancer Imaging
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Number-of-references]
19
[Other-IDs]
NLM/ PMC1828369
Advertisement
4.
Reckamp KL, Strieter RM, Figlin RA:
Chemokines as therapeutic targets in renal cell carcinoma.
Expert Rev Anticancer Ther
; 2008 Jun;8(6):887-93
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Chemokines as therapeutic targets in
renal cell carcinoma
.
Targeting novel pathways associated with
tumor
angiogenesis, invasion and immunity, may lead to improvement in patient outcomes for
renal cell carcinoma
.
Chemokines potentiate
tumor
growth, metastasis, angiogenesis and immune evasion through interactions with stromal
cells
and neoplastic
cells
.
Further understanding of the mechanisms involved in chemokine-mediated angiogenesis and metastasis may lead to improved therapeutic strategies in this
disease
.
Interactions between chemokine expression and signaling, and the VEGF and hypoxia-inducible factor pathways offer important opportunities to intervene in the process of
renal cell carcinoma
proliferation, angiogenesis and invasion.
Modulation of the CXCR3/CXCR3-ligand or the CXCR4/CXCL12 biologic axis may be potential therapeutic targets for the treatment of
renal cell carcinoma
.
Furthermore, combination treatment with agents targeting chemokine signaling with therapies directed at angiogenesis and
tumor
immunity may lead to improved outcomes in this
disease
.
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 2002 Oct 15;62(20):5930-8
[
12384559.001
]
[Cites]
AIDS. 2002 Dec 6;16(18):2385-90
[
12461411.001
]
[Cites]
Nature. 2002 Dec 19-26;420(6917):860-7
[
12490959.001
]
[Cites]
Semin Immunol. 2003 Feb;15(1):49-55
[
12495640.001
]
[Cites]
Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86
[
12626353.001
]
[Cites]
J Clin Oncol. 2003 Aug 15;21(16):3127-32
[
12915604.001
]
[Cites]
Nature. 2003 Sep 18;425(6955):307-11
[
13679920.001
]
[Cites]
Clin Cancer Res. 2003 Oct 15;9(13):4641-52
[
14581333.001
]
[Cites]
J Exp Med. 2003 Nov 3;198(9):1391-402
[
14597738.001
]
[Cites]
Br J Cancer. 2003 Dec 15;89(12):2213-8
[
14676797.001
]
[Cites]
Nat Rev Cancer. 2004 Jul;4(7):540-50
[
15229479.001
]
[Cites]
Semin Cancer Biol. 2004 Jun;14(3):171-9
[
15246052.001
]
[Cites]
Semin Cancer Biol. 2004 Jun;14(3):181-5
[
15246053.001
]
[Cites]
Nat Med. 2004 Aug;10(8):858-64
[
15235597.001
]
[Cites]
J Mol Histol. 2004 Mar;35(3):233-45
[
15339043.001
]
[Cites]
Nat Genet. 1994 May;7(1):85-90
[
7915601.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4
[
7937876.001
]
[Cites]
J Clin Oncol. 1995 Mar;13(3):688-96
[
7884429.001
]
[Cites]
J Biol Chem. 1995 Nov 10;270(45):27348-57
[
7592998.001
]
[Cites]
Nat Med. 1998 Jan;4(1):72-7
[
9427609.001
]
[Cites]
J Biol Chem. 1998 Feb 13;273(7):4282-7
[
9461627.001
]
[Cites]
N Engl J Med. 1998 Apr 30;338(18):1272-8
[
9562581.001
]
[Cites]
FEBS Lett. 1998 Apr 17;426(2):271-8
[
9599023.001
]
[Cites]
J Immunol. 1998 Jul 15;161(2):927-32
[
9670971.001
]
[Cites]
J Clin Oncol. 2005 Jan 1;23(1):133-41
[
15625368.001
]
[Cites]
Cancer. 2005 Jan 15;103(2):258-67
[
15578685.001
]
[Cites]
Clin Cancer Res. 2005 Mar 1;11(5):1743-50
[
15755995.001
]
[Cites]
Cancer Res. 2005 Apr 1;65(7):2738-45
[
15805273.001
]
[Cites]
Clin Cancer Res. 2005 Apr 1;11(7):2459-65
[
15814620.001
]
[Cites]
J Biol Chem. 2005 Jun 10;280(23):22473-81
[
15802268.001
]
[Cites]
Clin Cancer Res. 2005 Jul 1;11(13):4658-65
[
16000558.001
]
[Cites]
Cancer Res. 2005 Jul 15;65(14):6178-88
[
16024619.001
]
[Cites]
Clin Cancer Res. 2005 Aug 15;11(16):5686-93
[
16115904.001
]
[Cites]
J Immunol. 2005 Oct 15;175(8):5351-7
[
16210641.001
]
[Cites]
Cancer Res. 2005 Nov 1;65(21):9891-8
[
16267013.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18111-6
[
16326806.001
]
[Cites]
Cancer Res. 2006 Jan 1;66(1):517-26
[
16397268.001
]
[Cites]
J Immunol. 2006 Feb 1;176(3):1456-64
[
16424173.001
]
[Cites]
Cancer Res. 2006 Feb 15;66(4):2000-11
[
16488999.001
]
[Cites]
Cancer Res. 2006 Feb 15;66(4):2181-7
[
16489019.001
]
[Cites]
Blood. 2006 Mar 1;107(5):1761-7
[
16269611.001
]
[Cites]
Cancer Res. 2006 Mar 15;66(6):3071-7
[
16540656.001
]
[Cites]
J Leukoc Biol. 2006 Apr;79(4):639-51
[
16478915.001
]
[Cites]
Cancer Sci. 2006 Aug;97(8):780-6
[
16863511.001
]
[Cites]
Cancer Lett. 2006 Sep 28;241(2):221-7
[
16458421.001
]
[Cites]
Mol Cancer. 2006;5:56
[
17083723.001
]
[Cites]
N Engl J Med. 2007 Jan 11;356(2):115-24
[
17215529.001
]
[Cites]
N Engl J Med. 2007 Jan 11;356(2):125-34
[
17215530.001
]
[Cites]
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):667s-670s
[
17255291.001
]
[Cites]
J Immunother. 2007 May-Jun;30(4):417-24
[
17457216.001
]
[Cites]
N Engl J Med. 2007 May 31;356(22):2271-81
[
17538086.001
]
[Cites]
J Urol. 2008 Jan;179(1):61-6
[
17997430.001
]
[Cites]
Clin Cancer Res. 2007 Dec 15;13(24):7388-93
[
18094421.001
]
[Cites]
Lancet. 2007 Dec 22;370(9605):2103-11
[
18156031.001
]
[Cites]
Clin Cancer Res. 2008 Feb 1;14(3):782-7
[
18245539.001
]
[Cites]
Clin Cancer Res. 1999 Oct;5(10):2780-9
[
10537342.001
]
[Cites]
J Immunol. 2000 Jul 1;165(1):461-72
[
10861085.001
]
[Cites]
Nature. 2001 Mar 1;410(6824):50-6
[
11242036.001
]
[Cites]
Nat Immunol. 2001 Apr;2(4):285-6
[
11276195.001
]
[Cites]
N Engl J Med. 2001 Sep 13;345(11):833-5
[
11556308.001
]
[Cites]
Cytokine Growth Factor Rev. 2001 Dec;12(4):313-35
[
11544102.001
]
[Cites]
J Immunol. 2002 Apr 1;168(7):3557-62
[
11907119.001
]
[Cites]
Br J Cancer. 2002 Apr 22;86(8):1250-6
[
11953881.001
]
[Cites]
J Biol Chem. 2002 Jul 5;277(27):24515-21
[
11923301.001
]
[Cites]
J Natl Cancer Inst. 2002 Oct 16;94(20):1569-75
[
12381710.001
]
(PMID = 18533798.001).
[ISSN]
1744-8328
[Journal-full-title]
Expert review of anticancer therapy
[ISO-abbreviation]
Expert Rev Anticancer Ther
[Language]
ENG
[Grant]
United States / NHLBI NIH HHS / HL / HL66027; United States / NCI NIH HHS / CA / R01 CA087879-09; United States / NCI NIH HHS / CA / CA087879-09; United States / NCI NIH HHS / CA / K12 CA01727; United States / NHLBI NIH HHS / HL / HL066027-03; United States / NHLBI NIH HHS / HL / R01 HL066027-03; United States / NCI NIH HHS / CA / R01 CA087879; United States / NCI NIH HHS / CA / K12 CA001727-15; United States / NHLBI NIH HHS / HL / R01 HL066027; United States / NCI NIH HHS / CA / CA87879; United States / NCI NIH HHS / CA / CA001727-15; United States / NCI NIH HHS / CA / K12 CA001727
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Chemokines
[Number-of-references]
68
[Other-IDs]
NLM/ NIHMS199931; NLM/ PMC2884168
5.
Zucchetto A, Dal Maso L, Tavani A, Montella M, Ramazzotti V, Talamini R, Canzonieri V, Garbeglio A, Negri E, Franceschi S, La Vecchia C:
History of treated hypertension and diabetes mellitus and risk of renal cell cancer.
Ann Oncol
; 2007 Mar;18(3):596-600
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
History of treated hypertension and diabetes mellitus and risk of
renal cell cancer
.
BACKGROUND: An increased risk of
renal cell cancer
(
RCC
) has been reported in subjects with hypertension.
Whether this association may vary according to sex, smoking, obesity, or
RCC
clinical presentation is unclear.
Results on the link between diabetes mellitus and
RCC
are inconclusive.
PATIENTS AND METHODS: We conducted an Italian multicenter case-
control
study, including 767 (494 men, 273 women) incident cases of
RCC
, under 80 years of age, and 1534 hospital controls, frequency-matched to cases.
Multiple logistic regression models, conditioned to
center
, sex, and age, and adjusted for period of interview, education, smoking, and body mass were used to estimate odds ratios (OR).
RESULTS: Compared with subjects never treated, patients with a history of treated hypertension [OR = 1.7, 95% confidence interval (CI) 1.4-2.1] reported an excess risk of
RCC
.
This pattern was confirmed in different strata of sex, education, smoking habits, body mass,
tumor
histological type,
stage
, or grade.
The attributable risk of
RCC
for treated hypertension in this population was 16%.
CONCLUSION: A possible causal role of hypertension in
renal cell
carcinogenesis is supported by the consistency of the direct association.
Genetic Alliance.
consumer health - Diabetes
.
Genetic Alliance.
consumer health - Kidney cancer
.
MedlinePlus Health Information.
consumer health - Blood Pressure Medicines
.
MedlinePlus Health Information.
consumer health - Diabetes
.
MedlinePlus Health Information.
consumer health - Diabetes Complications
.
MedlinePlus Health Information.
consumer health - Diabetes Medicines
.
MedlinePlus Health Information.
consumer health - High Blood Pressure
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17158772.001).
[ISSN]
0923-7534
[Journal-full-title]
Annals of oncology : official journal of the European Society for Medical Oncology
[ISO-abbreviation]
Ann. Oncol.
[Language]
ENG
[Publication-type]
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antihypertensive Agents; 0 / Hypoglycemic Agents
6.
Seliger B, Lichtenfels R, Atkins D, Bukur J, Halder T, Kersten M, Harder A, Ackermann A, Malenica B, Brenner W, Zobawa M, Lottspeich F:
Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma.
Proteomics
; 2005 Jul;5(10):2631-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of
renal cell carcinoma
.
Renal cell carcinoma
(
RCC
) representing the most
common
neoplasia of the
kidney
in Western countries is a histologic diverse
disease
with an often unpredictable course.
The prognosis of
RCC
is worsened with the onset of metastasis, and the therapies currently available are of limited success for the treatment of metastatic
RCC
.
Although gene expression analyses and other methods are promising tools clarifying and standardizing the pathological classification of
RCC
, novel innovative molecular markers for the
diagnosis
, prognosis, and for the monitoring of this
disease
during therapy as well as potential therapeutic targets are urgently needed.
Using proteome-based strategies, a number of
RCC
-associated markers either over-expressed or down-regulated in
tumor
lesions in comparison to the normal epithelium have been identified which have been implicated in tumorigenesis, but never linked to the initiation and/or progression of
RCC
.
These include members of the fatty acid binding protein family, which have the potential to serve as diagnostic or prognostic markers for the screening of
RCC
patients.
[MeSH-major]
Carcinoma
,
Renal Cell
/ physiopathology. Carrier Proteins / analysis.
Kidney
Neoplasms / physiopathology
[MeSH-minor]
Biomarkers,
Tumor
/ analysis. Biomarkers,
Tumor
/ isolation & purification.
Cell
Line,
Tumor
. DNA Primers.
Disease
Progression. Electrophoresis, Gel, Two-Dimensional / methods. Fatty Acid-Binding Proteins. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry.
Kidney
. Prognosis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Urothelium / chemistry. Urothelium / metabolism
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15892167.001).
[ISSN]
1615-9853
[Journal-full-title]
Proteomics
[ISO-abbreviation]
Proteomics
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / DNA Primers; 0 / Fatty Acid-Binding Proteins
7.
Flaig TW, La Rosa FG, McKinney K, Maroni P, Wilson S:
A man with changes in the urinary bladder: benign metaplasia or adenocarcinoma?
Oncology (Williston Park)
; 2009 Feb;23(2):177-80
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A man with changes in the urinary bladder: benign metaplasia or
adenocarcinoma
?
[MeSH-major]
Adenocarcinoma
/
diagnosis
. Cystitis /
diagnosis
.
Kidney
Neoplasms /
diagnosis
. Lymphatic Diseases / pathology
[MeSH-minor]
Adult.
Diagnosis
, Differential. Humans. Male. Metaplasia. Nephrolithiasis / complications. Referral and Consultation
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
MedlinePlus Health Information.
consumer health - Lymphatic Diseases
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19323300.001).
[ISSN]
0890-9091
[Journal-full-title]
Oncology (Williston Park, N.Y.)
[ISO-abbreviation]
Oncology (Williston Park, N.Y.)
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
8.
Poon SA, Gonzalez JR, Benson MC, McKiernan JM:
Invasion of renal sinus fat is not an independent predictor of survival in pT3a renal cell carcinoma.
BJU Int
; 2009 Jun;103(12):1622-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Invasion of
renal
sinus fat is not an independent predictor of survival in pT3a
renal cell carcinoma
.
OBJECTIVE: To clarify the significance of the location of extrarenal
tumour
extension of
renal cell carcinoma
(
RCC
) as in the 2002
Tumour
-Nodes-Metastasis classification.
Renal
cortical
tumours
with perirenal fat invasion (PFI) or sinus fat invasion (SFI) are consolidated within the pT3a grouping;
tumours
with SFI are close to the
renal
veins, lymphatics and the collecting
system
.
This might carry a worse prognosis for
disease
-specific survival (DSS), but reports are limited and contradictory.
PATIENTS AND METHODS: We retrospectively reviewed 1244 patients treated with nephrectomy from 1988 to 2007, to identify patients with pT3a
renal tumours
.
CONCLUSION: Patients with
renal tumours
with SFI are more likely to die from
RCC
than those with PFI.
[MeSH-major]
Adipose Tissue / pathology.
Carcinoma
,
Renal Cell
/ pathology.
Kidney
Neoplasms / pathology.
Kidney
Pelvis / pathology
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19154464.001).
[ISSN]
1464-410X
[Journal-full-title]
BJU international
[ISO-abbreviation]
BJU Int.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
9.
Negrier S, Jäger E, Porta C, McDermott D, Moore M, Bellmunt J, Anderson S, Cihon F, Lewis J, Escudier B, Bukowski R:
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
Med Oncol
; 2010 Sep;27(3):899-906
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Efficacy and safety of sorafenib in patients with advanced
renal cell carcinoma
with and without prior cytokine therapy, a subanalysis of TARGET.
Before the development of targeted therapies, administration of cytokines (e.g., interleukin-2, interferon-alpha) was the primary systemic treatment option for advanced
renal cell carcinoma
.
Sorafenib, an oral targeted, multikinase inhibitor, significantly prolonged progression-free survival and overall survival in the Treatment Approaches in
Renal Cancer
Global Evaluation Trial (TARGET), a large (N = 903) phase III, double-blind, randomised, placebo-controlled study of patients with advanced
renal cell carcinoma
resistant to standard therapy.
Sorafenib demonstrated a consistent, significant clinical benefit against advanced
renal cell carcinoma
, with a twofold improvement in progression-free survival and
disease control
rate, with similar toxicities in patients with or without prior cytokine treatment.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Carcinoma
,
Renal Cell
/ drug therapy.
Kidney
Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use
[MeSH-minor]
Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Benzenesulfonates / administration & dosage. Benzenesulfonates / adverse effects. Cardiovascular Diseases / chemically induced. Diarrhea / chemically induced.
Disease
-Free Survival. Double-Blind Method. Female. Hematologic Diseases / chemically induced. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Interleukin-2 / administration & dosage. Interleukin-2 / adverse effects. Kaplan-Meier Estimate. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Progestins / administration & dosage. Progestins / adverse effects. Pyridines / administration & dosage. Pyridines / adverse effects. Treatment Outcome. Vinca Alkaloids / administration & dosage. Vinca Alkaloids / adverse effects
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
NICOTINAMIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2007 Aug 1;25(22):3296-301
[
17664477.001
]
[Cites]
Cancer Res. 2004 Oct 1;64(19):7099-109
[
15466206.001
]
[Cites]
Nature. 1999 May 20;399(6733):271-5
[
10353251.001
]
[Cites]
Lancet. 1998 Nov 21;352(9141):1691-6
[
9853456.001
]
[Cites]
J Clin Oncol. 1999 Jul;17 (7):2039-43
[
10561255.001
]
[Cites]
N Engl J Med. 1996 Sep 19;335(12):865-75
[
8778606.001
]
[Cites]
Ann Oncol. 2006 Aug;17(8):1185-96
[
16418310.001
]
[Cites]
Clin Cancer Res. 2004 Sep 15;10 (18 Pt 2):6388S-92S
[
15448036.001
]
[Cites]
Semin Oncol. 2006 Oct;33(5):527-33
[
17045081.001
]
[Cites]
N Engl J Med. 2007 Jan 11;356(2):125-34
[
17215530.001
]
[Cites]
Nat Genet. 1994 May;7(1):85-90
[
7915601.001
]
[Cites]
J Clin Oncol. 1999 Aug;17(8):2530-40
[
10561319.001
]
[Cites]
Mol Cancer Ther. 2008 Oct;7(10 ):3129-40
[
18852116.001
]
[Cites]
Curr Treat Options Oncol. 2001 Oct;2(5):437-45
[
12057107.001
]
[Cites]
Nat Clin Pract Urol. 2006 Sep;3(9):478-84
[
16964189.001
]
[Cites]
J Clin Oncol. 2009 Jul 10;27(20):3312-8
[
19451442.001
]
[Cites]
N Engl J Med. 1998 Apr 30;338(18):1265-71
[
9562580.001
]
[Cites]
J Clin Oncol. 1995 Mar;13(3):688-96
[
7884429.001
]
[Cites]
N Engl J Med. 1998 Apr 30;338(18):1272-8
[
9562581.001
]
[Cites]
J Clin Oncol. 2007 Aug 1;25(22):3288-95
[
17664476.001
]
[Cites]
Cancer Res. 2003 Oct 1;63(19):6130-4
[
14559790.001
]
[Cites]
Semin Oncol. 2000 Apr;27(2):124-37
[
10768592.001
]
[Cites]
Nat Clin Pract Urol. 2007 Apr;4(4):205-17
[
17415353.001
]
[Cites]
Blood. 2006 Aug 15;108(4):1374-6
[
16645167.001
]
[Cites]
Ann Oncol. 2002 Sep;13(9):1460-8
[
12196373.001
]
[Cites]
J Clin Oncol. 1996 Aug;14(8):2410-1
[
8708739.001
]
[Cites]
J Clin Oncol. 2000 May;18(9):1928-35
[
10784634.001
]
[Cites]
J Clin Oncol. 2003 Nov 1;21(21):3987-94
[
14581421.001
]
[Cites]
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425
[
15674877.001
]
(PMID = 19757215.001).
[ISSN]
1559-131X
[Journal-full-title]
Medical oncology (Northwood, London, England)
[ISO-abbreviation]
Med. Oncol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0 / Benzenesulfonates; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Phenylurea Compounds; 0 / Progestins; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Vinca Alkaloids; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
10.
Autenrieth M, Heidenreich A, Gschwend JE:
[Systemic therapy of metastatic renal cell carcinoma].
Urologe A
; 2006 May;45(5):594-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Systemic therapy of metastatic
renal cell carcinoma
].
Cytokine-based immunotherapy was the only viable option in metastatic, nonresectable
renal cell carcinoma
(
RCC
) for many years.
In this context, interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) turned out to be the most effective single agents in
RCC
.
Such small molecules like tyrosine kinase inhibitors, monoclonal antibodies, or the mTOR inhibitor CCI-779 may dramatically change the established concepts of systemic
RCC
treatment.
This paper gives an overview of established, current, and evolving concepts of systemic therapy in
RCC
.
[MeSH-major]
Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use.
Carcinoma
,
Renal Cell
/ drug therapy.
Carcinoma
,
Renal Cell
/ secondary. Drug Delivery
Systems
/ methods. Immunotherapy / methods.
Kidney
Neoplasms / drug therapy
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Chemother Pharmacol. 2006 Apr;57(4):533-9
[
16052341.001
]
[Cites]
N Engl J Med. 2001 Dec 6;345(23 ):1655-9
[
11759643.001
]
[Cites]
Invest New Drugs. 2006 Jan;24(1):85-8
[
16380835.001
]
[Cites]
N Engl J Med. 1996 Sep 19;335(12):865-75
[
8778606.001
]
[Cites]
Br J Urol. 1995 May;75(5):586-9
[
7613793.001
]
[Cites]
Urologe A. 2002 May;41(3):282-7
[
12132280.001
]
[Cites]
Semin Oncol. 2000 Apr;27(2):177-86
[
10768596.001
]
[Cites]
J Clin Oncol. 2005 Nov 1;23(31):7889-96
[
16204015.001
]
[Cites]
Lancet. 2001 Sep 22;358(9286):966-70
[
11583750.001
]
[Cites]
Semin Oncol. 1991 Oct;18(5 Suppl 7):108-12
[
1948123.001
]
[Cites]
Eur Urol. 2006 Jan;49(1):76-81
[
16310929.001
]
[Cites]
Cancer. 2004 Oct 1;101(7):1545-51
[
15378501.001
]
[Cites]
J Clin Oncol. 2002 Jan 1;20(1):289-96
[
11773181.001
]
[Cites]
Curr Treat Options Oncol. 2003 Oct;4(5):385-90
[
12941198.001
]
[Cites]
Br J Cancer. 2004 Mar 8;90(5):985-90
[
14997194.001
]
[Cites]
J Clin Oncol. 2005 Jan 1;23 (1):133-41
[
15625368.001
]
[Cites]
J Urol. 2004 Jun;171(6 Pt 1):2176-80
[
15126780.001
]
[Cites]
N Engl J Med. 2003 Jul 31;349(5):427-34
[
12890841.001
]
[Cites]
Urologe A. 2006 Mar;45(3):328, 330-5
[
16465522.001
]
[Cites]
J Clin Oncol. 1999 Sep;17 (9):2859-67
[
10561363.001
]
[Cites]
Presse Med. 1987 Nov 21;16(39):1953-6
[
2962158.001
]
[Cites]
J Clin Oncol. 2004 Mar 1;22(5):909-18
[
14990647.001
]
[Cites]
J Clin Oncol. 2006 Jan 1;24(1):16-24
[
16330672.001
]
[Cites]
Br J Cancer. 2005 Mar 14;92 (5):843-6
[
15756254.001
]
[Cites]
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425
[
15674877.001
]
(PMID = 16622645.001).
[ISSN]
0340-2592
[Journal-full-title]
Der Urologe. Ausg. A
[ISO-abbreviation]
Urologe A
[Language]
ger
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents
[Number-of-references]
35
11.
Tomadoni A, García C, Márquez M, Ayala JC, Prado F:
Stauffer's syndrome with jaundice, a paraneoplastic manifestation of renal cell carcinoma: a case report.
Arch Esp Urol
; 2010 Mar;63(2):154-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Stauffer's syndrome with jaundice, a paraneoplastic manifestation of
renal cell carcinoma
: a case report.
OBJECTIVE: To report an infrequent case of Stauffer's Syndrome with jaundice as a paraneoplastic syndrome of a metastatic
renal cancer
.
METHODS: We describe the set up of cholestatic jaundice without neoplastic liver infiltration in a patient with a metastatic
renal cell carcinoma
, which turned back with surgery and systemic treatment.
RESULTS: Proper treatment of baseline
disease
enables turn back paraneoplastic signs and symptoms of Stauffer's Syndrome.
CONCLUSIONS: Reversible cholestatic jaundice without evidence of hepatic
disease
is an infrequent form of the Stauffer's syndrome.
This paraneoplastic syndrome is associated particularly with
renal carcinoma
but was described in lymphoproliferative diseases, prostate
cancer
and broncogenic
tumors
.
[MeSH-major]
Carcinoma
,
Renal Cell
/ complications. Jaundice, Obstructive / etiology.
Kidney
Neoplasms / complications. Paraneoplastic Syndromes / etiology
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20378939.001).
[ISSN]
1576-8260
[Journal-full-title]
Archivos españoles de urología
[ISO-abbreviation]
Arch. Esp. Urol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Spain
12.
Boczko J, Joseph JV:
Robot-assisted extraperitoneal radical prostatectomy in a patient with a pelvic kidney.
Urology
; 2006 Nov;68(5):1122.e3-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Robot-assisted extraperitoneal radical prostatectomy in a patient with a pelvic
kidney
.
The ectopic position of a pelvic
kidney
can present a unique challenge to the success of robot-assisted radical prostatectomy while preserving function in
the kidney
.
We describe our experience of performing extraperitoneal robot-assisted radical prostatectomy in a patient with a pelvic
kidney
.
[MeSH-major]
Adenocarcinoma
/ surgery.
Kidney
/ abnormalities. Prostatectomy / methods. Prostatic Neoplasms / surgery. Robotics
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17095077.001).
[ISSN]
1527-9995
[Journal-full-title]
Urology
[ISO-abbreviation]
Urology
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
13.
Sonpavde G, Hutson TE:
Recent advances in the therapy of renal cancer.
Expert Opin Biol Ther
; 2007 Feb;7(2):233-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Recent advances in the therapy of
renal cancer
.
Metastatic clear
cell renal cell cancer
has traditionally been treated with cytokines (interferon or interleukin-2).
Vascular endothelial growth factor, the related
receptor
and the mTOR signal transduction pathway have particularly been exploited.
The future of the therapy of
renal cancer
appears promising owing to the efficacy of these novel agents.
[MeSH-major]
Antineoplastic Agents / therapeutic use.
Carcinoma
,
Renal Cell
/ drug therapy.
Kidney
Neoplasms / drug therapy
Genetic Alliance.
consumer health - Kidney cancer
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17250461.001).
[ISSN]
1744-7682
[Journal-full-title]
Expert opinion on biological therapy
[ISO-abbreviation]
Expert Opin Biol Ther
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents
[Number-of-references]
68
14.
Ulamec M, Tomas D, Perić-Balja M, Spajić B, Hes O, Kruslin B:
Neuroendocrine breast carcinoma metastatic to renal cell carcinoma and ipsilateral adrenal gland.
Pathol Res Pract
; 2008;204(11):851-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Neuroendocrine breast
carcinoma
metastatic to
renal cell carcinoma
and ipsilateral adrenal gland.
We report on a 60-year-old woman with neuroendocrine
carcinoma
of the left breast metastasizing to
renal cell carcinoma
(
RCC
) of the left
kidney
and to adrenal gland.
A yellow, well-circumscribed
tumor
, 11 cm in largest diameter and limited to
the kidney
, was found.
Histopathology revealed
RCC
with foci of neuroendocrine differentiation.
Solid sheets of hyperchromatic epithelioid
cells
with high mitotic activity were found between typical clear
cells
of
RCC
.
These
cells
were CAM5,2 and E-cadherin focally positive, synaptophysin and NSE weakly positive, CK19 moderately positive, and AE1-AE3 and EMA strongly positive.
The left adrenal gland contained multiple, separate foci of
a tumor
composed of neuroendocrine components.
Because of the biphasic
tumor
in
the kidney
, extensive clinical examination and further analyses were recommended.
Tumor
in the left breast was revealed.
The
tumor
was histologically and immunohistochemically similar to the neuroendocrine component within
RCC
.
To our knowledge, this is the first case of neuroendocrine breast
carcinoma
with metastasis to
renal cell carcinoma
and ipsilateral adrenal gland.
[MeSH-major]
Breast Neoplasms / pathology.
Carcinoma
, Neuroendocrine / secondary.
Carcinoma
,
Renal Cell
/ pathology.
Kidney
Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18538946.001).
[ISSN]
0344-0338
[Journal-full-title]
Pathology, research and practice
[ISO-abbreviation]
Pathol. Res. Pract.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
15.
Petrella BL, Lohi J, Brinckerhoff CE:
Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Oncogene
; 2005 Feb 3;24(6):1043-52
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau
renal cell carcinoma
.
Metastatic
renal cell carcinoma
(
RCC
) resulting from the hereditary loss of the von Hippel-Lindau (VHL)
tumor
suppressor gene is the leading cause of death in VHL patients due to the deleterious effects of the metastatic
tumor
(s).
The process of
tumor
invasion and metastasis involves the destruction of the extracellular matrix, which is accomplished primarily by the matrix metalloproteinase (MMP) family of enzymes.
Here, we describe a connection between the loss of VHL
tumor
suppressor function and the upregulation of membrane type-1 MMP (MT1-MMP) gene expression and protein.
Specifically, MT1-MMP is upregulated in VHL-/-
RCC cells
through an increase in gene transcription, which is mediated by the cooperative effects of the transcription factors, HIF-2 and Sp1.
To our knowledge, this is the first report to show direct regulation of MT1-MMP by HIF-2 and to provide a direct link between the loss of VHL
tumor
suppressor function and an increase in MMP gene and protein expression.
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
MedlinePlus Health Information.
consumer health - Von Hippel-Lindau Disease
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Trends Mol Med. 2004 Sep;10(9):466-72
[
15350900.001
]
[Cites]
J Urol. 1999 Sep;162(3 Pt 1):905-9
[
10458406.001
]
[Cites]
J Biol Chem. 1995 Mar 10;270(10):5331-8
[
7890645.001
]
[Cites]
Nat Med. 1995 Aug;1(8):822-6
[
7585187.001
]
[Cites]
J Biol Chem. 1996 Jul 26;271(30):17771-8
[
8663540.001
]
[Cites]
Genes Dev. 1997 Jan 1;11(1):72-82
[
9000051.001
]
[Cites]
Medicine (Baltimore). 1997 Nov;76(6):381-91
[
9413424.001
]
[Cites]
Mech Dev. 1998 Apr;73(1):117-23
[
9545558.001
]
[Cites]
J Intern Med. 1998 Jun;243(6):527-33
[
9681854.001
]
[Cites]
Biochem J. 1998 Sep 1;334 ( Pt 2):345-53
[
9716492.001
]
[Cites]
Blood. 1998 Oct 1;92(7):2260-8
[
9746763.001
]
[Cites]
Nature. 1999 May 20;399(6733):271-5
[
10353251.001
]
[Cites]
Nucleic Acids Res. 1999 Sep 1;27(17):3402-9
[
10446226.001
]
[Cites]
Gene. 2000 Jan 25;242(1-2):75-86
[
10721699.001
]
[Cites]
J Cell Biol. 2000 Jun 12;149(6):1309-23
[
10851027.001
]
[Cites]
Curr Opin Cell Biol. 2001 Oct;13(5):534-40
[
11544020.001
]
[Cites]
Br J Cancer. 2001 Sep 14;85(6):881-90
[
11556841.001
]
[Cites]
Surv Ophthalmol. 2001 Sep-Oct;46(2):117-42
[
11578646.001
]
[Cites]
Neth J Med. 2001 Nov;59(5):225-34
[
11705642.001
]
[Cites]
Nat Rev Cancer. 2002 Jan;2(1):38-47
[
11902584.001
]
[Cites]
Nat Rev Cancer. 2002 Mar;2(3):161-74
[
11990853.001
]
[Cites]
Carcinogenesis. 2002 May;23(5):769-76
[
12016149.001
]
[Cites]
Cancer Cell. 2002 Apr;1(3):237-46
[
12086860.001
]
[Cites]
Cancer Cell. 2002 Apr;1(3):247-55
[
12086861.001
]
[Cites]
EMBO J. 2002 Aug 1;21(15):3949-59
[
12145196.001
]
[Cites]
Nat Rev Cancer. 2002 Sep;2(9):673-82
[
12209156.001
]
[Cites]
J Biol Chem. 2002 Oct 11;277(41):38737-45
[
12138160.001
]
[Cites]
J Biol Chem. 2002 Nov 15;277(46):43799-808
[
12228247.001
]
[Cites]
Cancer Lett. 2003 May 8;194(1):1-11
[
12706853.001
]
[Cites]
Circ Res. 2003 May 2;92(8):827-39
[
12730128.001
]
[Cites]
Stem Cells. 2003;21(3):337-47
[
12743328.001
]
[Cites]
Cell. 2003 Jul 11;114(1):33-45
[
12859896.001
]
[Cites]
Nature. 2003 Sep 18;425(6955):307-11
[
13679920.001
]
[Cites]
Oncogene. 2003 Sep 29;22(42):6524-36
[
14528277.001
]
[Cites]
J Urol. 2003 Dec;170(6 Pt 1):2163-72
[
14634372.001
]
[Cites]
Oncogene. 2003 Nov 27;22(54):8716-22
[
14647466.001
]
[Cites]
J Mol Biol. 2004 Feb 6;336(1):9-24
[
14741200.001
]
[Cites]
J Invest Dermatol. 2004 Jan;122(1):167-76
[
14962105.001
]
[Cites]
Mol Cancer Res. 2004 Feb;2(2):89-95
[
14985465.001
]
[Cites]
PLoS Biol. 2003 Dec;1(3):E83
[
14691554.001
]
[Cites]
Cancer Res. 2004 Apr 1;64(7):2534-43
[
15059909.001
]
[Cites]
J Biol Chem. 2004 Apr 9;279(15):15025-31
[
14742449.001
]
[Cites]
Mol Vis. 2004 May 17;10:341-50
[
15162095.001
]
[Cites]
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4038-47
[
15217936.001
]
[Cites]
Mol Cell Biol. 1999 Sep;19(9):5902-12
[
10454537.001
]
[Cites]
Nature. 1994 Jul 7;370(6484):61-5
[
8015608.001
]
(PMID = 15592504.001).
[ISSN]
0950-9232
[Journal-full-title]
Oncogene
[ISO-abbreviation]
Oncogene
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA-77267; United States / NCI NIH HHS / CA / R01 CA077267; United States / NIAMS NIH HHS / AR / AR-26599; United States / NIAMS NIH HHS / AR / R01 AR026599; United States / NIAMS NIH HHS / AR / R37 AR026599; United States / NIAID NIH HHS / AI / T32 AI007363
[Publication-type]
Journal Article; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
England
[Chemical-registry-number]
0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Trans-Activators; 0 / Tumor Suppressor Proteins; 0 / endothelial PAS domain-containing protein 1; EC 3.4.24.- / Matrix Metalloproteinases, Membrane-Associated; EC 3.4.24.- / Metalloendopeptidases; EC 6.3.2.19 / Ubiquitin-Protein Ligases; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
[Other-IDs]
NLM/ NIHMS15822; NLM/ PMC1847637
16.
Kanao K, Mizuno R, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Nakashima J, Oya M:
Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification.
J Urol
; 2009 Feb;181(2):480-5; discussion 485
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Preoperative prognostic nomogram (probability table) for
renal cell carcinoma
based on TNM classification.
PURPOSE: Recently several prognostic nomograms have been developed to predict the prognosis of
malignant
diseases, including
renal cell carcinoma
.
However, to our knowledge a preoperative prognostic nomogram that predicts survival in patients with
renal cell carcinoma
is not available.
We developed a preoperative nomogram based on the TNM classification that predicts cause specific survival in patients with
renal cell carcinoma
.
MATERIALS AND METHODS: A total of 545 patients with
renal cell carcinoma
, including metastatic
disease
, who underwent radical nephrectomy or nephron sparing surgery at our institution were included in the study.
Cases were staged according to the 2002 UICC TNM
system
, 6th edition.
CONCLUSIONS: The preoperative information shown by this nomogram may be important for obtaining informed consent from patients with
renal cell carcinoma
who have indications for surgery.
[MeSH-major]
Carcinoma
,
Renal Cell
/ mortality.
Carcinoma
,
Renal Cell
/ pathology.
Kidney
Neoplasms / mortality.
Kidney
Neoplasms / pathology. Neoplasm Invasiveness / pathology. Nomograms
[MeSH-minor]
Aged. Aged, 80 and over. Cohort Studies. Confidence Intervals.
Disease
-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Nephrectomy / methods. Nephrectomy / mortality. Predictive Value of Tests. Preoperative Care / methods. Probability. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Rate. Treatment Outcome
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19100568.001).
[ISSN]
1527-3792
[Journal-full-title]
The Journal of urology
[ISO-abbreviation]
J. Urol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
17.
White NM, Bui A, Mejia-Guerrero S, Chao J, Soosaipillai A, Youssef Y, Mankaruos M, Honey RJ, Stewart R, Pace KT, Sugar L, Diamandis EP, Doré J, Yousef GM:
Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs.
Biol Chem
; 2010 Apr;391(4):411-23
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Dysregulation of kallikrein-related peptidases in
renal cell carcinoma
: potential targets of miRNAs.
Renal cell carcinoma
(
RCC
) accounts for 3% of all adult malignancies and currently no diagnostic marker exists.
Kallikrein-related peptidases (KLKs) have been implicated in numerous
cancers
including ovarian, prostate, and breast
carcinoma
.
KLKs 5, 6, 10, and 11 have decreased expression in
RCC
when compared to normal
kidney
tissue.
Our bioinformatic analysis indicated that the KLK 1, 6, and 7 genes have decreased expression in
RCC
.
We experimentally verified these results and found that decreased expression of KLKs 1 and 3 were significantly associated with the clear
cell RCC
subtype (p<0.001).
An analysis of miRNAs differentially expressed in
RCC
showed that 61 of the 117 miRNAs that were reported to be dysregulated in
RCC
were predicted to target KLKs.
Transfection of miR-224 into HEK-293
cells
resulted in decreased KLK1 protein levels.
A luciferase assay demonstrated that hsa-let-7f can target KLK10 in the
RCC cell
line ACHN.
Our results, showing differential expression of KLKs in
RCC
, suggest that KLKs could be novel diagnostic markers for
RCC
and that their dysregulation could be under miRNA
control
.
[MeSH-major]
Carcinoma
,
Renal Cell
/ metabolism. Kallikreins / metabolism.
Kidney
Neoplasms / metabolism. MicroRNAs / metabolism
[MeSH-minor]
Biomarkers,
Tumor
/ metabolism. Chromosome Aberrations. Computational Biology. Evolution, Molecular. Gene Expression Regulation, Neoplastic. Humans. Phylogeny. Reproducibility of Results
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20180642.001).
[ISSN]
1437-4315
[Journal-full-title]
Biological chemistry
[ISO-abbreviation]
Biol. Chem.
[Language]
eng
[Grant]
Canada / Canadian Institutes of Health Research / / 86490
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / MicroRNAs; EC 3.4.21.- / Kallikreins
18.
Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB:
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy.
J Immunother
; 2005 Sep-Oct;28(5):488-95
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Histologic predictors of
renal cell carcinoma
response to interleukin-2-based therapy.
The authors examined pathology from patients with
renal cancer
(
RCC
) treated with IL-2 to determine response rates for clear
cell
and variant
RCC
and to identify histologic features that predict response.
Of 163 primary
RCCs
, the response rate was 21% (30/146) for patients with clear
cell
versus 6% (1/17) for patients with variant or indeterminate type
RCC
(P = 0.20).
For clear
cell carcinomas
, response to IL-2 was associated with the presence of alveolar features and the absence of
papillary
and granular features.
Patients with more than 50% alveolar features and no granular or
papillary
features had a 39% response rate (14/36).
Patients with alveolar and granular features representing less than 50% of the specimen and
no papillary
features had a 19% response rate (15/77).
Response rates in the three prognostic groups and for patients with
non
-clear
cell cancers
were 25% (5/20), 9% (2/22), 0% (0/16), and 0% (0/10), respectively.
Median survivals for all patients with clear
cell tumors
by risk group were 2.87, 1.36, and 0.87 years, respectively (P < 0.001).
These data suggest that patients with
non
-clear
cell RCC
or with clear
cell RCC
with
papillary
, no alveolar, and/or more than 50% granular features respond poorly to IL-2 and should be considered for alternative treatments.
Investigation of other
tumor
-related predictors of IL-2 responsiveness is warranted.
[MeSH-major]
Carcinoma
,
Renal Cell
/ pathology.
Carcinoma
,
Renal Cell
/ therapy. Immunotherapy / methods. Interleukin-2 / therapeutic use.
Kidney
Neoplasms / pathology.
Kidney
Neoplasms / therapy
[MeSH-minor]
Adenocarcinoma
, Clear
Cell
/ therapy. Aged.
Cell
Line,
Tumor
. Cytoplasm / metabolism. Female. Humans. Immunohistochemistry.
Kidney
/ pathology. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Risk. Time Factors. Treatment Outcome
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16113605.001).
[ISSN]
1524-9557
[Journal-full-title]
Journal of immunotherapy (Hagerstown, Md. : 1997)
[ISO-abbreviation]
J. Immunother.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Interleukin-2
19.
Komai Y, Fujiwara M, Fujii Y, Mukai H, Yonese J, Kawakami S, Yamamoto S, Migita T, Ishikawa Y, Kurata M, Nakamura T, Fukui I:
Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry.
Clin Cancer Res
; 2009 Feb 15;15(4):1170-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adult Xp11 translocation
renal cell carcinoma
diagnosed by cytogenetics and immunohistochemistry.
PURPOSE: To determine the incidence of Xp11 translocation
renal cell carcinoma
(
RCC
) in adult patients using cytogenetics and immunohistochemstry.
EXPERIMENTAL DESIGN: Cytogenetic studies were prospectively done using
tumor
samples from 443 consecutive adult Japanese patients (ages 15-89 years) who underwent nephrectomy for
RCC
.
Clinicopathologic characteristics of Xp11 translocation
RCC
were examined.
RESULTS: Mitotic
cells
suitable for cytogenetic analysis were obtained in 244
tumor
samples (55%); among these, we identified 4 cases (1.6%) of Xp11 translocation
RCC
.
The median age of the 7 patients was 41 years (range, 15-59 years), and 15% of
RCC
patients (4 of 26) who were younger than ages 45 years had this type of
RCC
.
Of the four Xp11 translocation
RCC
patients whose karyotypes were determined, two had an ASPL-TFE3 gene fusion.
Of these 2, 1 had pulmonary metastasis at presentation, and the other developed liver metastasis 12 months after nephrectomy and died of the
disease
.
Both had nodal involvement but remained
disease
free for 3 and 5 years, respectively, after surgical resection of lymph node metastases.
CONCLUSIONS: This is the first report to determine the incidence of Xp11 translocation
RCC
in adult patients.
We found that this
disease
is relatively
common
in young adults.
[MeSH-major]
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / analysis.
Carcinoma
,
Renal Cell
/ genetics. Chromosomes, Human, X.
Kidney
Neoplasms / genetics. Translocation, Genetic
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19228722.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; 0 / TFE3 protein, human; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
20.
Ma J, Zhou XJ, Huang WB, Zhou HB, Jiang SJ, Rao Q, Lu ZF, Shi QL:
[Clinicopathologic study of renal cell carcinoma with rhabdoid features].
Zhonghua Bing Li Xue Za Zhi
; 2007 Mar;36(3):166-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Clinicopathologic study of
renal cell carcinoma
with rhabdoid features].
OBJECTIVE: To study the clinicopathologic features and biologic behavior of
renal cell carcinoma
(
RCC
) with rhabdoid features.
METHODS: Ten cases of
RCC
with rhabdoid features collected during the period from 1995 to 2005 were enrolled into the study.
Histologically, the rhabdoid foci were characterized by loosely cohesive trabeculae, acini, lobules and clusters of rhabdoid
cells
in otherwise clear
cell RCC
(9 cases) or
papillary RCC
(1 case).
The rhabdoid
cells
were round to polygonal in shape and contained globular eosinophilic inclusion bodies in the cytoplasm, eccentric nuclei, vesicular chromatin pattern and prominent nucleoli.
Coagulative
tumor
necrosis was commonly seen.
Immunohistochemical study showed that the rhabdoid
cells
were diffusely positive for CD10 (10/10), cytokeratin AE1/AE3 (10/10), epithelial membrane antigen (10/10) and vimentin (10/10).
The mean Ki-67 labeling index of the rhabdoid component was higher than that of the
non
-rhabdoid component (P < 0.05).
While 6 patients are still alive without recurrence, 2 patients died of the
disease
6 and 29 months respectively after the operation.
CONCLUSIONS:
RCC
with rhabdoid elements are mainly observed in clear
cell RCC
and need to be distinguished from oncocytic
renal tumors
and
malignant
rhabdoid
tumor
of kidney
.
[MeSH-major]
Carcinoma
,
Renal Cell
/ pathology.
Kidney
Neoplasms / pathology. Rhabdoid
Tumor
/ pathology
[MeSH-minor]
Adult. Aged.
Carcinoma
, Transitional
Cell
/ metabolism.
Carcinoma
, Transitional
Cell
/ pathology.
Diagnosis
, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / metabolism. Lymphatic Metastasis. Male. Middle Aged. Mucin-1 / metabolism. Nephrectomy. Neprilysin / metabolism. Vimentin / metabolism
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17535682.001).
[ISSN]
0529-5807
[Journal-full-title]
Zhonghua bing li xue za zhi = Chinese journal of pathology
[ISO-abbreviation]
Zhonghua Bing Li Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Mucin-1; 0 / Vimentin; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
21.
Henske EP:
Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond.
Pediatr Nephrol
; 2005 Jul;20(7):854-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Tuberous sclerosis and
the kidney
: from mesenchyme to epithelium, and beyond.
The
renal
manifestations of tuberous sclerosis
complex
(TSC) are remarkably diverse, including polycystic
kidney
disease
, oncocytomas,
renal cell carcinomas
, and both benign and
malignant
angiomyolipomas.
What is particularly unusual about TSC, setting it apart from virtually all other inherited forms of
renal disease
, is the abnormalities of both mesenchymal
cells
(angiomyolipomas) and epithelial
cells
(cysts, oncocytomas, and
carcinomas
).
Recently, the TSC1/TSC2 protein
complex
was shown to inhibit the kinase mTOR (mammalian target of rapamycin).
This places TSC1/TSC2 at
center stage
in signaling pathways that regulate
cell
growth.
Here, we will address the genetic, cellular and biochemical mechanisms that may contribute to the unusually broad spectrum of
renal disease
in
cells
with TSC1 or TSC2 mutations, and consider how the TSC signaling pathways may be linked to other
renal
diseases such as polycystic
kidney
disease
and
renal cell carcinoma
.
[MeSH-major]
Angiomyolipoma / etiology.
Carcinoma
/ etiology.
Kidney
Neoplasms / etiology. Tuberous Sclerosis / complications
[MeSH-minor]
Humans. Mutation. Repressor Proteins / genetics. Repressor Proteins / metabolism. Signal Transduction.
Tumor
Suppressor Proteins / genetics.
Tumor
Suppressor Proteins / metabolism
Genetic Alliance.
consumer health - Tuberous sclerosis
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
MedlinePlus Health Information.
consumer health - Tuberous Sclerosis
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Cell Biol. 2000 May;2(5):281-7
[
10806479.001
]
[Cites]
Am J Hum Genet. 2001 Jan;68(1):64-80
[
11112665.001
]
[Cites]
Cancer Cell. 2003 Aug;4(2):147-58
[
12957289.001
]
[Cites]
Cell. 1993 Dec 31;75(7):1305-15
[
8269512.001
]
[Cites]
Am J Pathol. 2003 Feb;162(2):457-68
[
12547704.001
]
[Cites]
Am J Hum Genet. 1999 May;64(5):1305-15
[
10205261.001
]
[Cites]
Oncogene. 2002 Sep 12;21(41):6356-65
[
12214276.001
]
[Cites]
Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L694-700
[
12922981.001
]
[Cites]
Am J Hum Genet. 2001 Sep;69(3):493-503
[
11468687.001
]
[Cites]
Oncogene. 2004 Apr 19;23(18):3151-71
[
15094765.001
]
[Cites]
Oncogene. 2002 Dec 5;21(55):8470-6
[
12466966.001
]
[Cites]
Hum Mol Genet. 1998 Jun;7(6):1053-7
[
9580671.001
]
[Cites]
J Urol. 1998 Jul;160(1):141-5
[
9628635.001
]
[Cites]
Pediatr Radiol. 2002 Sep;32(9):677-80
[
12195309.001
]
[Cites]
Lancet. 2003 Apr 19;361(9366):1348-9
[
12711473.001
]
[Cites]
Am J Surg Pathol. 1998 Feb;22(2):180-7
[
9500218.001
]
[Cites]
Cell. 2003 Nov 26;115(5):577-90
[
14651849.001
]
[Cites]
Am J Pathol. 2003 Feb;162(2):491-500
[
12547707.001
]
[Cites]
Cancer. 1998 Nov 15;83(10):2208-16
[
9827727.001
]
[Cites]
Cancer Res. 1998 Nov 1;58(21):4766-70
[
9809973.001
]
[Cites]
Am J Surg Pathol. 1998 Jun;22(6):663-72
[
9630173.001
]
[Cites]
Mod Pathol. 2002 Mar;15(3):205-10
[
11904337.001
]
[Cites]
J Urol. 2003 Dec;170(6 Pt 1):2163-72
[
14634372.001
]
[Cites]
J Biol Chem. 2004 Jul 16;279(29):29930-7
[
15150271.001
]
[Cites]
Cancer Res. 2003 May 15;63(10):2675-80
[
12750296.001
]
[Cites]
Mayo Clin Proc. 1991 Aug;66(8):792-6
[
1861550.001
]
[Cites]
J Biol Chem. 2003 Dec 19;278(51):51372-9
[
14551205.001
]
[Cites]
Am J Pathol. 1996 Oct;149(4):1201-8
[
8863669.001
]
[Cites]
Mol Cell. 2001 Apr;7(4):823-32
[
11336705.001
]
[Cites]
J Clin Invest. 1997 Jan 15;99(2):194-9
[
9005987.001
]
[Cites]
Am J Hum Genet. 1996 Aug;59(2):400-6
[
8755927.001
]
[Cites]
Urology. 1991 Apr;37(4):340-3
[
2014599.001
]
[Cites]
Eur J Radiol. 1998 May;27(2):131-8
[
9639138.001
]
[Cites]
Nat Genet. 1994 Dec;8(4):328-32
[
7894481.001
]
[Cites]
Nat Genet. 1994 Feb;6(2):193-6
[
8162074.001
]
[Cites]
Hum Mol Genet. 1994 Oct;3(10):1829-32
[
7849708.001
]
[Cites]
Kidney Int. 2004 Sep;66(3):924-34
[
15327383.001
]
[Cites]
J Pediatr Surg. 1996 May;31(5):729-30
[
8861495.001
]
[Cites]
Am J Surg Pathol. 2000 Jun;24(6):889-94
[
10843294.001
]
[Cites]
Hum Mol Genet. 1994 Oct;3(10):1833-4
[
7849709.001
]
[Cites]
Science. 1997 Aug 8;277(5327):805-8
[
9242607.001
]
(PMID = 15856327.001).
[ISSN]
0931-041X
[Journal-full-title]
Pediatric nephrology (Berlin, Germany)
[ISO-abbreviation]
Pediatr. Nephrol.
[Language]
eng
[Grant]
United States / NIDDK NIH HHS / DK / DK 51052
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
[Publication-country]
Germany
[Chemical-registry-number]
0 / Repressor Proteins; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
[Number-of-references]
43
22.
Siemer S, Lahme S, Altziebler S, Machtens S, Strohmaier W, Wechsel HW, Goebell P, Schmeller N, Oberneder R, Stolzenburg JU, Becker H, Lüftenegger W, Tetens V, Van Poppel H:
Efficacy and safety of TachoSil as haemostatic treatment versus standard suturing in kidney tumour resection: a randomised prospective study.
Eur Urol
; 2007 Oct;52(4):1156-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Efficacy and safety of TachoSil as haemostatic treatment versus standard suturing in
kidney
tumour
resection: a randomised prospective study.
OBJECTIVE: Elective nephron-sparing surgery (NSS) for
renal cell carcinoma
(
RCC
) has gained general acceptance as an alternative to radical nephrectomy.
To achieve haemostasis without risk of local ischaemia and necrosis
of kidney
parenchyma after standard haemostatic suturing, we investigated TachoSil's efficacy and safety as atraumatic haemostatic treatment after
kidney
tumour
resection.
METHODS: A total of 185 patients scheduled for NSS for small, superficial
kidney
tumours
were included in an open, randomised, prospective, multicentre, parallel-group trial.
CONCLUSION: TachoSil was superior to standard suturing in obtaining intraoperative
control
of haemorrhage and was as well tolerated as standard haemostatic treatment during NSS.
[MeSH-major]
Carcinoma
,
Renal Cell
/ surgery. Fibrinogen / therapeutic use. Hemostatics / therapeutic use.
Kidney
Neoplasms / surgery. Surgical Sponges. Thrombin / therapeutic use
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Eur Urol. 2007 Oct;52(4):1162-3
[
17467888.001
]
(PMID = 17467884.001).
[ISSN]
0302-2838
[Journal-full-title]
European urology
[ISO-abbreviation]
Eur. Urol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Drug Combinations; 0 / Hemoglobins; 0 / Hemostatics; 0 / TachoSil; 9001-32-5 / Fibrinogen; EC 3.4.21.5 / Thrombin
23.
Yoo C, Song C, Hong JH, Kim CS, Ahn H:
Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
J Urol
; 2008 Aug;180(2):486-91; discussion 491
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic significance of perinephric fat infiltration and
tumor
size in
renal cell carcinoma
.
PURPOSES: It is controversial that perinephric fat infiltration has an impact on survival in patients with
renal cell carcinoma
.
Therefore, we evaluated the influence of perinephric fat infiltration and
tumor
size on patient survival.
MATERIALS AND METHODS: We retrospectively reviewed the medical records of 783 and 77 patients with pT1-2 (cN0M0) and pT3a (cN0M0)
renal cell carcinoma
, respectively.
Sporadic unilocular noncystic
renal cell carcinoma
was included.
Univariate and multivariate analyses of prognostic factors, including perinephric fat infiltration, on
cancer
specific and
disease
-free survival were performed.
RESULTS: Patients with pT1-2 and pT3a
tumors
had a 5-year
cancer
specific survival rate of 96.1% and 84.9%, and a 5-year
disease
-free survival rate of 93.4% and 74.7%, respectively (each p <0.01).
Age,
tumor
size and Fuhrman nuclear grade were independent prognostic factors for
cancer
specific and
disease
-free survival, whereas perinephric fat infiltration was significant only for
disease
-free survival.
However, perinephric fat infiltration had a significant effect on
cancer
specific survival in patients with pT3a
tumors
more than 7 cm (p = 0.001).
In contrast, patients with pT3a
tumors
7 cm or less had
cancer
specific and
disease
-free survival similar to that of patients with pT2
tumors
.
Recurrence of pT3a
tumors
greater than 7 cm was observed in 44% of patients but in only 14.6% of those with pT3a
tumors
7 cm or less (p = 0.029).
In contrast to the recurrence of
tumors
7 cm or less, recurrence of pT3a
tumors
more than 7 cm usually developed at multiple sites with a large
tumor
burden and it progressed rapidly.
Consequently 85% of patients with recurrence of pT3a
tumors
larger than 7 cm died of
renal cell carcinoma
compared with 33% of those with recurrence of pT3a
tumors
7 cm or less (p = 0.001).
CONCLUSIONS: In pT3a
renal cell carcinoma tumor
size was the strongest prognostic factor of
disease
-free and
cancer
specific survival.
Perinephric fat infiltration was an independent prognostic factor for
disease
-free survival but not for
cancer
specific survival due to the less aggressive behavior of small (7 cm or less) pT3a
tumors
after recurrence.
Tumor
size and perinephric fat infiltration should be included in T3a
renal cell carcinoma
staging.
[MeSH-major]
Adipose Tissue / pathology.
Carcinoma
,
Renal Cell
/ mortality.
Carcinoma
,
Renal Cell
/ pathology.
Kidney
Neoplasms / mortality.
Kidney
Neoplasms / pathology.
Tumor
Burden
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18550101.001).
[ISSN]
1527-3792
[Journal-full-title]
The Journal of urology
[ISO-abbreviation]
J. Urol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
24.
Margulis V, Wood CG:
The role of lymph node dissection in renal cell carcinoma: the pendulum swings back.
Cancer J
; 2008 Sep-Oct;14(5):308-14
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The role of lymph node dissection in
renal cell carcinoma
: the pendulum swings back.
The incidence of regional lymph node metastases in patients with
renal cell carcinoma
ranges from 13% to over 30%, and portends a poor prognosis in both locally advanced and metastatic settings.
Patients with small, organ confined
tumors
are at low risk for regional lymph node metastases and lymph node dissection can be omitted in these patients.
Patients with locally advanced primary
tumors
but no clinical evidence of lymphadenopathy can be selectively targeted for aggressive lymph node dissection as an adjunct to radical nephrectomy, based on their individual risk of harboring micrometastatic lymph node
disease
.
Although early identification of micrometastatic nodal
disease
in this group of patients has not conclusively been shown to improve survival, accurate pathologic nodal staging allows for early implementation of adjuvant systemic therapies in these high-risk patients.
[MeSH-major]
Carcinoma
,
Renal Cell
/ pathology.
Kidney
Neoplasms / pathology. Lymph Node Excision
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18836335.001).
[ISSN]
1528-9117
[Journal-full-title]
Cancer journal (Sudbury, Mass.)
[ISO-abbreviation]
Cancer J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
25.
Flörcken A, Denecke T, Kretzschmar A, Gollasch H, Reich G, Westermann J:
Long-lasting remission of pulmonary metastases of renal cell cancer under IFN-beta therapy in a patient with multiple sclerosis.
Onkologie
; 2006 Sep;29(8-9):382-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Long-lasting remission of pulmonary metastases of
renal cell cancer
under IFN-beta therapy in a patient with multiple sclerosis.
BACKGROUND: Immunomodulary therapy based on interferon (IFN)-a has been shown to be effective in a subset of patients with advanced
renal cell carcinoma
(
RCC
).
IFN-Beta has occasionally been reported to induce remissions in
RCC
, but is well established in the treatment of multiple sclerosis (MS).
There is an ongoing debate whether hyperactivation of the immune
system
may convey protection against the development of
cancer
in MS patients.
PATIENTS AND METHODS: A 54-year-old female MS patient underwent
tumor
nephrectomy for
RCC
in 1994.
CONCLUSION: To our knowledge, this is the longest remission under IFN-Beta treatment ever reported in an
RCC
patient.
We conclude that IFN-Beta should be particularly considered as a therapeutic option in the rare occasion of metastatic
RCC
in patients with MS.
[MeSH-major]
Carcinoma
,
Renal Cell
/ prevention &
control
.
Carcinoma
,
Renal Cell
/ secondary. Interferon-beta / therapeutic use.
Kidney
Neoplasms / drug therapy. Lung Neoplasms / prevention &
control
. Lung Neoplasms / secondary. Multiple Sclerosis / drug therapy
Genetic Alliance.
consumer health - Kidney cancer
.
Genetic Alliance.
consumer health - Multiple Sclerosis
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Multiple Sclerosis
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16974116.001).
[ISSN]
0378-584X
[Journal-full-title]
Onkologie
[ISO-abbreviation]
Onkologie
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Switzerland
[Chemical-registry-number]
77238-31-4 / Interferon-beta
26.
Pachon G, Rasoanaivo H, Azqueta A, Rakotozafy JC, Raharisololalao A, De Cerain AL, De Lapuente J, Borràs M, Moukha S, Centelles JJ, Creppy EE, Cascante M:
Anticancer effect of a new benzophenanthridine isolated from Zanthoxylum madagascariense (Rutaceline).
In Vivo
; 2007 Mar-Apr;21(2):417-22
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Rutaceline was evaluated for its antiproliferative capacity on the human colorectal
adenocarcinoma
(Caco-2) and the African green monkey
kidney
(Vero)
cell
lines.
The 50% inhibition of
cell
growth (IC50) obtained after 24 h incubation was similar for both
cells
lines (110-115 microg/ml, i.e.
269-281 microM), but at 48 h the IC50 value for the Caco-2
cells
was lower than for the Vero
cells
(20 microg/lml, i.e.
220 microM) indicating a higher
cell
growth inhibitory effect on the colon
adenocarcinoma
cells
.
At the respective IC50 concentrations, Rutaceline did not significantly induce apoptosis but induced
cell
cycle arrest in the GO/G1 phase, as well as a decrease of
cells
in S phase.
Rutaceline also induced DNA fragmentation in both
cell
lines, as revealed by agarose gel electrophoresis, and a dose-dependent clastogenic effect in both
cell
lines as revealed by the Comet assay.
[MeSH-minor]
Adenocarcinoma
. Animals.
Cell
Line.
Cell
Line,
Tumor
. Cercopithecus aethiops. Colorectal Neoplasms. Humans.
Kidney
/ drug effects. Kinetics. Madagascar. Vero
Cells
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17436597.001).
[ISSN]
0258-851X
[Journal-full-title]
In vivo (Athens, Greece)
[ISO-abbreviation]
In Vivo
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Benzophenanthridines
27.
Bravi F, Bosetti C, Scotti L, Talamini R, Montella M, Ramazzotti V, Negri E, Franceschi S, La Vecchia C:
Food groups and renal cell carcinoma: a case-control study from Italy.
Int J Cancer
; 2007 Feb 1;120(3):681-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Food groups and
renal cell carcinoma
: a case-
control
study from Italy.
Although nutrition and diet have been related to
renal cell carcinoma
(
RCC
), the role of specific foods or nutrients on this
cancer
is still controversial.
We evaluated the relation between a wide range of foods and the risk of
RCC
in an Italian case-
control
study including 767 patients (494 men and 273 women) younger than 79 years with incident, histologically confirmed
RCC
, and 1,534 controls (988 men and 546 women) admitted to the same hospitals as cases for a wide spectrum of acute,
non
-neoplastic conditions, not related to long term diet modifications.
A validated and reproducible food frequency questionnaire, including 78 foods and beverages, plus a separate section on alcohol drinking, was used to assess patients' dietary habits 2 years before
diagnosis
or hospital admission.
Poultry (OR = 0.74), processed meat (OR = 0.64) and vegetables (OR = 0.65) were inversely associated with
RCC
risk.
No relation was found for coffee and tea, soups, eggs,
red
meat, fish, cheese, pulses, potatoes, fruits, desserts and sugars.
The results of this study provide further indications on dietary correlates of
RCC
, and in particular indicate that a diet rich in refined cereals and poor in vegetables may have an unfavorable role on
RCC
.
[MeSH-major]
Carcinoma
,
Renal Cell
/ pathology.
Carcinoma
,
Renal Cell
/ physiopathology. Energy Intake / physiology. Food.
Kidney
Neoplasms / pathology
[MeSH-minor]
Aged. Alcohol Drinking. Body Mass Index. Case-
Control
Studies. Diet. Educational Status. Female. Humans. Italy. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Risk Factors. Smoking
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Int J Cancer. 2007 Nov 1;121(9):2116-7
[
17640056.001
]
(PMID = 17058282.001).
[ISSN]
0020-7136
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
28.
Smaldone MC, Cannon GM Jr, Hrebinko RL:
Resection of recurrent inferior vena cava tumor after radical nephrectomy for renal cell carcinoma.
Urology
; 2006 May;67(5):1084.e5-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Resection of recurrent inferior vena cava
tumor
after radical nephrectomy for
renal cell carcinoma
.
Management of recurrent
tumor
in the inferior vena cava (IVC) after radical nephrectomy is surgically challenging.
We report 3 cases of recurrent
renal cell carcinoma
within the IVC managed by three different surgical techniques.
One patient was treated with
tumor
thrombus removal and primary cavotomy closure.
Although technically difficult, repeat resection of IVC
tumor
recurrence after nephrectomy for
renal cell carcinoma
is an acceptable method of treatment.
[MeSH-major]
Carcinoma
,
Renal Cell
/ surgery.
Kidney
Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Vascular Neoplasms / surgery. Vena Cava, Inferior
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16698379.001).
[ISSN]
1527-9995
[Journal-full-title]
Urology
[ISO-abbreviation]
Urology
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
29.
Van Gool AR, Verkerk R, Fekkes D, Sleijfer S, Bannink M, Kruit WH, van der Holt B, Scharpé S, Eggermont AM, Stoter G, Hengeveld MW:
Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma.
J Interferon Cytokine Res
; 2008 May;28(5):283-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with
renal cell carcinoma
.
In 24 patients (16 men, 8 women, median age 60.5 years, range 47-72 years) with metastatic
renal cell carcinoma
(
RCC
), psychiatric assessment and blood sampling were performed before and at 4 and 8 weeks and at 6 months after initiation of treatment with IFN-alpha.
[MeSH-major]
Carcinoma
,
Renal Cell
/ drug therapy.
Carcinoma
,
Renal Cell
/ psychology. Immunotherapy. Interferon-alpha / therapeutic use.
Kidney
Neoplasms / drug therapy.
Kidney
Neoplasms / psychology. Serine Endopeptidases / blood
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18547158.001).
[ISSN]
1079-9907
[Journal-full-title]
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
[ISO-abbreviation]
J. Interferon Cytokine Res.
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Interferon-alpha; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.26 / prolyl oligopeptidase
30.
Yao XD, Ye DW, Zhang SL, Dai B, Zhang HL, Shen YJ, Zhu Y, Zhu YP, Shi GH, Ma CG, Xiao WJ, Qin XJ, Lin GW:
[Experiences of open transperitoneal radical nephrectomy for large renal masses].
Zhonghua Yi Xue Za Zhi
; 2010 Apr 27;90(16):1117-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Experiences of open transperitoneal radical nephrectomy for large
renal
masses].
OBJECTIVE: To evaluate the effect of technical improvements of transperitoneal radical nephrectomy on the patients with large
renal cell carcinoma
.
METHODS: From May 2002 until May 2009, 45 patients with large (> 12 cm)
renal cell carcinoma
underwent transperitoneal radical nephrectomy.
The modified operative methods included exposing the operative field via a liver retractor and initially ligating
renal
artery to block the blood supply
of kidney
and
tumor
.
The method of
tumor
-free tissue dissociation was applied.
RESULTS: The
tumor
diameter was from 12.2 cm to 28.3 cm with a mean of 14.5 cm.
The pathological diagnoses were all of
renal cell carcinoma
.
The pathological
stage
included T(2)N(0 approximately 1)M(0 approximately 1)(n = 13), T(3)N(0 approximately 1)M(0 approximately 1)(n = 23), T(4)N(0 approximately 1)M(0 approximately 1)(n = 9).
After a follow-up period of 3 - 63 months, 3 cases of
tumor
recurrence were found in primary
renal
clutch.
CONCLUSION: Improved radical nephrectomy is feasible for large
renal cell carcinoma
.
[MeSH-major]
Abdominal Cavity / surgery.
Kidney
Neoplasms / surgery. Nephrectomy / methods
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20646430.001).
[ISSN]
0376-2491
[Journal-full-title]
Zhonghua yi xue za zhi
[ISO-abbreviation]
Zhonghua Yi Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Evaluation Studies; Journal Article
[Publication-country]
China
31.
Habib SL, Simone S, Barnes JJ, Abboud HE:
Tuberin haploinsufficiency is associated with the loss of OGG1 in rat kidney tumors.
Mol Cancer
; 2008 Jan 24;7:10
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Tuberin haploinsufficiency is associated with the loss of OGG1 in rat
kidney
tumors
.
BACKGROUND: Tuberous sclerosis
complex
(TSC) is caused by defects in one of two
tumor
suppressor genes, TSC-1 or TSC-2.
TSC-2 gene encodes tuberin, a protein involved in the pathogenesis
of kidney
tumors
.
Loss of heterozygosity (LOH) at the TSC2 locus has been detected in TSC-associated
renal cell carcinoma
(
RCC
) and in
RCC
in the Eker rat.
Tuberin downregulates the DNA repair enzyme 8-oxoguanine DNA-glycosylase (OGG1) with important functional consequences, compromising the ability of
cells
to repair damaged DNA resulting in the accumulation of the mutagenic oxidized DNA, 8-oxo-dG.
Loss of function mutations of OGG1 also occurs in human
kidney
clear
cell carcinoma
and may contribute to tumorgenesis.
We investigated the distribution of protein expression and the activity of OGG1 and 8-oxo-dG and correlated it with the expression of tuberin in
kidneys
of wild type and Eker rats and
tumor
from Eker rat.
RESULTS: Tuberin expression, OGG1 protein expression and activity were higher in
kidney
cortex than in medulla or papilla in both wild type and Eker rats.
In
kidney
tumors
from Eker rats, the loss of the second TSC2 allele is associated with loss of OGG1 expression.
Immunostaining
of kidney
tissue shows localization of tuberin and OGG1 mainly in the cortex.
CONCLUSION: These results demonstrate that OGG1 localizes with tuberin preferentially in
kidney
cortex.
In addition, the predominant expression of OGG1 in the cortex and its decreased expression and activity in the Eker rat may account for the predominant cortical localization of
renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3523-8
[
11904416.001
]
[Cites]
Am J Physiol Renal Physiol. 2008 Jan;294(1):F281-90
[
17989114.001
]
[Cites]
Carcinogenesis. 2003 Mar;24(3):573-82
[
12663520.001
]
[Cites]
Antioxid Redox Signal. 2004 Jun;6(3):561-70
[
15130282.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
J Urol. 1984 Dec;132(6):1170-4
[
6502814.001
]
[Cites]
J Urol. 1987 Sep;138(3):477-81
[
3625844.001
]
[Cites]
Cancer Res. 1991 Jun 15;51(12):3075-9
[
2039987.001
]
[Cites]
J Biol Chem. 1992 Jan 5;267(1):166-72
[
1730583.001
]
[Cites]
Science. 1992 Mar 27;255(5052):1693-5
[
1553556.001
]
[Cites]
J Biol Chem. 1993 Nov 5;268(31):23524-30
[
8226881.001
]
[Cites]
Biochimie. 2000 Jan;82(1):59-64
[
10717388.001
]
[Cites]
Cancer Res. 2000 Sep 1;60(17):4740-4
[
10987279.001
]
[Cites]
Regul Toxicol Pharmacol. 2000 Dec;32(3):264-75
[
11162720.001
]
[Cites]
Cancer Lett. 2001 May 10;166(1):65-9
[
11295288.001
]
[Cites]
Cancer Res. 2001 Jul 15;61(14):5378-81
[
11454679.001
]
[Cites]
Environ Mol Mutagen. 2001;38(2-3):180-90
[
11746753.001
]
[Cites]
J Biol Chem. 1994 May 27;269(21):15318-24
[
7515054.001
]
[Cites]
J Toxicol Environ Health B Crit Rev. 1998 Jul-Sep;1(3):181-97
[
9644327.001
]
[Cites]
Oncogene. 1998 Jun 11;16(23):3083-6
[
9662341.001
]
[Cites]
Jpn J Cancer Res. 1998 Aug;89(8):825-8
[
9765618.001
]
[Cites]
Cancer. 1998 Nov 15;83(10):2208-16
[
9827727.001
]
[Cites]
J Histochem Cytochem. 1999 Apr;47(4):533-44
[
10082755.001
]
[Cites]
DNA Repair (Amst). 2006 Nov 8;5(11):1337-45
[
16861056.001
]
[Cites]
DNA Repair (Amst). 2007 Apr 1;6(4):544-59
[
17112792.001
]
[Cites]
Toxicol Pathol. 2002 Nov-Dec;30(6):675-80
[
12512868.001
]
(PMID = 18218111.001).
[ISSN]
1476-4598
[Journal-full-title]
Molecular cancer
[ISO-abbreviation]
Mol. Cancer
[Language]
ENG
[Grant]
United States / NIDDK NIH HHS / DK / P50 DK061597; United States / NIDDK NIH HHS / DK / R37 DK33665
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Tumor Suppressor Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / OGG1 protein, rat; G9481N71RO / Deoxyguanosine
[Other-IDs]
NLM/ PMC2265742
32.
Seliger B, Fedorushchenko A, Brenner W, Ackermann A, Atkins D, Hanash S, Lichtenfels R:
Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration.
Clin Cancer Res
; 2007 Jan 1;13(1):27-37
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Ubiquitin COOH-terminal hydrolase 1: a biomarker of
renal cell carcinoma
associated with enhanced
tumor cell
proliferation and migration.
PURPOSE:
Renal cell carcinoma
(
RCC
) accounts for 2% to 3% of all malignancies.
It represents one of the most radiation- and chemotherapy-resistant
tumors
and surgical resections are only effective in organ-defined
disease
.
However,
RCC
is an immunogenic
tumor
with response rates to immunotherapies between 10% and 20% of the treated patients.
Due to the currently inefficient therapies and the low 5-year survival rates of
RCC
patients, novel diagnostic, prognostic, and therapeutic markers are urgently needed for this
disease
.
EXPERIMENTAL DESIGN: Proteome-based approaches were used to identify (a) differentially expressed proteins in
RCC
compared with normal
kidney
epithelium and (b) proteins that are able to induce an antibody response in
RCC
patients.
RESULTS: The ubiquitin COOH-terminal hydrolase L1 (UCHL1) was found to be differentially expressed in both
RCC
lesions and
RCC cell
lines and immunoreactive using patients' sera.
UCHL1 expression was often down-regulated in primary
RCC
when compared with normal
kidney
epithelium but dependent on the
RCC
subtype, the von Hippel-Lindau phenotype, and the
tumor
grading.
Moreover, the frequency and the level of UCHL1 expression were higher in metastases when compared with primary
RCC
lesions.
Gain-of-function transfectants exhibited a significant higher proliferation and migration rate than UCHL1-negative
RCC cells
.
CONCLUSIONS: UCHL1 expression seems to be associated with the metastatic phenotype of
RCC
and therefore might serve as potential biomarker for the
diagnosis
and prognosis of
RCC
patients.
[MeSH-major]
Biomarkers,
Tumor
.
Carcinoma
,
Renal Cell
/ drug therapy. Gene Expression Regulation, Neoplastic.
Kidney
Neoplasms / drug therapy. Ubiquitin Thiolesterase / biosynthesis
[MeSH-minor]
Antineoplastic Agents / pharmacology.
Cell
Line,
Tumor
.
Cell
Movement.
Cell
Proliferation. Humans.
Kidney
/ metabolism. Neoplasm Metastasis. Phenotype. Protein Structure, Tertiary. Proteomics / methods
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
Cellosaurus - a cell line knowledge resource.
culture/stock collections - Cell lines described in this publication
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17200335.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 3.1.2.15 / UCHL1 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
33.
Rey Rey J, León Ramírez D, López García S, Fernández Vázquez P, Benavente Delgado J, Ojea Calvo A:
[Pathological prognostic indicators in renal cell carcinoma].
Actas Urol Esp
; 2010 Jan;34(1):71-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Pathological prognostic indicators in
renal cell carcinoma
].
[Transliterated title]
Indicadores pronósticos anatomopatológicos
del
cáncer
de
riñón.
OBJECTIVE: To analyze histological factors not routinely assessed as potential prognostic factors in
renal cell carcinoma
, such as
tumor
necrosis, microscopic vascular invasion, and sinus fat invasion.
MATERIALS AND METHODS: A retrospective, analytical study was conducted of surgical specimens from 139 patients with localized
renal cell carcinoma
who underwent nephrectomy from 1993 to 2005.
Tumor
necrosis, microscopic vascular invasion, and sinus fat invasion were analyzed and compared to the classical factors: TNM classification, Fuhrman grade, and
tumor
size.
For statistical analysis, variables analyzed were categorized as pT1, 2 vs pT3, 4; Fuhrman grade 1, 2 vs 3, 4;
tumor
size < 7 cm vs >or= 7cm;
tumor
necrosis vs
no tumor
necrosis; microvascular invasion of sinus fat vs no invasion.
Cancer
-specific survival probability and
disease
-free survival were calculated.
Dependent variables were used to analyze
cancer
-specific survival rates.
Disease
-free survival was estimated using a Cox regression model and Kaplan-Meier curves.
RESULTS: In the univariate analysis, all variables analyzed had a significant influence on death for
renal cell carcinoma
.
The variables significantly influencing
disease
-free survival, estimated by the Cox method, were the pT
stage
(p = 0.038) and Fuhrman grade (p = 0.048).
CONCLUSIONS: In patients with clinically localized
renal cell carcinoma
undergoing nephrectomy, pT
stage
and Fuhrman grade are the most important prognostic factors for survival and
disease
-free survival.
Tumor
necrosis, microscopic vascular invasion, and sinus fat invasion are prognostic factors for death from
renal carcinoma
which are associated to TNM classification, Fuhrman grade, and
tumor
size.
[MeSH-major]
Carcinoma
,
Renal Cell
/ pathology.
Kidney
Neoplasms / pathology
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20223135.001).
[ISSN]
1699-7980
[Journal-full-title]
Actas urologicas españolas
[ISO-abbreviation]
Actas Urol Esp
[Language]
spa
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Spain
34.
Hamamoto S, Okamura T, Mizuno K, Kamisawa H, Mogami T, Kohri K:
Renal oncocytoma with bilateral synchronous renal cell carcinoma in a patient undergoing long-term hemodialysis.
Int J Urol
; 2008 Jan;15(1):87-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Renal
oncocytoma with bilateral synchronous
renal cell carcinoma
in a patient undergoing long-term hemodialysis.
We report a case of bilateral synchronous
renal cell carcinoma
and
renal
oncocytoma in a 56-year-old male who had been treated with hemodialysis for 32 years.
Because anemia gradually worsened, computed tomography and magnetic resonance imaging were carried out and revealed bilateral
renal tumors
within acquired cystic
disease
of the
kidney
.
Bilateral nephrectomy was carried out, and the patient was diagnosed with multiple
renal cell carcinomas
and a single
renal
oncocytoma.
To our knowledge, this is the first reported case of
renal
oncocytoma with synchronous
renal cell carcinoma
in a patient undergoing long-term hemodialysis.
[MeSH-major]
Adenoma, Oxyphilic / etiology.
Carcinoma
,
Renal Cell
/ etiology.
Kidney
Neoplasms / etiology. Neoplasms, Multiple Primary / etiology.
Renal
Dialysis / adverse effects
[MeSH-minor]
Humans.
Kidney
Failure, Chronic / complications.
Kidney
Failure, Chronic / therapy. Male. Middle Aged
Genetic Alliance.
consumer health - Oncocytoma renal
.
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Dialysis
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18184181.001).
[ISSN]
1442-2042
[Journal-full-title]
International journal of urology : official journal of the Japanese Urological Association
[ISO-abbreviation]
Int. J. Urol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Australia
35.
Ishizaki H, Yano H, Tsuneoka M, Ogasawara S, Akiba J, Nishida N, Kojiro S, Fukahori S, Moriya F, Matsuoka K, Kojiro M:
Overexpression of the myc target gene Mina53 in advanced renal cell carcinoma.
Pathol Int
; 2007 Oct;57(10):672-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Overexpression of the myc target gene Mina53 in advanced
renal cell carcinoma
.
The myc target gene Mina53 was reported to be overexpressed in esophageal
cancer
with a poor prognosis.
The purpose of the present study was to examined Mina53 expression and its relationship to clinicopathological parameters in human
renal cell carcinoma
(
RCC
).
Mina53 and Ki-67 expression was examined on immunohistochemistry for 64 surgically resected
RCC
and
non
-cancerous tissue.
In addition, the relationship between Mina53 expression and clinicopathological prognostic factors of
RCC
such as age,
stage
, microvenous invasion (MVI), histological subtype, Ki-67 labeling index (LI), and prognosis, was examined.
Mina53 was expressed in the nuclei of
tumor cells
and tubular nuclei of normal
renal
tissue.
The expression level of Mina53 was significantly higher in patients with poor prognostic factors (
stage
IV, MVI-positive, and sarcomatoid
RCC
, and high Ki-67 LI).
The prognosis of high Mina53-expressing
tumors
was significantly poorer than that of
non
-Mina53-high
tumors
(P < 0.0001).
In conclusion, Mina53 is overexpressed in
RCC
tissue from patients with poor prognostic factors, suggesting that Mina53 overexpression is one of the factors for poor prognosis in
RCC
.
[MeSH-major]
Carcinoma
,
Renal Cell
/ genetics. Gene Expression Regulation, Neoplastic.
Kidney
Neoplasms / genetics. Nuclear Proteins / genetics
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Biomarkers,
Tumor
/ genetics. Biomarkers,
Tumor
/ metabolism.
Cell
Line,
Tumor
.
Cell
Nucleus / metabolism. Female. Humans. Immunoenzyme Techniques. Japan / epidemiology. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Nephrectomy. Prognosis. Survival Rate
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17803656.001).
[ISSN]
1320-5463
[Journal-full-title]
Pathology international
[ISO-abbreviation]
Pathol. Int.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Australia
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / MINA protein, human; 0 / Nuclear Proteins
36.
Benincasa E, Conti A, Bossone G, Gallà DA, Gianciotta A, Zuccaro SM, Madaio R:
A case of complete clinical response with sorafenib in a patient with thyroid gland metastases from renal cell carcinoma 17 years from diagnosis.
Tumori
; 2009 May-Jun;95(3):403
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A case of complete clinical response with sorafenib in a patient with thyroid gland metastases from
renal cell carcinoma
17 years from
diagnosis
.
[MeSH-major]
Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use.
Carcinoma
,
Renal Cell
/ drug therapy.
Carcinoma
,
Renal Cell
/ secondary.
Kidney
Neoplasms / pathology. Pyridines / therapeutic use. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / secondary
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
Hazardous Substances Data Bank.
NICOTINAMIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19688987.001).
[ISSN]
0300-8916
[Journal-full-title]
Tumori
[ISO-abbreviation]
Tumori
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
United States
[Chemical-registry-number]
0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
37.
Song Y, He ZS, Li NC, Li M, Zhou LQ, Na YQ:
[Outcome of surgical management of renal cell carcinoma with renal vein or inferior vena cava tumor thrombus].
Zhonghua Wai Ke Za Zhi
; 2006 May 15;44(10):678-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Outcome of surgical management of
renal cell carcinoma
with
renal
vein or inferior vena cava
tumor
thrombus].
OBJECTIVE: To investigate the prognosis of surgical treatment for
renal cell carcinoma
with
renal
vein or inferior vena cava
tumor
thrombus.
METHODS: Between August 1994 and July 2004, 33 patients with
renal cell carcinoma
with
renal
vein or inferior vena cava
tumor
thrombus underwent radical nephrectomy and thrombectomy.
Level of
tumor
thrombus was
renal
vein in 15 patients, infrahepatic (level I) in 9, intrahepatic (level II) in 5, suprahepatic (level III) in 1, and
right
atrial extension (level IV) in 3.
The mean survival time of patients with
renal
vein involvement [(49.9 +/- 9.8) months] versus level I [(16.7 +/- 1.9) months] was significantly different (P < 0.05).
CONCLUSIONS: Radical nephrectomy plus thrombectomy is a valuable method for the treatment of
renal cell carcinoma
with
renal
vein or inferior vena cava involvement.
Patients with
renal
vein
tumor
thrombus appear to have better survival compared to patients with inferior vena cava
tumor
thrombus.
[MeSH-major]
Carcinoma
,
Renal Cell
/ surgery. Embolectomy / methods.
Kidney
Neoplasms / surgery. Neoplastic
Cells
, Circulating. Nephrectomy / methods.
Renal
Veins / surgery. Vena Cava, Inferior / surgery
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16784678.001).
[ISSN]
0529-5815
[Journal-full-title]
Zhonghua wai ke za zhi [Chinese journal of surgery]
[ISO-abbreviation]
Zhonghua Wai Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
38.
Saidi RF, Remine SG:
Isolated gastric metastasis from renal cell carcinoma 10 years after radical nephrectomy.
J Gastroenterol Hepatol
; 2007 Jan;22(1):143-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Isolated gastric metastasis from
renal cell carcinoma
10 years after radical nephrectomy.
[MeSH-major]
Carcinoma
,
Renal Cell
/ secondary.
Kidney
Neoplasms / pathology. Stomach Neoplasms / secondary
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17201902.001).
[ISSN]
0815-9319
[Journal-full-title]
Journal of gastroenterology and hepatology
[ISO-abbreviation]
J. Gastroenterol. Hepatol.
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
Australia
39.
Goregaonkar R, Shet T, Ramadwar M, Chinoy R:
Critical role of fine needle aspiration cytology and immunocytochemistry in preoperative diagnosis of pediatric renal tumors.
Acta Cytol
; 2007 Sep-Oct;51(5):721-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Critical role of fine needle aspiration cytology and immunocytochemistry in preoperative
diagnosis
of pediatric
renal tumors
.
OBJECTIVE: To evaluate accuracy and role of immunocytochemistry (ICC) in cytologic
diagnosis
of pediatric
renal tumors
.
STUDY DESIGN: Fine needle aspirates from 75 cases of pediatric
renal tumors
were studied.
Smears were screened without the knowledge of final histologic
diagnosis
.
Subsequently, clinical details, final histology and
diagnosis
rendered by the original cytologist were noted to judge accuracy of
diagnosis
by a sensitized cytologist.
Five neuroblastomas that entered close differentials for Wilms
tumor
were also evaluated.
RESULTS: Of 58 Wilms
tumors
, 5 were misdiagnosed; 3
renal
rhabdoid
tumors
and 1 clear
cell
sarcoma were missed on cytology.
Non
-Hodgkin's lymphomas presenting as
renal
masses were accurately diagnosed on cytology, but primitive neuroectodermal
tumors
(n = 3) and
renal cell carcinomas
(n = 2) were not accurately diagnosed.
Accuracy rate improved from 65% to 92% on review by a cytologist aware of cytologic features of pediatric
renal tumors
.
CONCLUSION: A good accuracy rate of
diagnosis
of pediatric
renal tumors
can be achieved by priming pathologists to typical features of
tumors
.
Immunocytochemistry plays a supportive role in cases with atypical
morphology
or unusual presentations.
[MeSH-major]
Kidney
/ pathology.
Kidney
Neoplasms /
diagnosis
.
Kidney
Neoplasms / pathology. Preoperative Care
[MeSH-minor]
Adolescent. Azure Stains. Biopsy, Fine-Needle.
Carcinoma
,
Renal Cell
/
diagnosis
.
Carcinoma
,
Renal Cell
/ pathology.
Cell
Nucleus / pathology. Child. Child, Preschool. Humans. Immunohistochemistry. Infant. Neuroectodermal
Tumors
, Primitive, Peripheral /
diagnosis
. Neuroectodermal
Tumors
, Primitive, Peripheral / pathology. Rhabdoid
Tumor
/
diagnosis
. Rhabdoid
Tumor
/ pathology. Wilms
Tumor
/
diagnosis
. Wilms
Tumor
/ pathology
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17910341.001).
[ISSN]
0001-5547
[Journal-full-title]
Acta cytologica
[ISO-abbreviation]
Acta Cytol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Azure Stains
40.
Sinha S, Dutta S, Datta K, Ghosh AK, Mukhopadhyay D:
Von Hippel-Lindau gene product modulates TIS11B expression in renal cell carcinoma: impact on vascular endothelial growth factor expression in hypoxia.
J Biol Chem
; 2009 Nov 20;284(47):32610-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Von Hippel-Lindau gene product modulates TIS11B expression in
renal cell carcinoma
: impact on vascular endothelial growth factor expression in hypoxia.
TIS11B has been shown to regulate vascular endothelial growth factor (VEGF) mRNA stability in adrenocorticotropic hormone-stimulated primary adrenocortical
cells
.
TIS11B has also been documented as a negative regulator of VEGF during development, but nothing has yet been reported in the context of human
cancers
.
The Von Hippel-Lindau (VHL)
tumor
suppressor protein regulates VEGF gene expression at both the transcriptional and post-transcriptional levels in normoxia.
Here, we report a unique regulatory function of VHL in VEGF expression in hypoxia that is mediated through modulation of TIS11B protein levels in
renal cancer cells
.
In normoxia, we detected increased expression of the microRNA hsa-miR-29b in the VHL-overexpressing
renal cancer cell
line 786-O.
In contrast, in hypoxia, increased TIS11B expression paralleled an increased TIS11B mRNA stability in VHL-overexpressing 786-
O cells
.
This VHL-mediated TIS11B up-regulation in hypoxia may be important for TIS11B-regulated gene expression: we observed a down-regulation of VEGF mRNA in hypoxia in VHL-overexpressing
cells
compared with parental 786-
O cells
, and this effect was reversible by silencing TIS11B expression.
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
Hazardous Substances Data Bank.
OXYGEN
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Semin Cancer Biol. 2004 Apr;14(2):123-30
[
15018896.001
]
[Cites]
Arch Biochem Biophys. 2007 Jun 15;462(2):278-85
[
17517366.001
]
[Cites]
Science. 1983 Feb 25;219(4587):983-5
[
6823562.001
]
[Cites]
Science. 1987 Jan 23;235(4787):442-7
[
2432664.001
]
[Cites]
Nature. 1989 May 4;339(6219):58-61
[
2469964.001
]
[Cites]
Science. 1989 Dec 8;246(4935):1306-9
[
2479986.001
]
[Cites]
Mol Cell Biol. 1991 Mar;11(3):1754-8
[
1996120.001
]
[Cites]
FEBS Lett. 1992 Jul 13;306(1):1-4
[
1628738.001
]
[Cites]
Nature. 1992 Oct 29;359(6398):843-5
[
1279431.001
]
[Cites]
Nature. 1993 Apr 29;362(6423):841-4
[
7683111.001
]
[Cites]
Science. 1993 May 28;260(5112):1317-20
[
8493574.001
]
[Cites]
Am J Pathol. 1993 Nov;143(5):1255-62
[
8238242.001
]
[Cites]
Nature. 1994 Feb 10;367(6463):576-9
[
8107827.001
]
[Cites]
Cancer Res. 1994 Aug 1;54(15):4233-7
[
7518352.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):768-72
[
7531342.001
]
[Cites]
Cancer Res. 1995 Mar 15;55(6):1358-64
[
7533661.001
]
[Cites]
FEBS Lett. 1995 Jul 10;368(1):160-4
[
7615073.001
]
[Cites]
Nat Med. 1995 Aug;1(8):822-6
[
7585187.001
]
[Cites]
Trends Biochem Sci. 1995 Nov;20(11):465-70
[
8578590.001
]
[Cites]
Cancer Res. 1996 May 15;56(10):2299-301
[
8625303.001
]
[Cites]
Sci Am. 1996 Sep;275(3):150-4
[
8701285.001
]
[Cites]
Cell. 1996 Aug 23;86(4):517-20
[
8752206.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10589-94
[
8855222.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9
[
8855223.001
]
[Cites]
Kidney Int. 1997 Feb;51(2):575-8
[
9027742.001
]
[Cites]
Mol Cell Biol. 1997 Sep;17(9):5629-39
[
9271438.001
]
[Cites]
Eur J Cell Biol. 2008 Jan;87(1):31-8
[
17889962.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12885-90
[
18728182.001
]
[Cites]
Medicine (Baltimore). 1997 Nov;76(6):381-91
[
9413424.001
]
[Cites]
J Biol Chem. 1998 Mar 13;273(11):6417-23
[
9497373.001
]
[Cites]
Nature. 1998 Jul 30;394(6692):485-90
[
9697772.001
]
[Cites]
Trends Genet. 1998 Oct;14(10):423-6
[
9820032.001
]
[Cites]
Nature. 1999 May 20;399(6733):271-5
[
10353251.001
]
[Cites]
Oncogene. 2004 Nov 11;23(53):8673-80
[
15467755.001
]
[Cites]
Oncogene. 2005 Nov 24;24(53):7850-8
[
16170373.001
]
[Cites]
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4
[
16381832.001
]
[Cites]
Genes Dev. 2006 Mar 1;20(5):515-24
[
16510870.001
]
[Cites]
Mol Endocrinol. 2006 Apr;20(4):916-30
[
16306087.001
]
[Cites]
J Natl Cancer Inst. 2001 Feb 21;93(4):266-76
[
11181773.001
]
[Cites]
Science. 2001 Apr 20;292(5516):464-8
[
11292862.001
]
[Cites]
Science. 2001 Apr 20;292(5516):468-72
[
11292861.001
]
[Cites]
Dev Dyn. 2006 Nov;235(11):3144-55
[
17013884.001
]
[Cites]
Mol Cell Biol. 2004 Jul;24(14):6445-55
[
15226444.001
]
(PMID = 19801654.001).
[ISSN]
1083-351X
[Journal-full-title]
The Journal of biological chemistry
[ISO-abbreviation]
J. Biol. Chem.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA078383; United States / NCI NIH HHS / CA / R29 CA078383; United States / NCI NIH HHS / CA / CA78383
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Butyrate Response Factor 1; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 0 / ZFP36L1 protein, human; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein; S88TT14065 / Oxygen
[Other-IDs]
NLM/ PMC2781675
41.
Kim SJ, Hwang SH, Kim IJ, Lee MK, Lee CH, Lee SY, Lee EY:
The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients.
J Exp Clin Cancer Res
; 2010;29:69
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in
non
-small
cell
lung
cancer
. SLC2A1 polymorphisms and FDG-PET in NSCLC patients.
BACKGROUND: Positron emission tomography imaging of lung
cancers
with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose is
a non
-invasive diagnostic, and prognostic tool that measures
tumor
metabolism.
METHODS: We investigated the association between solute carrier family 2 (facilitated glucose transporter), member 1 -2841A>T, hypoxia-inducible factor 1 alpha Pro582Ser, Ala588Thr, apurinic/apyimidinic endonuclease Asp148Glu, or vascular endothelial growth factor A +936C>T and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-uptake among 154 patients with
non
-small-
cell
lung
cancer
.
RESULTS: The solute carrier family 2 (facilitated glucose transporter), member 1 -2841A>T polymorphism was significantly associated with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-uptake in combination with the apurinic/apyimidinic endonuclease Asp148Glu (T>G) polymorphism in the squamous
cell
type of
non
-small-
cell
lung
cancer
.
CONCLUSION: A glucose transporter gene polymorphism was shown to be statistically associated with glucose-uptake when the apurinic/apyimidinic endonuclease genotype is TT in patients with the squamous
cell
type of
non
-small-
cell
lung
cancer
.
[MeSH-major]
Biomarkers,
Tumor
/ genetics.
Carcinoma
,
Non
-Small-
Cell
Lung / genetics.
Carcinoma
,
Non
-Small-
Cell
Lung / radionuclide imaging. Fluorodeoxyglucose F18. Polymorphism, Single Nucleotide / genetics. Positron-Emission Tomography
[MeSH-minor]
Adenocarcinoma
/ genetics.
Adenocarcinoma
/ pathology.
Adenocarcinoma
/ radionuclide imaging. Adult. Aged. Aged, 80 and over. Anoxia / radionuclide imaging.
Carcinoma
, Squamous
Cell
/ genetics.
Carcinoma
, Squamous
Cell
/ pathology.
Carcinoma
, Squamous
Cell
/ radionuclide imaging. DNA, Neoplasm / genetics. DNA-(Apurinic or Apyrimidinic Site) Lyase / genetics. Female. Genotype. Glucose Transporter Type 1 / genetics. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / genetics. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Lung Neoplasms / radionuclide imaging. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Prospective Studies. Radiopharmaceuticals. Vascular Endothelial Growth Factor A / genetics
Genetic Alliance.
consumer health - Lung Cancer
.
Genetic Alliance.
consumer health - Non-small cell lung cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Kidney Int. 2001 Feb;59(2):631-6
[
11168944.001
]
[Cites]
Nephrol Dial Transplant. 2001 Aug;16(8):1653-6
[
11477169.001
]
[Cites]
Trends Mol Med. 2002;8(4 Suppl):S62-7
[
11927290.001
]
[Cites]
Oncol Rep. 2004 Nov;12(5):1033-7
[
15492789.001
]
[Cites]
Cancer. 1994 Oct 15;74(8):2239-44
[
7922975.001
]
[Cites]
Ann Thorac Surg. 1995 Nov;60(5):1348-52
[
8526625.001
]
[Cites]
Curr Opin Genet Dev. 1998 Oct;8(5):588-94
[
9794818.001
]
[Cites]
J Nucl Med. 1999 Apr;40(4):556-65
[
10210213.001
]
[Cites]
Cancer Res. 1999 Nov 15;59(22):5830-5
[
10582706.001
]
[Cites]
FEBS Lett. 2000 Jun 30;476(1-2):73-7
[
10878254.001
]
[Cites]
Cancer Sci. 2009 Apr;100(4):753-8
[
19141127.001
]
[Cites]
J Exp Clin Cancer Res. 2008;27:49
[
18823566.001
]
[Cites]
Am J Clin Oncol. 2008 Aug;31(4):352-62
[
18845994.001
]
[Cites]
Anticancer Res. 2008 Mar-Apr;28(2B):1271-6
[
18505065.001
]
[Cites]
Cancer Biomark. 2008;4(2):63-71
[
18503157.001
]
[Cites]
Lung Cancer. 2008 May;60(2):277-84
[
18061304.001
]
[Cites]
Eur J Cardiothorac Surg. 2008 May;33(5):819-23
[
18374589.001
]
[Cites]
J Clin Oncol. 2008 Feb 20;26(6):856-62
[
18281657.001
]
[Cites]
Clin Cancer Res. 2008 Jan 15;14(2):612-7
[
18223238.001
]
[Cites]
DNA Repair (Amst). 2008 Feb 1;7(2):177-86
[
17974506.001
]
[Cites]
Hum Mol Genet. 2007 Oct 1;16(19):2333-40
[
17855454.001
]
[Cites]
Eur J Cancer. 2007 Jun;43(9):1392-8
[
17512190.001
]
[Cites]
Lung Cancer. 2006 Sep;53(3):257-62
[
16837101.001
]
[Cites]
Prostate. 2005 May 15;63(3):215-21
[
15538748.001
]
[Cites]
J Diabetes Complications. 2005 Mar-Apr;19(2):65-9
[
15745834.001
]
[Cites]
Breast Cancer Res Treat. 2004 Dec;88(3):205-8
[
15609122.001
]
[Cites]
Kidney Int. 1999 May;55(5):1843-8
[
10231446.001
]
[Cites]
Am J Pathol. 2000 Aug;157(2):411-21
[
10934146.001
]
[Cites]
Mutat Res. 2000 Oct 16;461(2):83-108
[
11018583.001
]
[Cites]
J Vasc Res. 2000 Nov-Dec;37(6):443-8
[
11146397.001
]
(PMID = 20540786.001).
[ISSN]
1756-9966
[Journal-full-title]
Journal of experimental & clinical cancer research : CR
[ISO-abbreviation]
J. Exp. Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Glucose Transporter Type 1; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Radiopharmaceuticals; 0 / SLC2A1 protein, human; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 4.2.99.18 / APEX1 protein, human; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase
[Other-IDs]
NLM/ PMC2898683
42.
Kobayashi N, Suzuki K, Murakami H, Kagawa E, Aoki I, Nagashima Y:
Chromophobe renal cell carcinoma with sarcomatoid transformation in a dog.
J Vet Diagn Invest
; 2010 Nov;22(6):983-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Chromophobe
renal cell carcinoma
with sarcomatoid transformation in a dog.
An abdominal ultrasonographic examination revealed a left
renal tumor
measuring 8 cm in diameter, and a nephrectomy was performed.
The resected
kidney
contained a cavitated
tumor
with a white solid region.
Histologically, this
tumor
was composed of large polygonal
cells
with abundant and cloudy cytoplasm and focal sarcomatoid change.
The neoplastic epithelial
cells
were reactive with colloidal iron staining; Dolichos biflorus agglutinin, peanut agglutinin, and Ulex europaeus agglutinin I lectins; and cluster of differentiation 10 and c-KIT antigens but not for periodic acid-Schiff or vimentin stain.
Neoplastic sarcomatoid
cells
stained positive for vimentin.
Because these histopathologic features are identical to those of human chromophobe
renal cell carcinoma
, the present case was diagnosed as canine chromophobe
renal cell carcinoma
.
[MeSH-major]
Carcinoma
,
Renal Cell
/ veterinary. Dog Diseases /
diagnosis
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21088189.001).
[ISSN]
1040-6387
[Journal-full-title]
Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
[ISO-abbreviation]
J. Vet. Diagn. Invest.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
43.
Banerjee D, Chadalavada RS, Bourdon V, Korkola JE, Motzer RJ, Chaganti RS:
Transcriptional program associated with IFN-alpha response of renal cell carcinoma.
J Interferon Cytokine Res
; 2006 Mar;26(3):156-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Transcriptional program associated with IFN-alpha response of
renal cell carcinoma
.
Metastatic
renal cell carcinoma
(
RCC
) is refractory to therapy; however, 10%-20% of patients respond favorably with interferon-alpha (IFN-alpha) treatment.
To understand the molecular basis of response to IFN-alpha therapy, we performed global gene expression analysis of sensitive and resistant
RCC cell
lines in the absence and in the presence of IFN-alpha, using high-density oligonucleotide arrays to detect differentially expressed genes.
In the absence of IFN-alpha, no significant differences in gene expression were observed between six sensitive and six resistant
cell
lines.
Gene expression analysis following a time course of IFN-alpha2b treatment in one sensitive (SK-RC-17) and one resistant (SK-RC-12)
cell
line revealed that 484 and 354 transcripts, respectively, were modulated.
A considerable number of these transcripts were similarly modulated between the two
cell
types that included several known targets of IFN signaling associated with antiviral and immunomodulatory activity.
A further analysis of gene expression pattern in response to IFN revealed that several transcripts associated with proapoptotic function were upregulated in the sensitive
cells
.
In the resistant
cells
, transcripts associated with
cell
survival and proliferation were induced, and key apoptotic molecules were suppressed.
This study suggests that the IFN-alpha response of individual
RCC tumors
is determined by the expression pattern of genes in the apoptosis vs. survival and proliferation pathways rather than by alterations in expression of one or more individual genes.
[MeSH-major]
Carcinoma
, Hepatocellular / immunology. Gene Expression Regulation, Neoplastic / drug effects. Immunologic Factors / pharmacology. Interferon-alpha / pharmacology. Liver Neoplasms / immunology. Transcription, Genetic / drug effects
[MeSH-minor]
Cell Culture
Techniques.
Cell
Death / drug effects.
Cell
Line,
Tumor
.
Cell
Proliferation / drug effects.
Cell
Survival / drug effects. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Gene Expression Profiling. Humans. Kinetics. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16542138.001).
[ISSN]
1079-9907
[Journal-full-title]
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
[ISO-abbreviation]
J. Interferon Cytokine Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Immunologic Factors; 0 / Interferon-alpha
44.
Moudouni SM, Tligui M, Doublet JD, Haab F, Gattegno B, Thibault P:
Nephron-sparing surgery for de novo renal cell carcinoma in allograft kidneys.
Transplantation
; 2005 Sep 27;80(6):865-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Nephron-sparing surgery for
de
novo
renal cell carcinoma
in allograft
kidneys
.
Renal cell carcinomas
account for 4.6% of post-transplant
cancers
, 10% of which occur in allograft
kidneys
.
We report three such cases among
kidney
grafts that were performed or followed from 1970 to 2004.
In all patients, we performed a partial allograft nephrectomy after consideration of the
tumor
size, location, and absence of metastases and local extension.
Renal
function has remained stable, and there has been no sign of graft rejection,
tumor
recurrence or metastases.
The lateral, peripherally located
tumor
allowed excision without
renal
hilar dissection or entry into the collecting
system
.
In agreement with data emerging from the literature, the present cases confirm that even in the setting of long-standing immunosuppression,
de
novo
RCC
of the
kidney
graft warrants a minimally invasive approach to spare patients graft loss and return to hemodialysis.
[MeSH-major]
Carcinoma
,
Renal Cell
/ surgery.
Kidney
Transplantation. Nephrons
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Transplantation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16210977.001).
[ISSN]
0041-1337
[Journal-full-title]
Transplantation
[ISO-abbreviation]
Transplantation
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
45.
Flaherty KT, Fuchs CS, Colditz GA, Stampfer MJ, Speizer FE, Willett WC, Curhan GC:
A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States).
Cancer Causes Control
; 2005 Nov;16(9):1099-106
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A prospective study of body mass index, hypertension, and smoking and the risk of
renal cell carcinoma
(United States).
OBJECTIVE: We prospectively investigated the independent association of hypertension, thiazide use, body mass index, weight change, and smoking with the risk of
renal cell carcinoma
among men and women using biennial mailed questionnaires.
RESULTS: During 24 years of follow-up for women and 12 years for men, 155 and 110 incident cases of
renal cell carcinoma
were confirmed, respectively.
After adjusting for age, updated BMI and smoking, an updated
diagnosis
of hypertension was associated with
renal cell carcinoma
(
RCC
); the relative risk (RR) was 1.9 (95% CI 1.4-2.7) for women and 1.8 (95% CI 1.2-2.7) for men.
Based on limited data regarding the use of thiazide diuretics, we did not observe a risk associated with their use, independent of the
diagnosis
of hypertension.
CONCLUSIONS:
Diagnosis
of hypertension, higher BMI, and increasing pack-years of smoking appear to independently increase the risk of
renal cell carcinoma
.
[MeSH-major]
Body Mass Index.
Carcinoma
,
Renal Cell
/ epidemiology. Hypertension / epidemiology. Smoking / epidemiology
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - High Blood Pressure
.
MedlinePlus Health Information.
consumer health - Smoking
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16184476.001).
[ISSN]
0957-5243
[Journal-full-title]
Cancer causes & control : CCC
[ISO-abbreviation]
Cancer Causes Control
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA40356; United States / NCI NIH HHS / CA / CA55075; United States / NCI NIH HHS / CA / CA87969; United States / NIDDK NIH HHS / DK / DK52866
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Sodium Chloride Symporter Inhibitors
46.
Ohno Y, Izumi M, Tachibana M, Kawamura T, Yoshioka K, Aoyagi T, Ohori M, Namiki K, Sakamoto N, Nakagami Y, Hatano T, Akimoto S, Nishimura T:
Characterization and gene expression analysis of novel matched primary and metastatic renal cell carcinoma cell lines.
Oncol Rep
; 2008 Sep;20(3):501-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Characterization and gene expression analysis of novel matched primary and metastatic
renal cell carcinoma cell
lines.
Despite recent advances in molecular biology that have clarified the mechanisms involved in the metastasis of several types of
cancer
, the molecular mechanism underlying the metastasis of
renal cell carcinoma
(
RCC
) remains unclear.
Two
RCC cell
lines were successfully established from the surgical specimens of a matched primary
tumor
and adrenal metastasis from the same
RCC
patient, and were designated as TMK-1P and TMK-1M, respectively.
DNA microarray analysis showed a large differential expression of genes related to
cell
adhesion and the extracellular matrix molecules of which hexabrachion (tenascin-C), epidermal growth factor
receptor
, cadherin-6, and beta1-catenin were down-regulated, and the 67 kDa laminin
receptor
1 and transforming growth factor-beta-induced 68 kDa protein (betaig-h3) were up-regulated in TMK-1M.
Real-time RT-PCR analysis confirmed this differential gene expression between the two
cell
lines.
The
RCC cell
lines may be useful in studying
tumor
invasion and screening markers for metastasis.
[MeSH-major]
Adrenal Gland Neoplasms / genetics. Biomarkers,
Tumor
/ genetics.
Carcinoma
,
Renal Cell
/ genetics. Gene Expression Regulation, Neoplastic.
Kidney
Neoplasms / genetics.
Kidney
Neoplasms / pathology
[MeSH-minor]
Cell
Line,
Tumor
. Gene Expression Profiling. Humans. Karyotyping. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Adrenal Gland Cancer
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18695898.001).
[ISSN]
1021-335X
[Journal-full-title]
Oncology reports
[ISO-abbreviation]
Oncol. Rep.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm
47.
Pepper K, Jaowattana U, Starsiak MD, Halkar R, Hornaman K, Wang W, Dayamani P, Tangpricha V:
Renal cell carcinoma presenting with paraneoplastic hypercalcemic coma: a case report and review of the literature.
J Gen Intern Med
; 2007 Jul;22(7):1042-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Renal cell carcinoma
presenting with paraneoplastic hypercalcemic coma: a case report and review of the literature.
We report a case of a 62-year-old woman with
renal cell carcinoma
(
RCC
) presenting with a hypercalcemia-induced coma.
Initial imaging was negative, but PET scan identified a mass in the upper pole of the left
kidney
.
Our patient underwent partial nephrectomy, and the mass was identified as
RCC
on final pathology.
This case report describes a patient with
RCC
with the unusual presentation of hypercalcemic coma.
We review the differential
diagnosis
of
malignant
hypercalcemia and the evaluation of hypercalcemia occurring with
RCC
.
[MeSH-major]
Carcinoma
,
Renal Cell
/ complications. Coma / etiology. Hypercalcemia / etiology.
Kidney
Neoplasms / complications
[MeSH-minor]
Diagnosis
, Differential. Female. Humans. Interleukin-6 / blood. Middle Aged. Parathyroid Hormone / blood.
Receptor
, Parathyroid Hormone, Type 1 / blood
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Coma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
JAMA. 1999 May 5;281(17):1628-31
[
10235157.001
]
[Cites]
Radiol Med. 2006 Dec;111(8):1146-55
[
17171520.001
]
[Cites]
Radiology. 2005 Jan;234(1):227-34
[
15564390.001
]
[Cites]
N Engl J Med. 2005 Jan 27;352(4):373-9
[
15673803.001
]
[Cites]
Eur J Nucl Med Mol Imaging. 2005 May;32(5):589-92
[
15726356.001
]
[Cites]
Clin Cancer Res. 2005 Jun 1;11(11):4198-203
[
15930357.001
]
[Cites]
Tumour Biol. 2005 Jul-Aug;26(4):201-6
[
16006777.001
]
[Cites]
N Engl J Med. 2005 Dec 8;353(23):2477-90
[
16339096.001
]
[Cites]
Am J Med Sci. 2006 Mar;331(3):119-23
[
16538071.001
]
[Cites]
Clin Calcium. 2006 Apr;16(4):665-69
[
16582519.001
]
[Cites]
Kidney Int Suppl. 2006 Jul;(102):S29-33
[
16810307.001
]
[Cites]
Endocr Pract. 2006 Sep-Oct;12(5):535-41
[
17002928.001
]
[Cites]
Semin Oncol. 2006 Oct;33(5):527-33
[
17045081.001
]
[Cites]
N Engl J Med. 2000 Jan 20;342(3):177-85
[
10639544.001
]
[Cites]
Int J Urol. 2000 Jun;7(6):239-42
[
10843457.001
]
[Cites]
Clin Chim Acta. 2000 Dec;302(1-2):59-68
[
11074064.001
]
[Cites]
Prog Urol. 2001 Apr;11(2):368-75
[
11400511.001
]
[Cites]
Urol Int. 2002;68(3):202-3
[
11919470.001
]
[Cites]
Mil Med. 2002 Dec;167(12):986-9
[
12502172.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Apr;88(4):1603-9
[
12679445.001
]
[Cites]
Endocr Relat Cancer. 2003 Sep;10(3):403-7
[
14503917.001
]
[Cites]
Curr Opin Urol. 2003 Nov;13(6):433-8
[
14560134.001
]
[Cites]
Endocrinology. 1970 Jun;86(6):1436-40
[
4315103.001
]
[Cites]
N Engl J Med. 1974 Jun 11;291(2):83-5
[
4835887.001
]
[Cites]
J Clin Endocrinol Metab. 1975 Jul;41(1):164-7
[
1150858.001
]
[Cites]
J Urol. 1977 Nov;118(5):720-3
[
916087.001
]
[Cites]
Eur J Clin Invest. 1978 Dec;8(6):425-6
[
217693.001
]
[Cites]
Cancer. 1980 May 15;45(10):2652-4
[
6155196.001
]
[Cites]
J Clin Endocrinol Metab. 1982 Aug;55(2):219-27
[
7085851.001
]
[Cites]
Am J Med. 1982 Nov;73(5):751-5
[
6291389.001
]
[Cites]
J Surg Oncol. 1983 Apr;22(4):265-8
[
6601207.001
]
[Cites]
Clin Endocrinol (Oxf). 1986 Jan;24(1):57-62
[
3085989.001
]
[Cites]
Science. 1987 Aug 21;237(4817):893-6
[
3616618.001
]
[Cites]
Urology. 1989 Mar;33(3):167-70
[
2521966.001
]
[Cites]
Endocrinology. 1997 May;138(5):1879-85
[
9112382.001
]
[Cites]
Bone. 1998 Mar;22(3):285-8
[
9514222.001
]
[Cites]
Mayo Clin Proc. 1990 Nov;65(11):1399-407
[
1700240.001
]
[Cites]
J Urol. 1991 Feb;145(2):248-50
[
1988711.001
]
[Cites]
Crit Rev Diagn Imaging. 1990;31(1):81-115
[
2288659.001
]
[Cites]
J Biol Chem. 1992 Sep 5;267(25):18236-43
[
1517251.001
]
[Cites]
Cancer. 1993 Feb 15;71(4):1309-12
[
8382106.001
]
[Cites]
Arch Intern Med. 1993 Sep 13;153(17):2043-5
[
8357289.001
]
[Cites]
Urology. 1993 Sep;42(3):250-7; discussion 257-8
[
8379024.001
]
[Cites]
N Engl J Med. 1996 Sep 19;335(12):865-75
[
8778606.001
]
[Cites]
Semin Urol Oncol. 1996 Nov;14(4):216-22
[
8946620.001
]
[Cites]
Cancer. 1999 Sep 15;86(6):1028-34
[
10491530.001
]
(PMID = 17443359.001).
[ISSN]
1525-1497
[Journal-full-title]
Journal of general internal medicine
[ISO-abbreviation]
J Gen Intern Med
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Interleukin-6; 0 / PTH1R protein, human; 0 / Parathyroid Hormone; 0 / Receptor, Parathyroid Hormone, Type 1
[Number-of-references]
48
[Other-IDs]
NLM/ PMC2219737
48.
Bukowski RM:
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Clin Genitourin Cancer
; 2009 Jan;7(1):9-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Tyrosine kinase inhibitors in advanced
renal cell carcinoma
: the evolving treatment paradigm.
[MeSH-major]
Carcinoma
,
Renal Cell
/ drug therapy.
Kidney
Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
Hazardous Substances Data Bank.
NICOTINAMIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Clin Genitourin Cancer. 2009 Jan;7(1):20-3
[
19213663.001
]
[CommentOn]
Clin Genitourin Cancer. 2009 Jan;7(1):11-9
[
19213662.001
]
(PMID = 19213661.001).
[ISSN]
1558-7673
[Journal-full-title]
Clinical genitourinary cancer
[ISO-abbreviation]
Clin Genitourin Cancer
[Language]
eng
[Publication-type]
Comment; Editorial
[Publication-country]
United States
[Chemical-registry-number]
0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Protein-Tyrosine Kinases
49.
Park H, Byun SS, Kim HH, Lee SB, Kwon TG, Jeon SH, Kang SH, Seo SI, Oh TH, Jeon YS, Lee W, Hwang TK, Rha KH, Seo IY, Kwon DD, Kim YJ, Choi Y, Park SK:
Comparison of laparoscopic and open partial nephrectomies in t1a renal cell carcinoma: a korean multicenter experience.
Korean J Urol
; 2010 Jul;51(7):467-71
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparison of laparoscopic and open partial nephrectomies in t1a
renal cell carcinoma
: a korean multicenter experience.
PURPOSE: We analyzed a series of patients who had undergone laparoscopic partial nephrectomies (LPNs) and open partial nephrectomies (OPNs) to compare outcomes of the two procedures in patients with pathologic T1a
renal cell carcinomas
(
RCCs
).
MATERIALS AND METHODS: From January 1998 to May 2009, 417 LPNs and 345 OPNs were performed on patients with small
renal tumors
in 15 institutions in Korea.
Of the patients, 273 and 279 patients, respectively, were confirmed to have pT1a
RCC
.
Although the
tumor
location was more exophytic (51% vs. 44%, p=0.047) and smaller (2.1 cm vs. 2.3 cm, p=0.026) in the LPN cohort, the OPN cohort demonstrated shorter ischemia times (23.4 min vs. 33.3 min, p<0.001).
The LPN may be an acceptable surgical option in patients with small
RCC
in Korea.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Curr Opin Urol. 2003 May;13(3):209-14
[
12692443.001
]
[Cites]
Urology. 2003 Jan;61(1):73-7
[
12559270.001
]
[Cites]
Ann Intern Med. 2003 Jul 15;139(2):137-47
[
12859163.001
]
[Cites]
J Urol. 2004 Jun;171(6 Pt 1):2181-5, quiz 2435
[
15126781.001
]
[Cites]
Urology. 2004 Jul;64(1):38-42
[
15245930.001
]
[Cites]
J Urol. 2004 Dec;172(6 Pt 1):2292-5
[
15538251.001
]
[Cites]
J Endourol. 2005 Apr;19(3):406-9
[
15865537.001
]
[Cites]
BJU Int. 2005 Oct;96(6):811-4
[
16153207.001
]
[Cites]
BJU Int. 2007 Feb;99(2):286-9
[
17155985.001
]
[Cites]
J Urol. 2007 Jan;177(1):70-4; discussion 74
[
17162003.001
]
[Cites]
J Urol. 2007 Jun;177(6):2067-73; discussion 2073
[
17509287.001
]
[Cites]
J Urol. 2007 Jul;178(1):41-6
[
17574056.001
]
[Cites]
Eur Urol. 2008 Mar;53(3):590-6
[
17997214.001
]
[Cites]
J Urol. 2008 Mar;179(3):847-51; discussion 852
[
18221958.001
]
[Cites]
Eur Urol. 2008 Apr;53(4):732-42; discussion 742-3
[
18222599.001
]
[Cites]
Curr Opin Urol. 2008 Mar;18(2):145-9
[
18303534.001
]
[Cites]
J Endourol. 2008 May;22(5):953-7
[
18363510.001
]
[Cites]
Eur Urol. 2009 May;55(5):1171-8
[
19232819.001
]
[Cites]
J Am Soc Nephrol. 2009 Nov;20(11):2305-13
[
19833901.001
]
[Cites]
J Urol. 1996 Jun;155(6):1868-73
[
8618276.001
]
[Cites]
J Urol. 1999 Jan;161(1):33-4; discussion 34-5
[
10037361.001
]
[Cites]
J Clin Oncol. 1999 Sep;17(9):2868-75
[
10561364.001
]
[Cites]
J Urol. 2000 Feb;163(2):442-5
[
10647650.001
]
[Cites]
J Urol. 2001 Jul;166(1):6-18
[
11435813.001
]
[Cites]
J Urol. 2002 Feb;167(2 Pt 1):469-7; discussion 475-6
[
11792899.001
]
[Cites]
Urology. 2003 May;61(5):906-9
[
12736001.001
]
(PMID = 20664779.001).
[ISSN]
2005-6745
[Journal-full-title]
Korean journal of urology
[ISO-abbreviation]
Korean J Urol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Korea (South)
[Other-IDs]
NLM/ PMC2907495
[Keywords]
NOTNLM ; Glomerular filtration rate / Kidney neoplasms / Nephrectomy / Outcomes assessment
50.
Volmar KE, Cummings TJ, Wang WH, Creager AJ, Tyler DS, Xie HB:
Clear cell hidradenoma: a mimic of metastatic clear cell tumors.
Arch Pathol Lab Med
; 2005 May;129(5):e113-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clear
cell
hidradenoma: a mimic of metastatic clear
cell tumors
.
Clear
cell
hidradenoma is a benign skin appendage
tumor
that may mimic conventional-type
renal cell carcinoma
.
Histologically, clear
cell
hidradenoma contains small ductular lumens, focal apocrine and squamoid change, and a less prominent vascular pattern than
renal cell carcinoma
.
Furthermore, immunohistochemical studies can aid in distinguishing the 2
tumors
.
Detailed clinical history, physical findings, and ancillary studies are essential for correct
diagnosis
and categorization of these
tumors
.
We report the rare case of a patient with
renal cell carcinoma
who underwent excision of an axillary clear
cell
hidradenoma, which was clinically suggestive of cutaneous metastatic
disease
.
[MeSH-major]
Adenoma, Sweat Gland /
diagnosis
.
Carcinoma
,
Renal Cell
/
diagnosis
.
Kidney
Neoplasms /
diagnosis
. Neoplasms, Multiple Primary /
diagnosis
. Sweat Gland Neoplasms /
diagnosis
[MeSH-minor]
Axilla. Biomarkers,
Tumor
/ analysis.
Diagnosis
, Differential. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymph Nodes / surgery. Male. Middle Aged. Mitotic Index. Neoplasm Metastasis /
diagnosis
. Treatment Outcome
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15859654.001).
[ISSN]
1543-2165
[Journal-full-title]
Archives of pathology & laboratory medicine
[ISO-abbreviation]
Arch. Pathol. Lab. Med.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor
51.
Jeong SJ, Kim KT, Chung MS, Hong SK, Byun SS, Lee SE:
The prognostic value of the width of the surgical margin in the enucleoresection of small renal cell carcinoma: an intermediate-term follow-up.
Urology
; 2010 Sep;76(3):587-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The prognostic value of the width of the surgical margin in the enucleoresection of small
renal cell carcinoma
: an intermediate-term follow-up.
OBJECTIVES: To assess the prognostic value of the width of a healthy surgical margin in the enucleoresection of small
renal cell carcinoma
, in which 68% of cases had a margin width of 3.0 mm or less.
METHODS: We retrospectively reviewed 98 consecutive enucleoresections regarding the width of healthy margin and
tumor
recurrence in 96 patients followed up for more than 3 years after surgery.
RESULTS: The mean
tumor
size was 2.8 cm (range, 1.0-6.1).
Only 1 patient developed
tumor
recurrence during follow-up, excluding a patient with von Hippel Lindau
disease
.
CONCLUSIONS: The width of the surgical margin was not associated with the oncological prognosis in our enucleoresection series of small
renal cell carcinoma
, in which the width of the margin was 3.0 mm or less in more than two-thirds of the cases.
[MeSH-major]
Carcinoma
,
Renal Cell
/ pathology.
Carcinoma
,
Renal Cell
/ surgery.
Kidney
Neoplasms / pathology.
Kidney
Neoplasms / surgery
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier Inc. All rights reserved.
(PMID = 20346491.001).
[ISSN]
1527-9995
[Journal-full-title]
Urology
[ISO-abbreviation]
Urology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
52.
Wells GM, Schroth W, Brauch H, Ross EA:
Bilateral renal-cell carcinoma associated with an acquired VHL mutation and long-term trichloroethylene exposure.
Clin Nephrol
; 2009 Jun;71(6):708-13
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Bilateral
renal
-
cell carcinoma
associated with an acquired VHL mutation and long-term trichloroethylene exposure.
BACKGROUND/AIMS: The genetic basis for clear-
cell renal carcinomas
has been established in familial and many sporadic forms.
METHODS: PCR amplification and sequencing of VHL exons 1 - 3 were performed on peripheral blood and
tumor
tissue.
RESULTS: The
tumor
alone had a previously undescribed mutation in exon 1 of the VHL gene: deletion of a cytidine residue at position 291 relative to the first ATG start codon of the wild-type sequence.
There is loss of suppressor function when substrates such as hypoxia-inducible factor have impaired degradation: they accumulate and ultimately cause uncontrolled
cell
turnover.
This association of a proposed occupational cause and occurrence of
renal
-
cell carcinoma
emphasizes the availability and use of VHL sequencing for both studying the pathophysiology of
malignant
transformation and potentially playing a clinical role in genetic counseling or risk assessment.
[MeSH-major]
Carcinoma
,
Renal Cell
/ genetics.
Kidney
Neoplasms / genetics. Mutation. Occupational Exposure / adverse effects. Solvents / adverse effects. Trichloroethylene / adverse effects
[MeSH-minor]
Humans.
Kidney
/ pathology. Male. Middle Aged. Nephrectomy. Tomography, X-Ray Computed. Von Hippel-Lindau
Tumor
Suppressor Protein / genetics
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
MedlinePlus Health Information.
consumer health - Occupational Health
.
Hazardous Substances Data Bank.
Trichloroethylene
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19473641.001).
[ISSN]
0301-0430
[Journal-full-title]
Clinical nephrology
[ISO-abbreviation]
Clin. Nephrol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Solvents; 290YE8AR51 / Trichloroethylene; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
53.
Thompson RH, Kwon ED:
Significance of B7-H1 overexpression in kidney cancer.
Clin Genitourin Cancer
; 2006 Dec;5(3):206-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Significance of B7-H1 overexpression in
kidney
cancer
.
B7-H1 is
a cell
surface glycoprotein belonging to the B7 family of costimulatory molecules.
Constitutive protein expression is restricted to a fraction of macrophage-lineage
cells
, although B7-H1 can be induced on activated T lymphocytes.
In addition, some human
tumor cells
can acquire the ability to aberrantly express B7-H1.
In vitro studies demonstrate that B7-H1, expressed by
tumor cells
or activated lymphocytes, impairs T-
cell
function and survival and enhances apoptosis of activated
tumor
-specific T
cells
.
Consistent with this, in vivo monoclonal antibody blockade of B7-H1 has been shown to potentiate antitumor responses in several murine
cancer
models.
Thus,
tumor
-associated B7-H1 has recently garnered much attention as a potential inhibitor of host antitumor immunity.
We describe herein the published investigations looking at the role of B7-H1 in
renal cell carcinoma
(
RCC
).
Clinical observations demonstrate that B7-H1 is aberrantly expressed in primary and metastatic
RCC
.
All patients had clear-
cell RCC
, and pathologic evaluation was performed by a single urologic pathologist.
Their results demonstrated that B7-H1, expressed by
tumor cells
or lymphocytes, is associated with aggressive pathologic features, including TNM
stage
, nuclear grade,
tumor
size, and coagulative necrosis.
With a median clinical follow-up of 11 years, patients with
tumor
B7-H1 were at significant risk of
disease
progression,
cancer
-specific death, and overall mortality even after multivariate analyses.
Five-year
cancer
-specific survival rates were 42% and 83% for patients with and without
tumor
B7-H1, respectively.
The basis for these associations could relate to the recognized ability of B7-H1 to inhibit antitumor T-
cell
-mediated immunity.
Based on the current literature, B7-H1 is an independent predictor of prognosis in
RCC
and represents a promising target for immune manipulation in this refractory
tumor
.
[MeSH-major]
Antigens, CD / metabolism.
Carcinoma
,
Renal Cell
/
diagnosis
.
Kidney
Neoplasms /
diagnosis
Genetic Alliance.
consumer health - Kidney cancer
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17239274.001).
[ISSN]
1558-7673
[Journal-full-title]
Clinical genitourinary cancer
[ISO-abbreviation]
Clin Genitourin Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD; 0 / Antigens, CD274; 0 / CD274 protein, human
[Number-of-references]
39
54.
Kavanagh E, Buchert M, Tsapara A, Choquet A, Balda MS, Hollande F, Matter K:
Functional interaction between the ZO-1-interacting transcription factor ZONAB/DbpA and the RNA processing factor symplekin.
J Cell Sci
; 2006 Dec 15;119(Pt 24):5098-105
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We demonstrate that ZONAB/DbpA and symplekin form
a complex
in
kidney
and intestinal epithelial
cells
that can be immunoprecipitated and that exists in the nucleus.
RNAi experiments indicate that symplekin depletion reduces the nuclear accumulation and the transcriptional activity of ZONAB/DbpA in colon
adenocarcinoma
cells
, resulting in inhibition of proliferation and reduced expression of the ZONAB/DbpA-target gene cyclin D1.
[MeSH-minor]
Animals. Caco-2
Cells
.
Cell
Line.
Cell
Line,
Tumor
. Dogs. Epithelial
Cells
/ metabolism. Fluorescent Antibody Technique. Humans. Immunoprecipitation. Protein Binding. RNA Interference.
Receptor
, ErbB-2 / genetics.
Receptor
, ErbB-2 / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tight Junctions / genetics. Tight Junctions / metabolism. Zonula Occludens-1 Protein
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17158914.001).
[ISSN]
0021-9533
[Journal-full-title]
Journal of cell science
[ISO-abbreviation]
J. Cell. Sci.
[Language]
eng
[Grant]
United Kingdom / Wellcome Trust / / 063661; United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/C514458/1; United Kingdom / Wellcome Trust / / 066100; United Kingdom / Medical Research Council / / G0100200; United Kingdom / Medical Research Council / / G0400678
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA-Binding Proteins; 0 / Membrane Proteins; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / SYMPK protein, human; 0 / TJP1 protein, human; 0 / Transcription Factors; 0 / ZONAB protein, Canis familiaris; 0 / Zonula Occludens-1 Protein; EC 2.7.10.1 / Receptor, ErbB-2
55.
Ficarra V, Guillè F, Schips L, de la Taille A, Prayer Galetti T, Tostain J, Cindolo L, Novara G, Zigeuner R, Bratti E, Li G, Altieri V, Abbou CC, Zanolla L, Artibani W, Patard JJ:
Proposal for revision of the TNM classification system for renal cell carcinoma.
Cancer
; 2005 Nov 15;104(10):2116-23
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Proposal for revision of the TNM classification
system
for
renal cell carcinoma
.
BACKGROUND: The current study defined an optimal
tumor
size breakpoint to stratify localized
renal cell carcinoma
(
RCC
) into groups with significantly different
cancer
-related outcomes and proposed a revision of the TNM classification
system
.
METHODS: The authors analyzed the data from 1138 patients who had undergone partial or radical nephrectomy for localized
RCC
at 7 European urologic
centers
.
The scatterplot of
tumor
size versus expected risk of death per patient suggested that an interval of 5-6 cm was appropriate.
A total of 720 (63.3%) and 418 (36.7%) patients had
tumors
measuring < or = 5.5-cm and
tumors
measuring > 5.5-cm, respectively.
Significant
cancer
-specific survival differences between the two groups of patients were reported in the series by all the
centers
participating in the study.
On univariate analysis, the other variables found to be associated with
cancer
-specific survival were the patient's age, symptomatic
tumor
presentation, and the Fuhrman nuclear grade.
On multivariate analysis, the pathologic
stage
of the primary
tumor
defined according to the 5.5-cm breakpoint was found to be an independent predictor of
cancer
-specific survival, as well as age, mode of presentation, and nuclear grade.
1) patients with < or = 5.5-cm incidentally detected
RCC
;.
2) patients with < or = 5.5-cm symptomatic
RCC
; and 3) patients with > 5.5-cm
RCC
.
This
cancer
-related outcome stratification was valid regardless of the patient's age.
CONCLUSIONS: The 5.5-cm breakpoint was found to be the optimal
tumor
size breakpoint with which to stratify patients with organ-confined
RCC
.
The study supported the upgrade of the TNM classification
system
according to this breakpoint.
[MeSH-major]
Carcinoma
,
Renal Cell
/ classification.
Carcinoma
,
Renal Cell
/ pathology.
Kidney
Neoplasms / classification.
Kidney
Neoplasms / pathology
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2005 American Cancer Society
(PMID = 16208703.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
United States
56.
Otgün I, Arda IS, Haberal N, Güney H, Hiçsönmez A:
Renal cell carcinoma: case report and literature review.
J Pediatr Surg
; 2005 May;40(5):e13-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Renal cell carcinoma
: case report and literature review.
Renal cell carcinoma
arising from epithelial
cells
of the
renal
tubule is a highly aggressive and
malignant tumor
in all ages.
Tumor
is presented with characteristic findings of flank pain, gross hematuria, and palpable mass.
Although one half of the patients have metastasis at the time of
diagnosis
, most cases are currently being incidentally detected using improved imaging techniques.
Tumor stage
and complete surgical resection have been reported as the most meaningful prognostic factors for the outcome.
The incidence of metastatic
disease
is same as in adults.
Cure is the most likely consequence in localized and completely resected
tumors
.
Here, we present an 8-year-old boy with
renal cell carcinoma
demonstrating only hematuria without any pathological physical examination findings.
The mass was described by abdominal ultrasonography and computed tomography in the left
kidney
.
[MeSH-major]
Carcinoma
,
Renal Cell
/ surgery.
Kidney
Neoplasms / surgery
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15937800.001).
[ISSN]
1531-5037
[Journal-full-title]
Journal of pediatric surgery
[ISO-abbreviation]
J. Pediatr. Surg.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Number-of-references]
30
57.
Roy S, Chu A, Trojanowski JQ, Zhang PJ:
D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas.
Acta Neuropathol
; 2005 May;109(5):497-502
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from
renal cell carcinomas
.
Hemangioblastomas (HB) are characterized by the presence of vacuolated
tumor cells
resembling the
tumor cells
seen in clear
cell renal cell carcinomas
(CRCC).
The issue is further complicated by the possibility of both HB and metastatic CRCC in brains of patients with Von Hippel Lindau (VHL)
disease
.
The vacuolated
tumor cells
in all HB were stained positively with D2-40.
Nineteen of 23 (83%) HB showed strong, membranous staining in the vacuolated
tumor cells
, and 4 of 23 (17%) showed weaker staining.
No expression was seen in CRCC, either primary in
the kidney
(0/20), or metastatic CRCC in the brain (0/8).
Three of the patients with HB also had VHL
disease
, and no difference was seen in D2-40 staining of HB in patients with or without VHL
disease
.
Two of these three VHL
disease
patients had both primary CRCC and HB resected at our institution.
In these two patients, strong D2-40 expression was seen in the HB, but no expression was seen in the CRCC, underlying the utility of this marker in distinguishing HB from CRCC in patients with VHL
disease
in addition to sporadic cases.
[MeSH-major]
Antibodies, Monoclonal. Antigens, Neoplasm / immunology. Biomarkers,
Tumor
/ metabolism.
Carcinoma
,
Renal Cell
/ metabolism. Hemangioblastoma / metabolism
[MeSH-minor]
Adult. Aged. Female. Humans. Immunohistochemistry / methods. Inhibins / metabolism. Male. Middle Aged. Staining and Labeling / methods. von Hippel-Lindau
Disease
/
diagnosis
. von Hippel-Lindau
Disease
/ metabolism
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15864611.001).
[ISSN]
0001-6322
[Journal-full-title]
Acta neuropathologica
[ISO-abbreviation]
Acta Neuropathol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / oncofetal antigens; 57285-09-3 / Inhibins
58.
Xu WG, Dai D, Fang N, Song XY, Wang J, Zhu YJ, Men XY:
[Molecular imaging for PET-CT reporter gene in breast adenocarcinoma (HSV1-tk) of subcutaneous xenografts in living nude mice].
Zhonghua Yi Xue Za Zhi
; 2009 Dec 29;89(48):3420-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Molecular imaging for PET-CT reporter gene in breast
adenocarcinoma
(HSV1-tk) of subcutaneous xenografts in living nude mice].
OBJECTIVE: To study the in vitro accumulation of (18)F-FHBG, its in vivo distribution and (18)F-FHBG PET-CT imaging for reporter gene (HSV1-tk) in nude mice with a xenograft of breast
adenocarcinoma
.
METHODS: The in vitro uptake of (18)F-FHBG in
tumor cells
of T47D and T47D-tk and the distribution of (18)F-FHBG in normal Kunming mice and nude mice with breast
adenocarcinoma
xenograft were detected by well-type gamma counter.
Reporter gene PET-CT imaging with (18)F-FHBG was performed in nude mice with a xenograft of breast
adenocarcinoma
.
RESULTS: The in vitro uptake of (18)F-FHBG in T47D-tk
cells
(143.67 dpm/10(4) +/- 5.82 dpm/10(4)
cells
) was significantly higher than that in T47D
cells
(2.23 dpm/10(4) +/- 0.23 dpm/10(4)
cells
) at 60 and 120 min post-injection (P < 0.001) and reaches a plateau at 60 min.
In normal Kunming mice, (18)F-FHBG was mainly distributed in liver, intestine,
kidney
and bladder while there was no obvious radioactive accumulation in brain. (18)F-FHBG accumulated at a significantly higher level in T47D-tk
tumors
than in T47D
tumors
and its accumulation yielded the best image effect at 2 h by PET-CT imaging in nude mice.
CONCLUSION: The in vitro uptake of (18)F-FHBG in T47D-tk
cells
is significantly higher than that in T47D
cells
. (18)F-FHBG is mainly excreted by digestive tract and urinary tract in mice.
This study will offer a monitoring method and scientific base for (18)F-FHBG reporter gene imaging and HSV1-tk gene therapy in
tumors
.
[MeSH-major]
Adenocarcinoma
/ radionuclide imaging. Breast Neoplasms / radionuclide imaging. Genes, Reporter. Positron-Emission Tomography
[MeSH-minor]
Animals.
Cell
Line,
Tumor
. Female. Fluorine Radioisotopes. Genetic Therapy. Guanine / analogs & derivatives. Humans. Mice. Mice, Inbred BALB C. Mice, Inbred Strains. Mice, Nude. Neoplasm Transplantation
MedlinePlus Health Information.
consumer health - Breast Cancer
.
Hazardous Substances Data Bank.
GUANINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20223118.001).
[ISSN]
0376-2491
[Journal-full-title]
Zhonghua yi xue za zhi
[ISO-abbreviation]
Zhonghua Yi Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / 9-(4-fluoro-3-hydroxymethylbutyl)guanine; 0 / Fluorine Radioisotopes; 5Z93L87A1R / Guanine
59.
Kawata N, Nagane Y, Yamaguchi K, Ichinose T, Hirakata H, Takahashi S:
How do symptoms have an impact on the prognosis of renal cell carcinoma?
Int J Urol
; 2008 Apr;15(4):299-303
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
How do symptoms have an impact on the prognosis of
renal cell carcinoma
?
AIM: Symptomatic
renal cell carcinoma
(
RCC
) is well known to have a characteristic behavior.
We therefore evaluated the impact of systemic symptoms on the prognosis of
RCC
.
METHODS: Patard's criteria were used to classify symptoms before operation into three groups defined as: S1 (incidental
tumor
), S2 (localized symptoms) and S3 (systemic symptoms).
Selected clinicopathological factors including gender, maximum
tumor
diameter, clinical
stage
, hemoglobin, C-reactive protein (CRP) and immunosuppressive acidic protein, nuclear grade and venous invasion were measured preoperatively in 252 patients.
To determine impacts of them on the prognosis of
RCC
, we compared quantitative results using Cox multivariate analysis.
RESULTS: The
cancer
-specific five-year survival rates were 93.1%, 71.0%, and 20.2% for S1 (144 patients), S2 (80 patients) and S3 (28 patients), respectively (P < 0.0001).
[MeSH-major]
Carcinoma
,
Renal Cell
/
diagnosis
.
Kidney
Neoplasms /
diagnosis
[MeSH-minor]
Aged. Biomarkers,
Tumor
/ blood. C-Reactive Protein / metabolism. Female. Hemoglobins / metabolism. Humans.
Kidney
/ pathology. Male. Middle Aged. Neoplasm Proteins / blood. Prognosis. Retrospective Studies
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18380815.001).
[ISSN]
1442-2042
[Journal-full-title]
International journal of urology : official journal of the Japanese Urological Association
[ISO-abbreviation]
Int. J. Urol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Australia
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Hemoglobins; 0 / Neoplasm Proteins; 0 / immunosuppressive acidic protein; 9007-41-4 / C-Reactive Protein
60.
Lu HS, Saito Y, Umeda M, Murata-Kamiya N, Zhang HM, Higashi H, Hatakeyama M:
Structural and functional diversity in the PAR1b/MARK2-binding region of Helicobacter pylori CagA.
Cancer Sci
; 2008 Oct;99(10):2004-11
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Helicobacter pylori (H. pylori) cagA-positive strains are associated with gastritis, peptic ulcerations, and gastric
adenocarcinoma
.
Upon delivery into gastric epithelial
cells
, the cagA-encoded CagA protein specifically binds and aberrantly activates SHP-2 oncoprotein in a manner that is dependent on CagA tyrosine phosphorylation.
CagA-deregulated SHP-2 then elicits aberrant Erk activation while causing an elongated
cell
shape known as the hummingbird phenotype.
In polarized epithelial
cells
, CagA also binds to PAR1b/MARK2 and inhibits the PAR1b kinase activity, thereby disrupting tight junctions and epithelial
cell
polarity independent of CagA tyrosine phosphorylation.
We show here that the CagA-multimerization (CM) sequence that mediates interaction of CagA with PAR1b is not only essential for the CagA-triggered junctional defects but also plays an important role in induction of the hummingbird phenotype by potentiating CagA-SHP-2
complex
formation.
[MeSH-minor]
Adenoviridae / genetics. Amino Acid Sequence. Animals. COS
Cells
.
Cell
Line.
Cell
Polarity. Cercopithecus aethiops. Dogs. Epithelial
Cells
/ cytology. Epithelial
Cells
/ metabolism. Epithelial
Cells
/ physiology. Genetic Vectors. Humans.
Kidney
/ cytology. Molecular Sequence Data. Mutation. Phosphorylation. Protein Tyrosine Phosphatase,
Non
-
Receptor
Type 11 / metabolism. Stomach / cytology. Tight Junctions / metabolism. Transduction, Genetic. Transfection. Virulence / genetics
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19016760.001).
[ISSN]
1349-7006
[Journal-full-title]
Cancer science
[ISO-abbreviation]
Cancer Sci.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Bacterial Proteins; 0 / Calgranulin A; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11
61.
Crépel M, Jeldres C, Perrotte P, Capitanio U, Isbarn H, Shariat SF, Liberman D, Sun M, Lughezzani G, Arjane P, Widmer H, Graefen M, Montorsi F, Patard JJ, Karakiewicz PI:
Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment.
Urology
; 2010 Feb;75(2):271-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0
renal cell carcinoma
: a population-based assessment.
OBJECTIVES: To test the effect of nephron-sparing surgery (NSS) vs radical nephrectomy (
RN
) on
cancer
-specific mortality (CSM) in patients with T1bN0M0
renal cell carcinoma
(
RCC
) in a population-based cohort.
To date, only few series from tertiary care
centers
supported the use of NSS for T1bN0M0 (range 4-7 cm)
RCC
.
METHODS: The Surveillance, Epidemiology, and End Results database allowed us to identify 275 NSS (5.3%) and 4866
RN
(94.7%) patients treated for T1bN0M0
RCC
between 1988 and 2004.
Analyses matched for age, year of surgery,
tumor
size, and Fuhrman grade addressed the effect of nephrectomy type (NSS vs
RN
) on CSM.
RESULTS: Five years after surgery, the surviving proportions of NSS and
RN
patients matched for age,
tumor
size, and year of surgery were respectively 91.4 and 95.3% and 90.1 and 93.8% in the cohort, where additional matching for Fuhrman grade was performed.
Neither of the matched analyses resulted in statistically significant CSM difference (P = .1 and .4) between NSS and
RN
.
CONCLUSIONS: Our study represents the largest and the only population-based analysis of
cancer control
efficacy of NSS vs
RN
in T1bN0M0
RCC
.
It indicates that NSS does provide equivalent
cancer control
relative to
RN
.
In consequence, based on
cancer control
equivalence, NSS should be given equal consideration to
RN
in patients with T1bN0M0 lesions.
[MeSH-major]
Carcinoma
,
Renal Cell
/ pathology.
Carcinoma
,
Renal Cell
/ surgery.
Kidney
Neoplasms / pathology.
Kidney
Neoplasms / surgery. Nephrectomy / methods
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Crown Copyright 2010. Published by Elsevier Inc. All rights reserved.
[CommentIn]
Urology. 2010 Feb;75(2):275-6; author reply 276
[
20152477.001
]
(PMID = 19962740.001).
[ISSN]
1527-9995
[Journal-full-title]
Urology
[ISO-abbreviation]
Urology
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
62.
Dillman RO, Wiemann MC, Tai DF, Depriest CB, Soori G, Stark JJ, Mahdavi K, Church CK:
Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09.
Cancer Biother Radiopharm
; 2006 Apr;21(2):130-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of
renal cell carcinoma
: final results of
Cancer
Biotherapy Research Group 95-09.
OBJECTIVE: We conducted a phase II trial in metastatic
renal cell cancer
of outpatient subcutaneous (s.c.) interferon-alpha2b (IFN), followed by an inpatient hybrid schedule of bolus and continuous interleukin-2 (IL- 2).
Sites of
disease
included 26 lung, 13 lymph node, 9 bone, 8 liver, 4
kidney
, and 4 adrenal locations.
RESULTS: There was 1 complete and 3 partial responses, for a response rate of 11% (3% to 27%; 95% confidence interval [CI]); 40% had stable
disease
.
The most frequent grade 3 or 4 toxicities were 11% fatigue, 9%
renal
insufficiency, and 7% hypotension.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / administration & dosage.
Carcinoma
,
Renal Cell
/ drug therapy.
Kidney
Neoplasms / drug therapy
Genetic Alliance.
consumer health - Kidney cancer
.
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16706633.001).
[ISSN]
1084-9785
[Journal-full-title]
Cancer biotherapy & radiopharmaceuticals
[ISO-abbreviation]
Cancer Biother. Radiopharm.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
63.
Kanda S, Miyata Y, Kanetake H:
Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.
Int J Clin Oncol
; 2006 Apr;11(2):90-107
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Current status and perspective of antiangiogenic therapy for
cancer
: urinary
cancer
.
Angiogenesis is considered a prerequisite for solid
tumor
growth.
Antiangiogenic therapy reduces
tumor
size and extends host survival in a number of preclinical animal models.
However, in humans antiangiogenic therapy is a poor promoter of
tumor
regression and has shown minimal effect on patient survival.
In urinary
cancers
, such as
renal cell cancer
, prostate
cancer
, and bladder
cancer
, advanced refractory
disease
is a good candidate for antiangiogenic therapy because of its resistance to ordinary chemotherapy, radiotherapy, and hormonal therapy.
Unique characteristics of molecular mechanisms underlie the induction of angiogenesis in urinary
cancers
.
In this review, we summarize these unique mechanisms and review the results of clinical trials of antiangiogenic therapy for these
cancers
, discussing prospects and problems relating to antiangiogenic therapy.
[MeSH-major]
Angiogenesis Inhibitors / therapeutic use. Neovascularization, Pathologic / prevention &
control
. Urogenital Neoplasms / blood supply. Vascular Endothelial Growth Factor A / antagonists & inhibitors
[MeSH-minor]
Humans. Lymphangiogenesis / drug effects. Male. Neoplasm Metastasis / prevention &
control
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer. 2002 Aug 15;95(4):758-65
[
12209719.001
]
[Cites]
Cancer Chemother Pharmacol. 1999;43 Suppl:S78-84
[
10357564.001
]
[Cites]
Cancer Cell. 2005 Oct;8(4):299-309
[
16226705.001
]
[Cites]
Cancer Res. 1989 Jun 15;49(12):3407-11
[
2720695.001
]
[Cites]
Cancer Res. 1990 Apr 15;50(8):2530-7
[
1690599.001
]
[Cites]
J Clin Oncol. 2005 Jun 1;23(16):3726-32
[
15923569.001
]
[Cites]
Biochem Biophys Res Commun. 1994 Nov 15;204(3):1067-73
[
7980579.001
]
[Cites]
Cancer Res. 2004 Oct 1;64(19):7099-109
[
15466206.001
]
[Cites]
Cancer Res. 1994 Sep 15;54(18):4855-78
[
8069852.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1307-11
[
7533291.001
]
[Cites]
Biochem Biophys Res Commun. 2003 Mar 21;302(4):892-7
[
12646256.001
]
[Cites]
Cancer Chemother Pharmacol. 2006 Apr;57(4):533-9
[
16052341.001
]
[Cites]
Cancer. 2000 Mar 1;88(5):1131-8
[
10699904.001
]
[Cites]
Oncogene. 2001 Nov 15;20(52):7610-23
[
11753639.001
]
[Cites]
Tohoku J Exp Med. 2001 Oct;195(2):101-13
[
11846206.001
]
[Cites]
Cancer. 1999 Aug 1;86(3):470-6
[
10430255.001
]
[Cites]
J Neurooncol. 2002 Jun;58(2):131-6
[
12164684.001
]
[Cites]
Br J Urol. 1994 Oct;74(4):416-21
[
7529632.001
]
[Cites]
J Biol Chem. 1988 Jan 15;263(2):988-93
[
2447083.001
]
[Cites]
J Natl Cancer Inst. 2000 Dec 6;92(23):1918-25
[
11106683.001
]
[Cites]
Clin Cancer Res. 2004 Nov 1;10(21):7112-20
[
15534081.001
]
[Cites]
Cancer Res. 1998 Jul 15;58(14):3028-31
[
9679967.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12 ):6099-103
[
9177176.001
]
[Cites]
Cancer Res. 1994 Aug 1;54(15):4233-7
[
7518352.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8
[
12177445.001
]
[Cites]
Urol Oncol. 2005 Mar-Apr;23(2):82-6
[
15869991.001
]
[Cites]
JAMA. 1965 Oct 25;194(4):345-50
[
5897417.001
]
[Cites]
Trends Cell Biol. 2005 Aug;15(8):434-41
[
16005628.001
]
[Cites]
Cancer. 2002 Oct 15;95(8):1629-36
[
12365009.001
]
[Cites]
Cancer Res. 2005 Jan 1;65(1):300-8
[
15665307.001
]
[Cites]
J Urol. 1990 Jun;143(6):1272-4
[
1692888.001
]
[Cites]
Cancer Cell. 2003 Apr;3(4):363-75
[
12726862.001
]
[Cites]
J Clin Oncol. 1997 May;15(5):1985-93
[
9164210.001
]
[Cites]
J Clin Oncol. 2002 Aug 15;20(16):3369-75
[
12177096.001
]
[Cites]
Endocr Relat Cancer. 2001 Sep;8(3):219-25
[
11566613.001
]
[Cites]
J Cell Sci. 1991 Mar;98 ( Pt 3):385-94
[
1829089.001
]
[Cites]
J Natl Cancer Inst. 1995 Nov 1;87(21):1603-12
[
7563203.001
]
[Cites]
Science. 2003 May 16;300(5622):1155-9
[
12750523.001
]
[Cites]
J Urol. 1998 Oct;160(4):1285-90
[
9751337.001
]
[Cites]
J Biol Chem. 2000 May 26;275(21):16091-7
[
10821861.001
]
[Cites]
J Biol Chem. 2001 Nov 23;276(47):43611-7
[
11574546.001
]
[Cites]
J Clin Oncol. 2002 Mar 1;20(5):1429-30
[
11870194.001
]
[Cites]
Oncogene. 1999 Apr 29;18(17):2755-61
[
10348350.001
]
[Cites]
EMBO J. 2001 Sep 3;20(17):4762-73
[
11532940.001
]
[Cites]
Anticancer Res. 2001 Jan-Feb;21(1A):77-88
[
11299793.001
]
[Cites]
Nat Med. 1995 Feb;1(2):149-53
[
7585012.001
]
[Cites]
J Urol. 2004 Jun;171(6 Pt 1):2171-5
[
15126779.001
]
[Cites]
J Biol Chem. 1996 Feb 16;271(7):3343-6
[
8631930.001
]
[Cites]
J Clin Oncol. 2005 Jan 20;23(3):455-60
[
15659491.001
]
[Cites]
J Clin Oncol. 2004 Aug 1;22(15):3003-15
[
15210739.001
]
[Cites]
Ann Oncol. 2002 Aug;13(8):1259-63
[
12181250.001
]
[Cites]
Cancer Res. 1993 May 15;53(10 Suppl):2239-48
[
8485709.001
]
[Cites]
J Cancer Res Clin Oncol. 2003 Jul;129(7):415-22
[
14605882.001
]
[Cites]
Biochem Biophys Res Commun. 1992 Mar 31;183(3):937-44
[
1567407.001
]
[Cites]
Science. 1994 Sep 9;265(5178):1582-4
[
7521539.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Dec 9;338(1):617-26
[
16139242.001
]
[Cites]
Anticancer Res. 1999 Sep-Oct;19(5C):4593-7
[
10650816.001
]
[Cites]
J Neurooncol. 1998 May;38(1):51-7
[
9540057.001
]
[Cites]
Endocr Rev. 2004 Aug;25(4):581-611
[
15294883.001
]
[Cites]
Nature. 1989 Apr 13;338(6216):557-62
[
2467210.001
]
[Cites]
J Cell Physiol. 1987 Jul;132(1):143-8
[
3496343.001
]
[Cites]
BJU Int. 2005 Mar;95(4):660-3
[
15705099.001
]
[Cites]
Pharmacol Rev. 2004 Sep;56(3):387-437
[
15317910.001
]
[Cites]
J Clin Oncol. 2004 Apr 1;22(7):1188-94
[
14981107.001
]
[Cites]
Cardiovasc Res. 2001 Feb 16;49(3):659-70
[
11166279.001
]
[Cites]
Cancer Sci. 2004 Nov;95(11):851-7
[
15546501.001
]
[Cites]
Clin Prostate Cancer. 2004 Dec;3(3):165-73
[
15636683.001
]
[Cites]
Clin Cancer Res. 2003 May;9(5):1741-9
[
12738729.001
]
[Cites]
Urol Oncol. 2001 Jul;6(4):145-148
[
11418320.001
]
[Cites]
Endocr Relat Cancer. 2004 Jun;11(2):255-63
[
15163301.001
]
[Cites]
Cancer Cell. 2004 Nov;6(5):507-16
[
15542434.001
]
[Cites]
Clin Cancer Res. 2001 Nov;7(11):3349-55
[
11705847.001
]
[Cites]
J Natl Cancer Inst. 2003 Mar 19;95(6):437-48
[
12644537.001
]
[Cites]
J Clin Oncol. 2005 Feb 10;23(5):1011-27
[
15585754.001
]
[Cites]
Br J Cancer. 2005 Sep 19;93(6):613-9
[
16222306.001
]
[Cites]
Oncogene. 2005 Aug 18;24(35):5510-20
[
15897888.001
]
[Cites]
Nature. 1990 Dec 6;348(6301):555-7
[
1701033.001
]
[Cites]
Cancer Res. 1993 Nov 1;53(21):5233-6
[
7693335.001
]
[Cites]
Clin Cancer Res. 2003 May;9(5):1666-72
[
12738719.001
]
[Cites]
Cancer Gene Ther. 2001 Oct;8(10):771-82
[
11687900.001
]
[Cites]
Int J Cancer. 2002 Dec 10;102(5):514-8
[
12432555.001
]
[Cites]
Oncogene. 1996 Apr 18;12(8):1833-5
[
8622905.001
]
[Cites]
Br J Cancer. 1992 Aug;66(2):367-72
[
1380282.001
]
[Cites]
Br J Cancer. 2001 Sep 28;85(7):953-8
[
11592764.001
]
[Cites]
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6169-78
[
15448004.001
]
[Cites]
Br J Cancer. 2001 Oct 19;85(8):1130-6
[
11710825.001
]
[Cites]
Int J Urol. 2005 Feb;12(2):152-8
[
15733109.001
]
[Cites]
Mol Cancer Ther. 2004 Mar;3(3):335-43
[
15026554.001
]
[Cites]
Ann Oncol. 2005 Aug;16(8):1391-7
[
15905307.001
]
[Cites]
Cancer. 2001 Nov 1;92(9):2435-43
[
11745301.001
]
[Cites]
Cancer Res. 1998 Feb 15;58(4):808-14
[
9485039.001
]
[Cites]
Trends Pharmacol Sci. 2002 Dec;23(12):576-82
[
12457776.001
]
[Cites]
Br J Cancer. 2004 Nov 1;91(9):1645-50
[
15354209.001
]
[Cites]
Nature. 1997 Nov 27;390(6658):404-7
[
9389480.001
]
[Cites]
J Clin Oncol. 2005 Nov 1;23(31):7889-96
[
16204015.001
]
[Cites]
Clin Cancer Res. 2005 Sep 15;11(18):6625-33
[
16166441.001
]
[Cites]
J Clin Oncol. 2004 Jul 1;22(13):2532-9
[
15226321.001
]
[Cites]
Br J Urol. 1989 Feb;63(2):128-31
[
2702395.001
]
[Cites]
Am J Physiol. 1993 Nov;265(5 Pt 2):F712-6
[
8238552.001
]
[Cites]
Oncogene. 1997 Oct;15(18):2145-50
[
9393972.001
]
[Cites]
Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49
[
15863030.001
]
[Cites]
J Clin Oncol. 2005 Aug 1;23(22):5188-97
[
16051960.001
]
[Cites]
Cancer Res. 2000 Aug 1;60(15):4066-9
[
10945611.001
]
[Cites]
Am J Physiol Heart Circ Physiol. 2002 May;282(5):H1821-7
[
11959648.001
]
[Cites]
Cancer Metastasis Rev. 2003 Dec;22(4):301-7
[
12884907.001
]
[Cites]
Urology. 1999 Mar;53(3):535-41
[
10096380.001
]
[Cites]
Semin Cell Dev Biol. 2002 Feb;13(1):19-27
[
11969368.001
]
[Cites]
Clin Cancer Res. 2001 Jul;7(7):1888-93
[
11448901.001
]
[Cites]
J Clin Oncol. 2001 Jul 1;19(13):3267-79
[
11432895.001
]
[Cites]
Immunity. 2004 Dec;21(6):831-42
[
15589171.001
]
[Cites]
J Clin Oncol. 1999 Aug;17 (8):2541-5
[
10561320.001
]
[Cites]
J Biol Chem. 1992 Dec 25;267(36):26031-7
[
1464614.001
]
[Cites]
Ann Oncol. 2002 Jul;13(7):1029-35
[
12176780.001
]
[Cites]
Cancer Res. 1997 Oct 15;57(20):4593-9
[
9377574.001
]
[Cites]
Br J Cancer. 1999 Apr;80(1-2):309-13
[
10390013.001
]
[Cites]
Oncogene. 2000 Sep 14;19(39):4549-52
[
11002428.001
]
[Cites]
J Clin Oncol. 2001 Mar 1;19(5):1304-11
[
11230472.001
]
[Cites]
Trends Endocrinol Metab. 2005 Sep;16(7):293-9
[
16061390.001
]
[Cites]
Eur J Cancer. 1999 Jan;35(1):133-7
[
10211101.001
]
[Cites]
Proc Natl Acad Sci U S A. 1986 Sep;83(17):6440-4
[
3018732.001
]
[Cites]
J Interferon Cytokine Res. 2001 Apr;21(4):257-63
[
11359657.001
]
[Cites]
Nat Genet. 1994 May;7(1):85-90
[
7915601.001
]
[Cites]
J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
[
1688381.001
]
[Cites]
Int J Cancer. 1996 Feb 20;69(1):17-22
[
8600053.001
]
[Cites]
Clin Cancer Res. 2003 May;9(5):1734-40
[
12738728.001
]
[Cites]
J Clin Oncol. 2005 Feb 10;23(5):965-72
[
15613696.001
]
[Cites]
Prostate. 2004 Jun 15;60(1):18-24
[
15129425.001
]
[Cites]
Clin Cancer Res. 2003 Oct 15;9(13):4772-81
[
14581348.001
]
[Cites]
Cancer Res. 1996 Oct 15;56(20):4799-804
[
8841001.001
]
[Cites]
Clin Cancer Res. 2005 May 1;11(9):3250-6
[
15867220.001
]
[Cites]
J Natl Cancer Inst. 2001 Feb 21;93(4):266-76
[
11181773.001
]
[Cites]
Cancer Res. 1998 Apr 1;58(7):1551-7
[
9537263.001
]
[Cites]
Cancer. 2004 Jan 1;100(1):65-71
[
14692025.001
]
[Cites]
Cancer Res. 2004 Nov 15;64(22):8249-55
[
15548691.001
]
[Cites]
J Clin Oncol. 1992 Jun;10(6):881-9
[
1375283.001
]
[Cites]
Clin Cancer Res. 2001 May;7(5):1198-203
[
11350884.001
]
[Cites]
Clin Cancer Res. 2005 Sep 1;11(17):6240-6
[
16144927.001
]
[Cites]
J Immunother. 2004 Jul-Aug;27(4):259-64
[
15235386.001
]
[Cites]
J Clin Oncol. 2002 Jan 1;20(1):302-6
[
11773183.001
]
[Cites]
Curr Top Dev Biol. 2004;62:37-54
[
15522738.001
]
[Cites]
Urology. 1980 Nov;16(5):488-91
[
6969486.001
]
[Cites]
Trends Biochem Sci. 2003 Sep;28(9):488-94
[
13678960.001
]
[Cites]
Clin Cancer Res. 1999 Jul;5(7):1738-44
[
10430077.001
]
[Cites]
Exp Cell Res. 1999 Nov 1;252(2):262-72
[
10527617.001
]
[Cites]
Clin Cancer Res. 2004 Apr 15;10 (8):2584-6
[
15102658.001
]
[Cites]
Cancer Res. 2004 Jul 15;64(14):4931-41
[
15256466.001
]
[Cites]
Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2666-73
[
15277490.001
]
[Cites]
Anticancer Res. 1999 Mar-Apr;19(2C):1563-5
[
10365146.001
]
[Cites]
Science. 1997 Jul 4;277(5322):55-60
[
9204896.001
]
[Cites]
Eur Urol. 2004 Aug;46(2):200-8
[
15245814.001
]
[Cites]
Matrix Biol. 2003 Mar;22(1):63-71
[
12714043.001
]
[Cites]
J Urol. 2003 Jan;169(1):357-60
[
12478189.001
]
[Cites]
J Clin Invest. 2003 May;111(9):1287-95
[
12727920.001
]
[Cites]
Cancer. 2005 Dec 1;104(11):2323-33
[
16240452.001
]
[Cites]
J Clin Oncol. 2000 Apr;18(7):1440-50
[
10735891.001
]
[Cites]
J Clin Oncol. 2001 Feb 15;19(4):1195-206
[
11181686.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35
[
15961063.001
]
[Cites]
Biochemistry. 1986 Sep 9;25(18):4988-93
[
3768327.001
]
[Cites]
Cancer. 2001 Jul 1;92(1):188-93
[
11443626.001
]
[Cites]
Clin Cancer Res. 1999 May;5(5):1063-71
[
10353739.001
]
[Cites]
Invest New Drugs. 2003 Feb;21(1):99-101
[
12795534.001
]
[Cites]
Nature. 2005 Dec 15;438(7070):932-6
[
16355210.001
]
[Cites]
J Clin Oncol. 2004 Apr 1;22(7):1174-6
[
14981101.001
]
[Cites]
Anticancer Res. 2004 May-Jun;24(3a):1797-804
[
15274358.001
]
[Cites]
Nat Rev Cancer. 2005 Sep;5(9):735-43
[
16079909.001
]
[Cites]
Am J Pathol. 1993 Nov;143(5):1255-62
[
8238242.001
]
[Cites]
J Cell Sci. 2002 Jan 1;115(Pt 1):175-83
[
11801735.001
]
[Cites]
Prostate. 2004 Sep 1;60(4):332-7
[
15264245.001
]
[Cites]
Cancer Res. 2000 Jul 1;60(13):3655-61
[
10910082.001
]
[Cites]
J Clin Invest. 1993 Jun;91(6):2504-12
[
7685771.001
]
[Cites]
Hematology. 2004 Jun;9(3):207-15
[
15204102.001
]
[Cites]
J Clin Oncol. 2005 Aug 20;23(24):5474-83
[
16027439.001
]
[Cites]
N Engl J Med. 1998 Apr 30;338(18):1265-71
[
9562580.001
]
[Cites]
J Pathol. 1999 Dec;189(4):564-9
[
10629559.001
]
[Cites]
N Engl J Med. 1998 Apr 30;338(18):1272-8
[
9562581.001
]
[Cites]
N Engl J Med. 2003 Jul 31;349(5):427-34
[
12890841.001
]
[Cites]
Mol Biol Cell. 1993 Dec;4(12):1317-26
[
8167412.001
]
[Cites]
Nature. 2000 Sep 14;407(6801):249-57
[
11001068.001
]
[Cites]
Prostate. 2001 Dec 1;49(4):293-305
[
11746276.001
]
[Cites]
Eur Urol. 1979;5(2):90-3
[
421708.001
]
[Cites]
Semin Oncol. 2001 Dec;28(6):620-5
[
11740820.001
]
[Cites]
J Biol Chem. 1997 May 16;272(20):13390-6
[
9148962.001
]
[Cites]
Cancer Res. 1992 Oct 15;52(20):5775-9
[
1394202.001
]
[Cites]
Crit Rev Oncol Hematol. 2004 Mar;49(3):245-58
[
15036264.001
]
[Cites]
Lab Invest. 2004 Jun;84(6):785-95
[
15107801.001
]
[Cites]
Cancer Res. 2000 Aug 1;60(15):4245-50
[
10945637.001
]
[Cites]
Int J Cancer. 2005 Dec 20;117(6):883-8
[
16152621.001
]
[Cites]
J Natl Cancer Inst. 1995 Apr 19;87(8):581-6
[
7538593.001
]
[Cites]
Urology. 2001 May;57(5):895-9
[
11337289.001
]
[Cites]
Curr Oncol Rep. 2002 Nov;4(6):510-4
[
12354364.001
]
[Cites]
Clin Cancer Res. 2004 Dec 1;10(23):7812-9
[
15585612.001
]
[Cites]
J Urol. 1994 Nov;152(5 Pt 1):1626-31
[
7523715.001
]
[Cites]
Trends Mol Med. 2005 Jun;11(6):284-92
[
15949770.001
]
[Cites]
J Clin Oncol. 2003 Oct 15;21(20):3770-6
[
14551295.001
]
[Cites]
Clin Oncol (R Coll Radiol). 2005 Oct;17(7):508-13
[
16238138.001
]
[Cites]
Int J Cancer. 1996 Jun 21;69(3):212-7
[
8682590.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12718-23
[
14555767.001
]
[Cites]
J Clin Oncol. 2003 Jul 1;21(13):2564-73
[
12829677.001
]
[Cites]
Mol Cancer Res. 2004 Jul;2(7):371-86
[
15280445.001
]
[Cites]
Int J Clin Oncol. 2004 Aug;9(4):283-7
[
15375704.001
]
[Cites]
Prostate Cancer Prostatic Dis. 2003;6(2):131-7
[
12806371.001
]
[Cites]
Cancer. 2006 Feb 1;106(3):566-75
[
16369983.001
]
[Cites]
Pharmacotherapy. 2003 Mar;23(3):315-8
[
12627929.001
]
[Cites]
Clin Cancer Res. 1999 Sep;5(9):2324-9
[
10499600.001
]
[Cites]
Cancer Res. 1997 Mar 15;57(6):1054-7
[
9067270.001
]
[Cites]
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):800-6
[
16467091.001
]
[Cites]
Blood. 1996 May 1;87(9):3877-82
[
8611715.001
]
[Cites]
Cancer Res. 1993 Jun 1;53(11):2566-70
[
7684319.001
]
[Cites]
Cancer Res. 1994 Jul 1;54(13):3407-12
[
8012959.001
]
[Cites]
Atherosclerosis. 2006 May;186(1):38-53
[
16076471.001
]
[Cites]
BJU Int. 2004 Feb;93(3):275-8
[
14764122.001
]
[Cites]
Biochem Biophys Res Commun. 1987 Feb 13;142(3):702-9
[
2435284.001
]
[Cites]
Cell. 1996 Dec 27;87(7):1171-80
[
8980224.001
]
[Cites]
J Mol Med (Berl). 1999 Jun;77(6):505-10
[
10475065.001
]
[Cites]
J Pathol. 1999 Jan;187(1):112-26
[
10341712.001
]
[Cites]
Prostate. 2001 Feb 1;46(2):163-72
[
11170144.001
]
[Cites]
J Clin Oncol. 2004 Jul 15;22(14 ):2891-900
[
15254058.001
]
[Cites]
J Exp Med. 1995 Jul 1;182(1):155-62
[
7540647.001
]
[Cites]
N Engl J Med. 1998 Apr 30;338(18):1305-6
[
9562587.001
]
[Cites]
Cancer Res. 2001 Apr 1;61(7):3206-11
[
11306510.001
]
[Cites]
J Biol Chem. 1996 Mar 29;271(13):7788-95
[
8631822.001
]
[Cites]
Cancer Res. 1993 Feb 1;53(3):533-5
[
7678775.001
]
[Cites]
Dev Cell. 2002 Sep;3(3):411-23
[
12361603.001
]
[Cites]
Invest New Drugs. 1999;17(2):183-6
[
10638490.001
]
[Cites]
J Clin Oncol. 2006 Jan 1;24(1):16-24
[
16330672.001
]
[Cites]
Biochem Biophys Res Commun. 2001 Dec 14;289(4):801-6
[
11735116.001
]
[Cites]
Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6
[
11685731.001
]
[Cites]
Exp Cell Res. 2004 Feb 15;293(2):331-45
[
14729471.001
]
[Cites]
Cancer Res. 2000 Nov 15;60(22):6298-302
[
11103787.001
]
[Cites]
Br J Cancer. 2003 Mar 24;88(6):822-7
[
12644816.001
]
[Cites]
Cancer Res. 1994 Jun 1;54(11):2852-5
[
8187067.001
]
[Cites]
Int J Clin Oncol. 2005 Dec;10(6):405-10
[
16369744.001
]
[Cites]
J Biol Chem. 2001 Jun 22;276(25):22382-7
[
11297551.001
]
[Cites]
Lancet Oncol. 2005 Sep;6(9):678-86
[
16129368.001
]
[Cites]
J Clin Oncol. 2000 Dec 15;18(24):4009-15
[
11118461.001
]
[Cites]
Expert Opin Investig Drugs. 2003 Aug;12(8):1403-11
[
12882625.001
]
[Cites]
Clin Oncol (R Coll Radiol). 2005 Oct;17(7):514-23
[
16238139.001
]
[Cites]
BJU Int. 2000 Jan;85(1):70-3
[
10619949.001
]
[Cites]
J Urol. 1988 Dec;140(6):1575-9
[
3193547.001
]
[Cites]
Cancer. 2005 Dec 1;104(11):2392-9
[
16222691.001
]
[Cites]
Endocr Relat Cancer. 2000 Sep;7(3):165-97
[
11021964.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14389-94
[
9826710.001
]
[Cites]
Ann Oncol. 2005 Oct;16(10):1688-94
[
16006586.001
]
[Cites]
J Med Chem. 2005 Apr 21;48(8):2838-46
[
15828822.001
]
[Cites]
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425
[
15674877.001
]
[Cites]
Br J Cancer. 2005 Jun 20;92(12):2140-7
[
15928663.001
]
[Cites]
Cancer Res. 1995 Feb 1;55(3):510-3
[
7530595.001
]
[Cites]
Clin Cancer Res. 2003 May;9(5):1648-55
[
12738717.001
]
[Cites]
Prostate. 2005 Mar 1;62(4):394-9
[
15378518.001
]
[Cites]
Int J Biochem Cell Biol. 2004 Jun;36(6):1038-45
[
15094119.001
]
[Cites]
Br J Cancer. 2005 May 23;92(10):1855-61
[
15870716.001
]
[Cites]
J Exp Med. 1993 Jun 1;177(6):1675-80
[
8496685.001
]
[Cites]
Genome Biol. 2001;2(3):REVIEWS3005
[
11276432.001
]
[Cites]
J Natl Cancer Inst. 1997 Feb 5;89(3):219-27
[
9017002.001
]
[Cites]
Br J Urol. 1996 Mar;77(3):352-7
[
8814837.001
]
[Cites]
Clin Cancer Res. 2004 May 15;10(10):3365-70
[
15161690.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9671-6
[
10449752.001
]
[Cites]
J Clin Invest. 2002 Apr;109(7):863-7
[
11927612.001
]
[Cites]
N Engl J Med. 1963 Jul 18;269:115-21
[
13929733.001
]
[Cites]
Nat Med. 2004 Mar;10 (3):255-61
[
14981512.001
]
[Cites]
Proc Natl Acad Sci U S A. 1981 Feb;78(2):1176-80
[
6262756.001
]
[Cites]
J Biol Chem. 1990 Nov 15;265(32):19461-6
[
2246236.001
]
[Cites]
Genes Dev. 2000 Jan 1;14(1):34-44
[
10640274.001
]
[Cites]
Front Biosci. 1999 Feb 15;4:D165-77
[
9989949.001
]
(PMID = 16622744.001).
[ISSN]
1341-9625
[Journal-full-title]
International journal of clinical oncology
[ISO-abbreviation]
Int. J. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Japan
[Chemical-registry-number]
0 / Angiogenesis Inhibitors; 0 / Vascular Endothelial Growth Factor A
[Number-of-references]
268
64.
Jeldres C, Bensalah K, Capitanio U, Zini L, Perrotte P, Suardi N, Tostain J, Valeri A, Descotes JL, Rambeaud JJ, de La Taille A, Salomon L, Abbou C, Patard JJ, Karakiewicz PI:
Baseline renal function, ischaemia time and blood loss predict the rate of renal failure after partial nephrectomy.
BJU Int
; 2009 Jun;103(12):1632-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Baseline
renal
function, ischaemia time and blood loss predict the rate of
renal
failure after partial nephrectomy.
OBJECTIVE: To identify independent predictors of
renal
failure after partial nephrectomy (PN) in patients with
renal cell carcinoma
(
RCC
).
PATIENTS AND METHODS: Data were available for 166 patients with pathological T1-3 N0M0
RCC
treated with PN.
Renal
failure after PN was defined as a decrease in glomerular filtration rate (GFR) of >25% (RIFLE criteria).
The GFR before and after PN was estimated using the Modification of Diet in
Renal Disease
study group equation.
Candidate predictor variables were age, gender, PN indication (absolute vs relative), preoperative GFR,
tumour
size, perioperative blood loss, surgery duration and clamping time.
It is possible that selective referral to experienced surgeons who can perform PN within short surgical and clamping times, and with minimal blood loss, could minimize the rate of
renal
failure, especially in patients with an underlying
renal
function impairment.
[MeSH-major]
Carcinoma
,
Renal Cell
/ surgery. Glomerular Filtration Rate / physiology.
Kidney
/ physiopathology.
Kidney
Neoplasms / surgery. Nephrectomy / adverse effects.
Renal
Insufficiency /
diagnosis
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Blood Loss, Surgical. Female. Humans. Ischemia / complications.
Kidney
Function Tests. Male. Middle Aged. Prognosis. Regression Analysis. Risk Factors. Treatment Outcome. Young Adult
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19545272.001).
[ISSN]
1464-410X
[Journal-full-title]
BJU international
[ISO-abbreviation]
BJU Int.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
65.
Kim J, Jonasch E, Alexander A, Short JD, Cai S, Wen S, Tsavachidou D, Tamboli P, Czerniak BA, Do KA, Wu KJ, Marlow LA, Wood CG, Copland JA, Walker CL:
Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma.
Clin Cancer Res
; 2009 Jan 1;15(1):81-90
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cytoplasmic sequestration of p27 via AKT phosphorylation in
renal cell carcinoma
.
PURPOSE: p27 localization and expression has prognostic and predictive value in
cancer
.
Little is known regarding expression patterns of p27 in
renal cell carcinoma
(
RCC
) or how p27 participates in
disease
progression or response to therapy.
EXPERIMENTAL DESIGN:
RCC
-derived
cell
lines, primary
tumors
, and normal
renal
epithelial
cells
were analyzed for p27 expression, phosphorylation (T157 of the NLS), and subcellular localization.
RCC
-derived
cell
lines were treated with phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitors and effects on p27 localization were assessed.
RESULTS: p27 was elevated in
tumors
compared with matched controls, and cytoplasmic mislocalization of p27 was associated with increasing
tumor
grade.
In
RCC cell
lines, activated PI3K/AKT signaling was accompanied by mislocalization of p27.
AKT activation and phosphorylation of p27 was associated with resistance to apoptosis, and small interfering RNA knockdown of p27 or relocalization to the nucleus increased apoptosis in
RCC cells
.
CONCLUSIONS: In
RCC
, p27 is phosphorylated at T157 of the NLS, with increasing
tumor
grade associated with cytoplasmic p27.
Clinical testing of these findings may provide a rational approach for use of mTOR and PI3K/AKT pathway inhibitors in patients with
RCC
.
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
PhosphoSitePlus.
gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 2006 May 15;66(10):5130-42
[
16707436.001
]
[Cites]
J Cell Biol. 2006 Apr 24;173(2):279-89
[
16636147.001
]
[Cites]
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):703s-708s
[
17255297.001
]
[Cites]
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):758s-763s
[
17255306.001
]
[Cites]
Nat Cell Biol. 2007 Feb;9(2):218-24
[
17237771.001
]
[Cites]
Cancer. 2007 Jun 1;109(11):2257-67
[
17440983.001
]
[Cites]
N Engl J Med. 2007 May 31;356(22):2271-81
[
17538086.001
]
[Cites]
J Clin Oncol. 1999 Aug;17(8):2530-40
[
10561319.001
]
[Cites]
J Cell Physiol. 2000 Apr;183(1):10-7
[
10699961.001
]
[Cites]
Urology. 2001 Sep;58(3):477-81
[
11549509.001
]
[Cites]
Cancer. 2002 Feb 15;94(4):973-9
[
11920465.001
]
[Cites]
Int J Cancer. 2002 May 1;99(1):53-7
[
11948491.001
]
[Cites]
Mod Pathol. 2002 May;15(5):479-85
[
12011252.001
]
[Cites]
Nat Med. 2002 Oct;8(10):1145-52
[
12244301.001
]
[Cites]
Nat Med. 2002 Oct;8(10):1153-60
[
12244302.001
]
[Cites]
Nat Med. 2002 Oct;8(10):1136-44
[
12244303.001
]
[Cites]
J Natl Cancer Inst. 2002 Oct 16;94(20):1569-75
[
12381710.001
]
[Cites]
Int J Cancer. 2002 Dec 20;102(6):601-7
[
12448001.001
]
[Cites]
Semin Cancer Biol. 2003 Feb;13(1):41-7
[
12507555.001
]
[Cites]
J Urol. 2003 Feb;169(2):710-3
[
12544348.001
]
[Cites]
Cell Cycle. 2002 Nov-Dec;1(6):394-400
[
12548012.001
]
[Cites]
Trends Cell Biol. 2003 Feb;13(2):65-70
[
12559756.001
]
[Cites]
Clin Cancer Res. 2003 Feb;9(2):802-11
[
12576453.001
]
[Cites]
Anticancer Res. 2003 Jan-Feb;23(1A):217-21
[
12680216.001
]
[Cites]
Br J Cancer. 2003 May 6;88(9):1417-23
[
12778072.001
]
[Cites]
J Clin Oncol. 2004 Feb 1;22(3):454-63
[
14752067.001
]
[Cites]
J Clin Oncol. 2004 Mar 1;22(5):909-18
[
14990647.001
]
[Cites]
J Clin Oncol. 2004 Jun 15;22(12):2336-47
[
15136596.001
]
[Cites]
Cancer Res. 1988 Dec 15;48(24 Pt 1):7310-3
[
3056613.001
]
[Cites]
J Pathol. 1991 Jan;163(1):31-7
[
2002422.001
]
[Cites]
Nat Med. 1997 Feb;3(2):152-4
[
9018230.001
]
[Cites]
Eur Urol. 1997;31(3):350-5
[
9129930.001
]
[Cites]
Cancer. 1997 Sep 1;80(5):981-6
[
9307202.001
]
[Cites]
J Surg Oncol. 1998 May;68(1):11-8
[
9610657.001
]
[Cites]
Eur Urol. 1999;35(3):242-8
[
10072628.001
]
[Cites]
Nat Cell Biol. 2004 Dec;6(12):1153-5
[
15573093.001
]
[Cites]
Virchows Arch. 2004 Dec;445(6):631-6
[
15517366.001
]
[Cites]
J Clin Oncol. 2005 Feb 1;23(4):832-41
[
15681528.001
]
[Cites]
J Urol. 2005 May;173(5):1496-501
[
15821467.001
]
[Cites]
Clin Cancer Res. 2005 May 15;11(10):3714-21
[
15897568.001
]
[Cites]
Ann Oncol. 2005 Jun;16(6):928-33
[
15851405.001
]
[Cites]
Br J Cancer. 2005 Jun 20;92(12):2266-77
[
15956968.001
]
[Cites]
Curr Med Chem. 2005;12(14):1589-605
[
16022660.001
]
[Cites]
J Clin Oncol. 2006 Jan 1;24(1):16-24
[
16330672.001
]
[Cites]
Nat Med. 2006 Jan;12(1):122-7
[
16341243.001
]
[Cites]
Cancer Res. 2006 Feb 15;66(4):2162-72
[
16489017.001
]
[Cites]
J Urol. 2007 Jan;177(1):346-52
[
17162089.001
]
(PMID = 19118035.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
ENG
[Grant]
United States / NIEHS NIH HHS / ES / P30 ES007784-13; United States / NCI NIH HHS / CA / R01 CA063613-13; United States / NCI NIH HHS / CA / R01 CA104505-05; United States / NICHD NIH HHS / HD / HD046282-05; United States / NICHD NIH HHS / HD / R01 HD046282; United States / NCI NIH HHS / CA / CA104505-05; United States / NICHD NIH HHS / HD / R01 HD046282-05; United States / NCI NIH HHS / CA / R01 CA104505; United States / NCI NIH HHS / CA / R01 CA063613; United States / NIEHS NIH HHS / ES / ES007784-13; United States / NCI NIH HHS / CA / CA063613-13; United States / NIEHS NIH HHS / ES / P30 ES007784; United States / NCI NIH HHS / CA / R01 CA63613
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Proliferating Cell Nuclear Antigen; 0 / RNA, Small Interfering; 0 / p27 antigen; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
[Other-IDs]
NLM/ NIHMS118521; NLM/ PMC3030253
66.
Fine SW, Argani P, DeMarzo AM, Delahunt B, Sebo TJ, Reuter VE, Epstein JI:
Expanding the histologic spectrum of mucinous tubular and spindle cell carcinoma of the kidney.
Am J Surg Pathol
; 2006 Dec;30(12):1554-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expanding the histologic spectrum of mucinous tubular and spindle
cell carcinoma
of the
kidney
.
Mucinous tubular and spindle
cell carcinomas
(MTSCs) are polymorphic neoplasms characterized by small, elongated tubules lined by cuboidal
cells
and/or cords of spindled
cells
separated by pale mucinous stroma.
Nonclassic
morphologic
variants and features of MTSC have not been well studied.
We identified 17 previously unreported MTSCs from Surgical Pathology and consultative files of the authors and their respective institutions and studied their
morphologic
features.
Four of these cases showed equal tubular and spindled
morphology
, 2 cases showed spindle
cell
predominance (70%; 95%), and 1 case showed tubular predominance (90%).
Unusual histologic features identified in the 17 cases were: foamy macrophages (n=8), papillations/well formed papillae (n=6/n=1), focal clear
cells
in tubules (n=3), necrosis (n=3), oncocytic tubules (n=2; 40%, 5%), numerous small vacuoles (n=2), heterotopic bone (n=1), psammomatous calcification (n=1), and nodular growth with lymphocytic cuffing (n=1).
MTSCs may be "mucin-poor" and show a marked predominance of either of its principal
morphologic
components, which coupled with the presence of other unusual features such as clear
cells
, papillations, foamy macrophages, and necrosis, may mimic other forms of
renal cell carcinoma
.
Pathologists must be aware of the spectrum of histologic findings within MTSCs to ensure their accurate
diagnosis
.
[MeSH-major]
Adenocarcinoma
/ pathology.
Adenocarcinoma
, Mucinous / pathology.
Carcinoma
/ pathology.
Kidney
Neoplasms / pathology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Alcian Blue / chemistry. Biomarkers,
Tumor
/ analysis.
Carcinoma
,
Renal Cell
/
diagnosis
. Coloring Agents / chemistry.
Diagnosis
, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucins / chemistry. Mucins / metabolism
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17122511.001).
[ISSN]
0147-5185
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Coloring Agents; 0 / Mucins; P4448TJR7J / Alcian Blue
67.
Iesalnieks I, Woenckhaus M, Glockzin G, Schlitt HJ, Agha A:
[Renal cell carcinoma metastases to the thyroid gland -- report of 3 cases and review of the literature].
Zentralbl Chir
; 2006 Jun;131(3):235-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Renal cell carcinoma
metastases to the thyroid gland -- report of 3 cases and review of the literature].
[Transliterated title]
Schilddrüsenmetastasen eines Nierenzellkarzinoms -- drei Fallvorstellungen und Ubersicht
der
Literatur.
The clear
cell carcinoma
of the
kidney
(
RCC
) is the most
common
primary
tumor
site.
Late recurrence is a notable feature of
renal carcinoma
.
We describe 3 cases of surgically treated thyroid metastases of
RCC
, and review the literature.
[MeSH-major]
Carcinoma
,
Renal Cell
/ secondary.
Kidney
Neoplasms / surgery. Thyroid Neoplasms / secondary
[MeSH-minor]
Aged. Fatal Outcome. Female. Humans. Male. Middle Aged. Neoplasm Staging. Nephrectomy. Postoperative Complications /
diagnosis
. Postoperative Complications / pathology. Postoperative Complications / surgery. Reoperation. Thyroid Gland / pathology. Thyroidectomy
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16739065.001).
[ISSN]
0044-409X
[Journal-full-title]
Zentralblatt für Chirurgie
[ISO-abbreviation]
Zentralbl Chir
[Language]
ger
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Germany
68.
Vanderbrink BA, Rastinehad A, Caplin D, Ost MC, Lobko I, Lee BR:
Successful conservative management of colorenal fistula after percutaneous cryoablation of renal-cell carcinoma.
J Endourol
; 2007 Jul;21(7):726-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Successful conservative management of colorenal fistula after percutaneous cryoablation of
renal
-
cell carcinoma
.
BACKGROUND: Cryoablation is an increasingly utilized treatment for
renal
-
cell carcinoma
.
We describe the first reported case of colorenal fistula resulting from percutaneous
renal
cryoablation.
CASE REPORT: A 63-year-old man with hematuria was found to have an enhancing
renal
mass that was treated with percutaneous CT-guided cryoablation.
CONCLUSIONS: Contrary to previously reported animal and clinical studies, our case report demonstrates that it is possible to incur serious harm to the
renal
collecting
system
as a result of percutaneous
renal
cryoablation.
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17705759.001).
[ISSN]
0892-7790
[Journal-full-title]
Journal of endourology
[ISO-abbreviation]
J. Endourol.
[Language]
ENG
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
69.
Audenet F, Rouprêt M, Méjean A:
[Renal cell carcinoma and antiangiogenic agents: ongoing controversies are seeking answers for improvement of therapeutic management].
Prog Urol
; 2009 Oct;19(9):596-605
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Renal cell carcinoma
and antiangiogenic agents: ongoing controversies are seeking answers for improvement of therapeutic management].
[Transliterated title]
Cancer du rein
et thérapies ciblées : controverses sur les prises
en
charge thérapeutiques.
The recent development of agents targeting VHL-related growth factors as therapy for metastatic
renal cell carcinoma
has generated a revolution in the management of these patients, with a clear improvement of survival.
Notably, the role for radical nephrectomy in metastatic cases, the interest of adjuvant treatment in high-risk recurrence cases, the place for neoadjuvant treatment in locally advanced
renal cell carcinoma
, the choice of the best agent at first-line treatment, the various therapeutic options and their consequences on the quality of life and the potential contribution of dynamic imaging to assess antiangiogenic treatment's efficiency.
[MeSH-major]
Angiogenesis Inhibitors / therapeutic use.
Carcinoma
,
Renal Cell
/ drug therapy.
Kidney
Neoplasms / drug therapy
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19800548.001).
[ISSN]
1166-7087
[Journal-full-title]
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
[ISO-abbreviation]
Prog. Urol.
[Language]
fre
[Publication-type]
English Abstract; Journal Article
[Publication-country]
France
[Chemical-registry-number]
0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal
70.
Maluf FC, Fernandes Gdos S, Kann AG, Aguilar-Ponce JL, de la Garza J, Buzaid AC:
Exploring the role of novel agents in the treatment of renal cell carcinoma.
Cancer Treat Rev
; 2008 Dec;34(8):750-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Exploring the role of novel agents in the treatment of
renal cell carcinoma
.
Renal cell carcinoma
represents nearly 3% of all
cancers
, predominantly affecting individuals >or=50 years of age, and until recently, few treatments options were available for metastatic
disease
.
The 5-year median survival for these patients with metastatic
renal cell carcinoma
has been estimated at <10%.
[MeSH-major]
Angiogenesis Inhibitors / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage.
Carcinoma
,
Renal Cell
/ drug therapy. Drug Delivery
Systems
.
Kidney
Neoplasms / drug therapy
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
Hazardous Substances Data Bank.
SIROLIMUS
.
Hazardous Substances Data Bank.
NICOTINAMIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18801619.001).
[ISSN]
1532-1967
[Journal-full-title]
Cancer treatment reviews
[ISO-abbreviation]
Cancer Treat. Rev.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 624KN6GM2T / temsirolimus; 9ZOQ3TZI87 / sorafenib; W36ZG6FT64 / Sirolimus
[Number-of-references]
57
71.
Merseburger AS, Kuczyk MA:
[Value of targeted therapies for renal cell cancer].
Urologe A
; 2008 Oct;47(10):1303-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Value of targeted therapies for
renal cell cancer
].
[Transliterated title]
Der
Stellenwert
der
Targeted-Therapie beim
Nierenzellkarzinom
.
Therapeutic approaches based solely on cytokine are meanwhile no longer recommended without restrictions as the primary therapy for metastatic
renal cancer
due to the reduced clinical response and the promising available data regarding molecular therapy.
Several randomized controlled studies have been performed since the introduction of the so-called targeted therapies for metastatic
renal cancer
.
Experimental investigations for a better understanding of signaling pathways will preferably allow preselecting patients for an individualized therapy in metastatic
renal cell cancer
(
RCC
).
The aim of the present paper is to address and to critically discuss the clinical data that are currently available regarding"targeted" therapeutics during the treatment of metastatic
RCC
.
[MeSH-major]
Antineoplastic Agents / administration & dosage.
Carcinoma
,
Renal Cell
/ drug therapy. Drug Delivery
Systems
.
Kidney
Neoplasms / drug therapy
[MeSH-minor]
Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzenesulfonates / administration & dosage. Bevacizumab.
Disease
Progression. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Humans. Indoles / administration & dosage. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyridines / administration & dosage. Pyrroles / administration & dosage. Randomized Controlled Trials as Topic. Sirolimus / administration & dosage. Sirolimus / analogs & derivatives. Survival Rate
Genetic Alliance.
consumer health - Kidney cancer
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
Hazardous Substances Data Bank.
SIROLIMUS
.
Hazardous Substances Data Bank.
NICOTINAMIDE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 2001 Dec 6;345(23 ):1655-9
[
11759643.001
]
[Cites]
Semin Oncol. 2000 Apr;27(2):187-93
[
10768597.001
]
[Cites]
J Clin Oncol. 2007 Nov 1;25(31):5026-8
[
17971604.001
]
[Cites]
Urologe A. 2007 May;46(5):504-8, 510
[
17437075.001
]
[Cites]
Clin Cancer Res. 2004 Sep 15;10 (18 Pt 2):6388S-92S
[
15448036.001
]
[Cites]
BJU Int. 2005 Mar;95 Suppl 2:2-7
[
15720328.001
]
[Cites]
N Engl J Med. 2007 Jan 11;356(2):115-24
[
17215529.001
]
[Cites]
J Clin Oncol. 2007 Oct 10;25(29):4536-41
[
17876014.001
]
[Cites]
J Clin Oncol. 2005 Feb 10;23(5):1011-27
[
15585754.001
]
[Cites]
N Engl J Med. 2007 Jan 11;356(2):125-34
[
17215530.001
]
[Cites]
J Clin Oncol. 2006 Jun 1;24(16):2505-12
[
16636341.001
]
[Cites]
Lancet. 2001 Sep 22;358(9286):966-70
[
11583750.001
]
[Cites]
JAMA. 2006 Jun 7;295(21):2516-24
[
16757724.001
]
[Cites]
Eur Urol. 2007 Jun;51(6):1502-10
[
17408850.001
]
[Cites]
N Engl J Med. 2007 May 31;356(22):2271-81
[
17538086.001
]
[Cites]
Anticancer Res. 2005 May-Jun;25(3B):1901-7
[
16158924.001
]
[Cites]
J Clin Oncol. 2002 Jan 1;20(1):289-96
[
11773181.001
]
[Cites]
Lancet. 2007 Dec 22;370(9605):2103-11
[
18156031.001
]
[Cites]
N Engl J Med. 2003 Jul 31;349(5):427-34
[
12890841.001
]
[Cites]
Oncol Rep. 2008 May;19(5):1141-7
[
18425369.001
]
[Cites]
Clin Cancer Res. 2006 Dec 15;12 (24):7215-20
[
17189392.001
]
[Cites]
J Clin Oncol. 2006 Jan 1;24(1):16-24
[
16330672.001
]
[Cites]
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425
[
15674877.001
]
[Cites]
Br J Cancer. 2005 May 23;92(10):1855-61
[
15870716.001
]
[Cites]
J Clin Oncol. 2008 May 10;26(14):2285-91
[
18467719.001
]
(PMID = 18587556.001).
[ISSN]
0340-2592
[Journal-full-title]
Der Urologe. Ausg. A
[ISO-abbreviation]
Urologe A
[Language]
ger
[Publication-type]
Journal Article; Review
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 624KN6GM2T / temsirolimus; 9ZOQ3TZI87 / sorafenib; V99T50803M / sunitinib; W36ZG6FT64 / Sirolimus
[Number-of-references]
35
72.
Shao ZQ, Zheng SB, Xiao YJ, Tan WL, Chen T, Qi H, Jiang YD, Yu ZC, Zhang HJ:
[Expressions of hypoxia inducible factor-1alpha and vascular endothelial growth factor in human renal cell carcinoma].
Di Yi Jun Yi Da Xue Xue Bao
; 2005 Aug;25(8):1034-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Expressions of hypoxia inducible factor-1alpha and vascular endothelial growth factor in human
renal cell carcinoma
].
OBJECTIVE: To explore the expression of hypoxia inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in
renal cell carcinoma
(
RCC
) and their relationship.
METHODS: The expression of HIF-1alphaand VEGF was examined in 42 patients with
renal cell carcinoma
by SABC methods of immunohistochemistry.
RESULTS: The positivity rate of HIF-1alpha was 57.1% in the
RCC
tissues, and there was no expression in the tissue adjacent to the
tumor
and normal tissues.
The positivity rate of VEGF was 61.9% in the
tumor
tissues, with significant difference from the
control
tissues (P<0.05).
The expression levels of HIF-1alpha and VEGF were significantly higher in metastatic
RCC
than in
non
-metastatic
RCC
(P<0.01) tissues, and there was a significant correlation between HIF-1alpha and VEGF expressions (Kappa=0.41, P<0.01).
CONCLUSIONS: HIF-1alpha is highly expressed in
renal cell carcinoma
tissues in close correlation with VEGF.
HIF-1alpha and VEGF may serve as important indicators to evaluate the biological behaviors of
RCC
such as metastasis and prognosis.
[MeSH-major]
Carcinoma
,
Renal Cell
/ metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis.
Kidney
Neoplasms / metabolism. Vascular Endothelial Growth Factor A / biosynthesis
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16109571.001).
[ISSN]
1000-2588
[Journal-full-title]
Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
[ISO-abbreviation]
Di Yi Jun Yi Da Xue Xue Bao
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Vascular Endothelial Growth Factor A
73.
Bai H, Zheng SB, Wu J, Liu DZ:
[Correlation of serum calcium level with tumor size and stage of renal cell carcinoma].
Di Yi Jun Yi Da Xue Xue Bao
; 2005 Nov;25(11):1435-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Correlation of serum calcium level with
tumor
size and
stage
of
renal cell carcinoma
].
OBJECTIVE: To analyze the correlation between serum calcium level and
tumor
size/
stage
in patients with
renal cell carcinoma
(
RCC
).
METHODS: Totally 173
RCC
cases were divided into 3 groups according to their serum calcium level, namely low, normal and high level groups.
SPSS10.0 software was used for statistical analysis of the
tumor
sizes/stages and their association with serum calcium level in the 3 groups.
RESULTS AND CONCLUSION: Kruskal-Wallis H test revealed no significant difference in the
tumor
size between the 3 groups (X(2)=4.768, df=2, P=0.092), but Spearman correlation analysis suggested inverse correlation between serum calcium and
tumor
size (r=-0.166, P=0.029).
Kruskal-Wallis H test also failed to suggest significant difference in the
tumor stage
between the 3 groups (X(2)=4.277, df=2, P=0.118), but serum calcium was found to be inversely correlated with the
tumor stage
(r=-0.157, P=0.039 by Spearman correlation analysis).
[MeSH-major]
Calcium / blood.
Carcinoma
,
Renal Cell
/ blood.
Carcinoma
,
Renal Cell
/ pathology.
Kidney
Neoplasms / blood.
Kidney
Neoplasms / pathology
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
Hazardous Substances Data Bank.
CALCIUM, ELEMENTAL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16305975.001).
[ISSN]
1000-2588
[Journal-full-title]
Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
[ISO-abbreviation]
Di Yi Jun Yi Da Xue Xue Bao
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
SY7Q814VUP / Calcium
74.
Khan T, Chakrabarty A, Baborie A:
Renal cell carcinoma in allograft kidney--a case report with unusual findings at autopsy.
Int J Urol
; 2007 Jul;14(7):652-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Renal cell carcinoma
in allograft
kidney
--a case report with unusual findings at autopsy.
A 30-year old male who had
a non
-related cadaveric
renal
transplant at the age of 12 years, presented with generalised CNS symptoms and meningeal enhancement on CT scan of the brain, 18 years after the transplantation.
Autopsy revealed
renal cell carcinoma
in the transplanted
kidney
and metastatic
tumour
in a variety of organs including the brain.
[MeSH-major]
Carcinoma
,
Renal Cell
/ pathology.
Kidney
Neoplasms / pathology.
Kidney
Transplantation
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
MedlinePlus Health Information.
consumer health - Kidney Transplantation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17645613.001).
[ISSN]
0919-8172
[Journal-full-title]
International journal of urology : official journal of the Japanese Urological Association
[ISO-abbreviation]
Int. J. Urol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Australia
75.
Frangione V, Mortara L, Castellani P, De Lerma Barbaro A, Accolla RS:
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
Int J Cancer
; 2010 Oct 1;127(7):1614-24
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CIITA-driven MHC-II positive
tumor cells
: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
In our study, we have investigated whether
tumors
of distinct histological origin can be rejected if expressing CIITA-driven MHC class II molecules.
Moreover, we assessed whether antitumor lymphocytes generated by this approach could be used as an immunotherapeutic tool for established
cancers
.
Stable CIITA-transfectants of C51colon
adenocarcinoma
, RENCA
renal
adenocarcinoma
, WEHI-164 sarcoma as well as TS/A mammary
adenocarcinoma
were generated.
Tumor cells
transfectants were injected in vivo, and their growth kinetics and recipient's immune response were analyzed.
Tumor
rejection and/or retardation of growth was found for the first 3 CIITA-transfected
tumor cell
lines and confirmed for TS/A-CIITA.
Animals rejecting CIITA-transfected
tumors
acquired specific immunological memory as demonstrated by resistance to challenge with parental
tumors
.
Adoptive
cell
transfer experiments demonstrated that
tumor
immunity correlates with the efficient priming of CD4(+) T helper
cells
and the consequent activation of CD8(+) T lymphocytes.
T
cells
from TS/A-vaccinated mice were used in an adoptive immunotherapy model of established
tumors
.
The results showed the cure at early stages and significantly prolonged survival at later stages of
tumor
progression.
Importantly, CD4(+) T
cells
were clearly superior to CD8(+) T
cells
in antitumor protective function.
These results establish the general application of our
tumor
vaccine model and disclose the additional application of this strategy for producing better lymphocyte effectors for adoptive antitumor immunotherapy.
[MeSH-major]
CD4-Positive T-Lymphocytes / immunology.
Cancer
Vaccines / therapeutic use. T-Lymphocytes / immunology
[MeSH-minor]
Adenocarcinoma
/ immunology. Adoptive Transfer. Animals. CD8-Positive T-Lymphocytes / immunology.
Carcinoma
,
Renal Cell
/ immunology. Colonic Neoplasms / immunology. Female. Humans. Immunotherapy / methods.
Kidney
Neoplasms / immunology. Mammary Neoplasms, Experimental / immunology. Mice. Mice, Inbred BALB C. Polymerase Chain Reaction. Sarcoma / immunology.
Tumor Cells
, Cultured
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20091859.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Cancer Vaccines
76.
Antonelli A, Cozzoli A, Nicolai M, Zani D, Zanotelli T, Perucchini L, Cunico SC, Simeone C:
Nephron-sparing surgery versus radical nephrectomy in the treatment of intracapsular renal cell carcinoma up to 7cm.
Eur Urol
; 2008 Apr;53(4):803-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Nephron-sparing surgery versus radical nephrectomy in the treatment of intracapsular
renal cell carcinoma
up to 7cm.
OBJECTIVE: To compare the oncologic outcomes of nephron-sparing surgery versus radical nephrectomy in intracapsular
renal cell carcinoma
(
RCC
) up to 7 cm by reviewing surgical experience retrospectively.
METHODS: Data from 1290 consecutive patients who had surgery for
RCC
have been stored in a dedicated database since 1983.
We selected and reviewed those related to
disease
-free patients who had been treated for unilateral pT1a/pT1b pN0/Nx M0
carcinomas
up to 7 cm and later followed for a minimum of 12 mo.
RESULTS: A total of 642 patients with mean follow-up of 72.9 mo were selected; 313 had been treated for
tumours
<4 cm in diameter (176 nephron-sparing surgery, 137 nephrectomy), whereas 329 had been treated for
tumours
measuring > or =4 cm (52 nephron-sparing surgery, 277 nephrectomy).
The comparison between
tumours
<4 cm or > or =4 cm in diameter showed worse progression and
disease
-free survival rates for the latter, but the type of surgery (nephron-sparing or radical) seemed to have no significant impact.
CONCLUSIONS: Conservative management can be cautiously suggested for
RCC
up to 7 cm because the worsening of prognosis as diameter increases shows no statistical differences for either nephron-sparing or radical surgery.
The agreement of our results with those of similar studies available in the literature may suggest designing a prospective study to compare conservative and more radical surgery in the management of
RCC
up to 7 cm.
[MeSH-major]
Carcinoma
,
Renal Cell
/ surgery.
Kidney
Neoplasms / surgery. Nephrectomy / methods
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Eur Urol. 2008 Apr;53(4):691-3
[
18060683.001
]
(PMID = 18036730.001).
[ISSN]
0302-2838
[Journal-full-title]
European urology
[ISO-abbreviation]
Eur. Urol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Switzerland
77.
Szabó KG, Szentkereszty Z, Tóth LA, Damjanovich L, Sápy P:
[Distal pancreas resection for metastasis of clear cell renal cancer].
Magy Seb
; 2010 Aug;63(4):161-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Distal pancreas resection for metastasis of clear
cell renal cancer
].
BACKGROUND: Distant spread from
renal cell carcinoma
is commonly found in the liver and lung.
Metastatic involvement of any other gastro-intestinal organ (duodenum, other
kidney
, adrenal gland) is unexpected.
However, clear
cell renal carcinoma
is known to cause pancreatic metastasis.
METHODS: The authors present the case of a successfully operated 82- year-old man, who was operated for a metastatic
tumor
in his pancreas.
8 years prior to his current hospitalization, a left sided nephrectomy was performed for
renal cell carcinoma
.
The CT scan revealed
a tumor
localised in the tail of the pancreas.
Histology revealed clear
cell renal carcinoma
metastasis.
CONCLUSIONS: pancreatic
tumors
are mostly primaries.
Renal cell carcinoma
generally gives hepatic and pulmonary metastases.
However, clear
cell renal carcinoma
is known to give pancreatic metastasis, too.
[MeSH-major]
Carcinoma
,
Renal Cell
/ secondary.
Carcinoma
,
Renal Cell
/ surgery.
Kidney
Neoplasms / pathology. Pancreatectomy / methods. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / surgery
Genetic Alliance.
consumer health - Kidney cancer
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20724240.001).
[ISSN]
0025-0295
[Journal-full-title]
Magyar sebészet
[ISO-abbreviation]
Magy Seb
[Language]
hun
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Hungary
78.
Griffiths RW, Gilham DE, Dangoor A, Ramani V, Clarke NW, Stern PL, Hawkins RE:
Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy.
Br J Cancer
; 2005 Sep 19;93(6):670-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of the 5T4 oncofoetal antigen in
renal cell carcinoma
: a potential target for T-
cell
-based immunotherapy.
The 5T4 oncofoetal antigen is a heavily glycosylated
cell
surface protein found on human placental trophoblast and on diverse types of human
cancer
but is not expressed at significant levels on adult human tissues in health.
It therefore satisfies the criteria for
a tumour
-associated antigen and is an ideal target for the immunotherapy of
cancer
.
We report here that 5T4 is strongly expressed on the majority of
renal cell carcinomas
and therefore this population of patients is suitable for trials of 5T4-targeted therapies.
In particular, we have shown that T
cells
from
renal cell carcinoma
patients can be genetically modified to kill 5T4 expressing
renal cancer cell
lines by introduction of a chimeric-signalling protein.
This protein consists of a single chain antibody fragment capable of binding antigen directly at the
cell
surface and then activating the T
cell
by virtue of a CD3zeta-signalling domain.
This is a powerful tool that bypasses a number of mechanisms that allow
tumours
to escape T-
cell
killing and can be readily scaled up for clinical use.
[MeSH-major]
Antigens, Neoplasm / immunology.
Carcinoma
,
Renal Cell
/ metabolism. Immunotherapy.
Kidney
Neoplasms / metabolism. Membrane Glycoproteins / metabolism. T-Lymphocytes / immunology
[MeSH-minor]
Adenocarcinoma
, Clear
Cell
/ metabolism. Adult. Aged. Antibodies, Monoclonal. Apoptosis.
Carcinoma
,
Papillary
/ metabolism. Chromium / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Humans. Interferon-gamma / metabolism. Male. Middle Aged
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CHROMIUM, ELEMENTAL
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Immunother. 2002 Mar-Apr;25(2):139-51
[
12074044.001
]
[Cites]
Blood. 2002 Jun 15;99(12):4336-42
[
12036859.001
]
[Cites]
Science. 2002 Oct 25;298(5594):850-4
[
12242449.001
]
[Cites]
Mol Cancer Ther. 2002 Oct;1(12):1129-37
[
12481437.001
]
[Cites]
Br J Cancer. 2003 Feb 10;88(3):348-53
[
12569375.001
]
[Cites]
Dis Colon Rectum. 2003 Jun;46(6):793-804
[
12794582.001
]
[Cites]
J Immunother. 2003 May-Jun;26(3):187-9
[
12806272.001
]
[Cites]
J Clin Oncol. 2003 Aug 15;21(16):3127-32
[
12915604.001
]
[Cites]
Lancet. 2004 Feb 21;363(9409):594-9
[
14987883.001
]
[Cites]
Br J Cancer. 2004 Mar 8;90(5):985-90
[
14997194.001
]
[Cites]
J Clin Oncol. 2004 Mar 15;22(6):1136-51
[
15020616.001
]
[Cites]
J Immunol. 2004 Apr 1;172(7):3983-8
[
15034008.001
]
[Cites]
J Immunother. 2004 May-Jun;27(3):184-90
[
15076135.001
]
[Cites]
Int J Cancer. 1986 Oct 15;38(4):489-94
[
2428759.001
]
[Cites]
Br J Cancer. 1988 Mar;57(3):239-46
[
3355761.001
]
[Cites]
Br J Cancer. 1990 Jan;61(1):89-95
[
2404511.001
]
[Cites]
Blood. 1994 Jan 1;83(1):43-50
[
8274751.001
]
[Cites]
J Biol Chem. 1994 Mar 25;269(12):9319-24
[
8132670.001
]
[Cites]
Br J Cancer. 1994 May;69(5):899-902
[
8180020.001
]
[Cites]
Clin Pharmacokinet. 1995 Feb;28(2):126-42
[
7736688.001
]
[Cites]
J Clin Oncol. 1995 Aug;13(8):1939-49
[
7636534.001
]
[Cites]
J Cell Sci. 1995 Aug;108 ( Pt 8):2905-16
[
7593330.001
]
[Cites]
Int J Cancer. 1996 Sep 27;68(1):84-92
[
8895545.001
]
[Cites]
Immunol Today. 1997 Feb;18(2):89-95
[
9057360.001
]
[Cites]
Lancet. 1999 Jan 2;353(9146):14-7
[
10023944.001
]
[Cites]
J Clin Oncol. 2004 Dec 1;22(23):4711-6
[
15483015.001
]
[Cites]
Cancer Biother Radiopharm. 2004 Dec;19(6):730-7
[
15665620.001
]
[Cites]
J Immunother. 2005 Mar-Apr;28(2):120-8
[
15725955.001
]
[Cites]
Curr Opin Mol Ther. 2005 Feb;7(1):48-55
[
15732529.001
]
[Cites]
J Immunother. 2005 May-Jun;28(3):203-11
[
15838376.001
]
[Cites]
J Clin Oncol. 1999 Aug;17(8):2521-9
[
10561318.001
]
[Cites]
J Clin Oncol. 1999 Sep;17(9):2639-48
[
10561337.001
]
[Cites]
Clin Cancer Res. 2000 Jan;6(1):260-70
[
10656457.001
]
[Cites]
J Immunol. 2000 Apr 1;164(7):3705-12
[
10725729.001
]
[Cites]
Nat Med. 2000 Apr;6(4):443-6
[
10742152.001
]
[Cites]
Clin Cancer Res. 2001 Mar;7(3 Suppl):759s-760s
[
11300469.001
]
[Cites]
Cancer Res. 2001 Jul 1;61(13):5215-22
[
11431362.001
]
[Cites]
Oncogene. 2001 Aug 30;20(38):5393-400
[
11536052.001
]
[Cites]
Annu Rev Biomed Eng. 1999;1:241-63
[
11701489.001
]
[Cites]
Cancer Gene Ther. 2002 Jul;9(7):613-23
[
12082462.001
]
(PMID = 16222313.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Membrane Glycoproteins; 0 / trophoblastic glycoprotein 5T4, human; 0R0008Q3JB / Chromium; 82115-62-6 / Interferon-gamma
[Other-IDs]
NLM/ PMC2361613
79.
Dall'Oglio MF, Antunes AA, Sarkis AS, Crippa A, Leite KR, Lucon AM, Srougi M:
Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor.
BJU Int
; 2007 Sep;100(3):552-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Microvascular
tumour
invasion in
renal cell carcinoma
: the most important prognostic factor.
OBJECTIVE: To evaluate the role of microvascular invasion (MVI) in the primary lesion for predicting
tumour
behaviour in patients with
renal cell carcinoma
(
RCC
), as reliable clinical prognostic factors would be very valuable.
PATIENTS AND METHODS: MVI was assessed in 230 patients with clinically localized
RCC
(stages T1-4NxM0) who had a radical nephrectomy and/or nephron-sparing surgery.
The impact of MVI on
disease
progression and its correlation with clinical and histopathological factors was analysed, including whether patients were symptomatic or not at presentation, Fuhrman nuclear grade,
tumour
size, pathological
stage
and lymph node metastasis.
Regression analyses and survival curves were used to determine if MVI was associated with the prognosis of
RCC
.
RESULTS: There was MVI in 59 patients (26%); of these, 46% developed
disease
recurrence.
Among the 171 patients with no MVI, only 11 (6%) had
tumour
recurrence.
MVI was associated with
tumour
diameter, nuclear grade, pathological
stage
, lymph node metastasis and the presence of sarcomatous elements in the
tumour
.
Multivariate analysis showed that MVI was an independent predictor of
disease
recurrence and the most important factor related to death.
CONCLUSION: MVI is an independent predictor of prognosis in patients with
RCC
.
[MeSH-major]
Carcinoma
,
Renal Cell
/ pathology.
Kidney
Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Vascular Neoplasms / pathology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Child.
Disease
Progression. Female. Humans. Male. Microcirculation / pathology. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Nephrectomy / methods. Prognosis. Retrospective Studies
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17555475.001).
[ISSN]
1464-4096
[Journal-full-title]
BJU international
[ISO-abbreviation]
BJU Int.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
80.
Dal Maso L, Zucchetto A, Tavani A, Montella M, Ramazzotti V, Talamini R, Canzonieri V, Garbeglio A, Negri E, Tonini A, La Vecchia C, Franceschi S:
Renal cell cancer and body size at different ages: an Italian multicenter case-control study.
Am J Epidemiol
; 2007 Sep 1;166(5):582-91
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Renal cell cancer
and body size at different ages: an Italian multicenter case-
control
study.
An increased risk of
renal cell cancer
(
RCC
) has been reported in overweight persons.
The authors aimed to clarify which anthropometric measures are associated with risk of
RCC
and whether risk may vary according to selected variables.
Between 1992 and 2004, they carried out an Italian multicenter case-
control
study including 767 (494 men, 273 women) incident cases of
RCC
and 1,534 hospital controls, frequency-matched to cases.
To estimate odds ratios and 95% confidence intervals, they used conditional logistic regression matched on study
center
, sex, and age and adjusted for period of interview, years of education, smoking habits, and family history
of kidney
cancer
.
Using body-size measurements taken 1 year prior to
diagnosis
/interview, the authors found an odds ratio of 1.3 (95% confidence interval (CI): 1.0, 1.7) among obese persons (body mass index (BMI; weight (kg)/height (m)(2)) > or =30) versus normal-weight persons (BMI <25) and an odds ratio of 1.5 (95% CI: 1.1, 2.0) among persons in the highest tertile of waist-to-hip ratio.
RCC
risks among overweight and obese persons were apparently higher in never smokers, persons with the clear-
cell
histologic type, and persons with a Fuhrman nuclear grade of G3-G4.
[MeSH-major]
Body Size.
Carcinoma
,
Renal Cell
/ epidemiology.
Kidney
Neoplasms / epidemiology
[MeSH-minor]
Adult. Age Factors. Aged. Body Mass Index. Case-
Control
Studies. Female. Humans. Incidence. Italy / epidemiology. Logistic Models. Male. Middle Aged. Risk Factors. Surveys and Questionnaires
Genetic Alliance.
consumer health - Kidney cancer
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17591592.001).
[ISSN]
0002-9262
[Journal-full-title]
American journal of epidemiology
[ISO-abbreviation]
Am. J. Epidemiol.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
81.
Master VA, Gottschalk AR, Kane C, Carroll PR:
Management of isolated renal fossa recurrence following radical nephrectomy.
J Urol
; 2005 Aug;174(2):473-7; discussion 477
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Management of isolated
renal
fossa recurrence following radical nephrectomy.
PURPOSE: Local recurrence of
renal cell carcinoma
in the
renal
fossa without distant metastatic
disease
is an infrequent occurrence.
MATERIALS AND METHODS: The University of California, San Francisco Urologic Oncology database and the University of California, San Francisco Radiation Oncology database were queried for all patients with locally recurrent
renal
fossa recurrence.
Only patients with recurrence of
renal cell carcinoma
in the
renal
fossa were included.
Only 1 patient was symptomatic preoperatively, while in 13
disease
had been detected on routine computerized tomography followup.
Mean size of the recurrent
tumor
was 6.35 cm (range 2 to 17).
9 patients died of progressive, metastatic
disease
after a mean of 17 months (range 1 to 56) and 5 are alive with a mean survival of 66 months (range 14 to 86).
The time to recurrence after nephrectomy approached statistical significance (p =0.06) when comparing the patients who were alive vs those who died of
disease
.
CONCLUSIONS: Selected patients with isolated local recurrence in the
renal
fossa may have favorable and durable outcomes following surgical resection and possibly adjuvant intraoperative radiation therapy for isolated
renal
fossa recurrence following radical nephrectomy.
Development of novel and effective systemic therapy is needed in high risk patients with
renal cancer
.
[MeSH-major]
Carcinoma
,
Renal Cell
/ surgery.
Kidney
Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Nephrectomy
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16006867.001).
[ISSN]
0022-5347
[Journal-full-title]
The Journal of urology
[ISO-abbreviation]
J. Urol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
82.
Weinzierl AO, Lemmel C, Schoor O, Müller M, Krüger T, Wernet D, Hennenlotter J, Stenzl A, Klingel K, Rammensee HG, Stevanovic S:
Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface.
Mol Cell Proteomics
; 2007 Jan;6(1):102-13
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Distorted relation between mRNA copy number and corresponding major histocompatibility
complex
ligand density on the
cell
surface.
The major histocompatibility
complex
(MHC) presents peptides derived from degraded cellular proteins to T-
cells
and is thus crucial for triggering specific immune responses against viral infections or
cancer
.
Up to now, there has been no evidence for a correlation between levels of mRNA (the "transcriptome") and the density of MHC-peptide
complexes
(the "MHC ligandome") on
cells
.
Because such dependences are of intrinsic importance for the detailed understanding of translation efficiency and protein turnover and thus for
systems
biology in general and for
tumor
immunotherapy in practical application, we quantitatively analyzed the levels of mRNA and corresponding MHC ligand densities in samples of
renal cell carcinomas
and their autologous normal
kidney
tissues.
In comparing more than 270 pairs of gene expression and corresponding peptide presentation ratios, we demonstrate that there is no clear correlation (r = 0.32) between mRNA levels and corresponding MHC peptide levels in
renal cell carcinoma
.
A significant number of peptides presented predominantly on
tumor
or normal tissue showed no or only minor changes in mRNA expression levels.
Thus we conclude that a majority of epitopes from
tumor
-associated antigens will not be found in approaches based mainly on mRNA expression studies as mRNA expression reflects a distorted picture of the situation on the
cell
surface as visible for T-
cells
.
[MeSH-major]
Gene Dosage.
Kidney
/ cytology.
Kidney
/ pathology. Major Histocompatibility
Complex
/ immunology. RNA, Messenger / genetics
COS Scholar Universe.
author profiles
.
Immune Epitope Database and Analysis Resource.
gene/protein/disease-specific - Related Immune Epitope Information
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17074750.001).
[ISSN]
1535-9476
[Journal-full-title]
Molecular & cellular proteomics : MCP
[ISO-abbreviation]
Mol. Cell Proteomics
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / HLA Antigens; 0 / Ligands; 0 / Peptides; 0 / RNA, Messenger
83.
Irvine J, Aho T, Davidson P, Searle M:
Rhabdomyolysis following laparoscopic radical nephrectomy: a case to heighten awareness.
Nephrology (Carlton)
; 2006 Aug;11(4):282-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Rhabdomyolysis, myoglobinuria and acute
renal
failure are rare complication of surgery.
The authors describe the case of a 70-year-old man with
renal cell carcinoma
who underwent a laparoscopic
right
radical nephrectomy in the lateral decubitus position.
His postoperative course was complicated by acute
renal
failure due to rhabdomyolysis.
Heightened awareness, early recognition and treatment of this condition are important, particularly as laparoscopic nephrectomy is becoming
a common
procedure for living donor transplantation.
[MeSH-minor]
Aged.
Carcinoma
,
Renal Cell
/ surgery. Humans.
Kidney
Neoplasms / surgery. Male
Genetic Alliance.
consumer health - Rhabdomyolysis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16889565.001).
[ISSN]
1320-5358
[Journal-full-title]
Nephrology (Carlton, Vic.)
[ISO-abbreviation]
Nephrology (Carlton)
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Australia
84.
Machens A, Dralle H:
Outcome after thyroid surgery for metastasis from renal cell cancer.
Surgery
; 2010 Jan;147(1):65-71
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Outcome after thyroid surgery for metastasis from
renal cell cancer
.
BACKGROUND: Owing to their rarity, the prognostic ramifications of thyroid metastases from
renal cell cancer
are unclear.
METHODS: This retrospective analysis comprised 17 patients who underwent thyroid surgery (15 total thyroidectomies, 2 lobectomies) for
renal cell cancer
metastases.
Powerful effects on cause-specific mortality after thyroid operation for
renal cell cancer
metastases were seen for extrathyroidal growth (means of 15 vs 69 months; P=.004) and recurrent laryngeal nerve invasion (means of 10 vs 56 months; P=.002).
CONCLUSION: Extrathyroidal metastatic growth reflects an aggressive
tumor
biology, which may extend to other
renal cell cancer
metastases outside the neck.
[MeSH-major]
Carcinoma
,
Renal Cell
/ pathology.
Kidney
Neoplasms / pathology. Thyroid Neoplasms / secondary. Thyroid Neoplasms / surgery
Genetic Alliance.
consumer health - Kidney cancer
.
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2010 Mosby, Inc. All rights reserved.
(PMID = 19878964.001).
[ISSN]
1532-7361
[Journal-full-title]
Surgery
[ISO-abbreviation]
Surgery
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
85.
Gong Y, Du C, Josephson DY, Wilson TG, Nelson R:
Four-arm robotic partial nephrectomy for complex renal cell carcinoma.
World J Urol
; 2010 Feb;28(1):111-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Four-arm robotic partial nephrectomy for
complex renal cell carcinoma
.
Complex renal tumors
add an additional challenge to a minimally invasive approach to nephron-sparing surgery (NSS).
We represented our technique and results of robotic partial nephrectomy (RPN) for hilar, endophytic, and multiple
renal tumors
.
MATERIALS AND METHODS: Between May 2006 and March 2008, 29 patients with
complex renal tumors
underwent RPN, including hilar (n = 14), endophytic (n = 12) and multiple
tumors
(n = 3).The hilar vessels were clamped with laparoscopic bulldog with warm ischemia.
The mean diameter of
tumors
was 3.0 cm (range 2.0-4.0).
Histopathology confirmed clear-
cell carcinoma
(n = 21), chromophobe
cell carcinoma
(n = 4), hybrid oncocytic
tumor
(n = 2), oncocytoma (n = 1), and cystic
renal cell carcinoma
(n = 1).
At the 3-23 months (mean of 15 mo) follow-up, no patients experienced a significant change of glomerular filtration rate compared to preoperative levels and there was no evidence of
tumor
recurrence.
RPN is a preferred approach for
complex renal tumors
when NSS is indicated.
For
complex
and technical challenging
renal tumors
, robotic assistance may provide patients the benefit of minimally invasive surgery.
[MeSH-major]
Carcinoma
,
Renal Cell
/ surgery.
Kidney
Neoplasms / surgery. Nephrectomy / instrumentation. Nephrectomy / methods. Robotics / instrumentation
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Urology. 2004 Nov;64(5):914-8
[
15533477.001
]
[Cites]
J Urol. 2006 Feb;175(2):541-6; discussion 546
[
16406991.001
]
[Cites]
Eur Urol. 2008 Jan;53(1):134-45
[
17597288.001
]
[Cites]
J Endourol. 2005 May;19(4):441-5; discussion 445
[
15910252.001
]
[Cites]
J Urol. 2006 Jul;176(1):36-9
[
16753361.001
]
[Cites]
J Robot Surg. 2008;1(4):297-302
[
25484981.001
]
[Cites]
J Urol. 2007 Jul;178(1):41-6
[
17574056.001
]
[Cites]
J Endourol. 2005 Jul-Aug;19(6):634-42
[
16053351.001
]
[Cites]
Eur Urol. 2007 Jan;51(1):186-91; discussion 191-2
[
16822607.001
]
[Cites]
Eur Urol. 2008 Mar;53(3):514-21
[
17961910.001
]
[Cites]
J Endourol. 2008 May;22(5):947-52
[
18397157.001
]
[Cites]
Curr Opin Urol. 2003 May;13(3):209-14
[
12692443.001
]
(PMID = 19499225.001).
[ISSN]
1433-8726
[Journal-full-title]
World journal of urology
[ISO-abbreviation]
World J Urol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
86.
Choi JY, Kim BS, Kim TH, Yoo ES, Kwon TG:
Correlation between Radiologic and Pathologic Tumor Size in Localized Renal Cell Carcinoma.
Korean J Urol
; 2010 Mar;51(3):161-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Correlation between Radiologic and Pathologic
Tumor
Size in Localized
Renal Cell Carcinoma
.
PURPOSE: To evaluate the accuracy of radiologic
tumor
size for making decisions regarding nephron-sparing surgery of localized
renal cell carcinomas
(
RCCs
), we compared
tumor
size measured by a preoperative radiologic modality with that measured in the pathologic specimen.
MATERIALS AND METHODS: Between January 2003 and December 2007, a total of 186 patients with pT1 or pT2
RCC
underwent radical or partial nephrectomy at our institute.
Radiologic size was defined as the largest diameter on computed tomography (CT), and pathologic size was defined as the largest diameter of the surgical specimen of the
tumor
.
We retrospectively analyzed the difference between radiologic and pathologic
tumor
size.
RESULTS: The radiologic and pathologic
tumor
sizes did not significantly differ (4.98+/-2.82 cm vs. 4.55+/-2.70 cm, respectively, p=0.152).
In the subgroup analysis, the size difference was statistically significant only for
tumor
sizes of less than 6 cm.
The size difference was largest in
tumors
of 3 to 4 cm, for which mean the radiologic size was 0.63+/-1.19 cm larger than the mean pathologic size (p=0.002).
CONCLUSIONS: The
tumor
size of
RCCs
in preoperative CT seems to correlate well with pathologic
tumor
size.
However, CT imaging may overestimate the size of
a tumor
in the small mass group (less than 6 cm).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Urol. 1979 May;121(5):581-6
[
374754.001
]
[Cites]
Urology. 2006 Oct;68(4):728-31
[
17070342.001
]
[Cites]
J Urol. 1984 Sep;132(3):450-4
[
6471175.001
]
[Cites]
Cancer. 1997 Sep 1;80(5):992-3
[
9307205.001
]
[Cites]
Urology. 1998 Feb;51(2):203-5
[
9495698.001
]
[Cites]
J Clin Oncol. 1999 Sep;17(9):2868-75
[
10561364.001
]
[Cites]
J Urol. 1999 Dec;162(6):1930-3
[
10569540.001
]
[Cites]
BJU Int. 2000 Jan;85(1):19-21
[
10619938.001
]
[Cites]
J Urol. 2000 Feb;163(2):442-5
[
10647650.001
]
[Cites]
Eur Urol. 2000 May;37(5):521-7
[
10765089.001
]
[Cites]
Urology. 2002 Jul;60(1):33-8
[
12100917.001
]
[Cites]
J Urol. 2004 Mar;171(3):1066-70
[
14767272.001
]
[Cites]
J Endourol. 2004 Feb;18(1):39-44
[
15006052.001
]
[Cites]
Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6322S-7S
[
15448025.001
]
[Cites]
Urology. 2006 Aug;68(2):292-5
[
16904439.001
]
[Cites]
Radiology. 1989 Mar;170(3 Pt 1):699-703
[
2644658.001
]
(PMID = 20414390.001).
[ISSN]
2005-6745
[Journal-full-title]
Korean journal of urology
[ISO-abbreviation]
Korean J Urol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Korea (South)
[Other-IDs]
NLM/ PMC2855455
[Keywords]
NOTNLM ; Nephrectomy / Radiology / Renal cell carcinoma
87.
Dancey J:
mTOR signaling and drug development in cancer.
Nat Rev Clin Oncol
; 2010 Apr;7(4):209-19
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
mTOR signaling and drug development in
cancer
.
Activation of mTOR in response to growth, nutrient and energy signals leads to an increase in protein synthesis, which is required for
tumor
development.
This feature makes mTOR an attractive target for
cancer
therapy.
First-generation mTOR inhibitors are sirolimus derivatives (rapalogs), which have been evaluated extensively in
cancer
patients.
Everolimus and temsirolimus are already approved for the treatment of
renal
-
cell carcinoma
.
Temsirolimus is also approved for the treatment of mantle-
cell
lymphoma.
These drugs, in addition to ridaforolimus (formerly deforolimus) and sirolimus, are currently being evaluated in clinical trials of various
cancers
.
[MeSH-minor]
Biomarkers,
Tumor
. Drug Design. Humans. Phosphorylation. Sirolimus / analogs & derivatives. Sirolimus / pharmacology. Sirolimus / therapeutic use
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
Hazardous Substances Data Bank.
SIROLIMUS
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20234352.001).
[ISSN]
1759-4782
[Journal-full-title]
Nature reviews. Clinical oncology
[ISO-abbreviation]
Nat Rev Clin Oncol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
[Number-of-references]
110
88.
Decastro GJ, McKiernan JM:
Epidemiology, clinical staging, and presentation of renal cell carcinoma.
Urol Clin North Am
; 2008 Nov;35(4):581-92; vi
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epidemiology, clinical staging, and presentation of
renal cell carcinoma
.
The increasing incidence of
renal cell carcinoma
over the past 2 decades can be partly explained by the expanding use of abdominal imaging.
As a result, the most incident
renal cancers
today are small, localized, and asymptomatic.
However, the well-documented rise in all stages of
RCC
calls into question the nature of these asymptomatic lesions.
The expected "screening effect" of detecting
RCC
when it is small and localized, with subsequent decreases in
disease
-specific mortality, has not been observed.
Disease
-specific mortality is actually rising, especially in African American patients.
Effective interventions aimed at reducing obesity, hypertension, and smoking may help in reducing the incidence of
RCC
in the future.
[MeSH-major]
Carcinoma
,
Renal Cell
/ epidemiology.
Carcinoma
,
Renal Cell
/ pathology.
Kidney
Neoplasms / epidemiology.
Kidney
Neoplasms / pathology
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18992612.001).
[ISSN]
0094-0143
[Journal-full-title]
The Urologic clinics of North America
[ISO-abbreviation]
Urol. Clin. North Am.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
77
89.
Adamo R, Greaney PJ Jr, Witkiewicz A, Kennedy EP, Yeo CJ:
Renal cell carcinoma metastatic to the duodenum: treatment by classic pancreaticoduodenectomy and review of the literature.
J Gastrointest Surg
; 2008 Aug;12(8):1465-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Renal cell carcinoma
metastatic to the duodenum: treatment by classic pancreaticoduodenectomy and review of the literature.
Renal cell cancer
(
RCC
) most commonly metastasizes to the lungs, bones, liver,
renal
fossa, and brain, although metastases can occur elsewhere.
RCC
metastatic to the duodenum is especially rare, with only a small number of cases reported in the literature.
Herein, we describe a case of an 86-year-old woman with a history of
RCC
treated by radical nephrectomy 13 years previously.
Preoperative imaging and intra-operative assessment showed no evidence of other
disease
.
Pathology confirmed metastatic
RCC
without lymph node involvement.
[MeSH-major]
Carcinoma
,
Renal Cell
/ surgery. Duodenal Neoplasms / surgery.
Kidney
Neoplasms / pathology. Pancreaticoduodenectomy / methods
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Intestinal Cancer
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Trop Gastroenterol. 2001 Jan-Mar;22(1):47-9
[
11398249.001
]
[Cites]
J Gastrointest Surg. 2001 Jul-Aug;5(4):346-51
[
11985973.001
]
[Cites]
Hepatogastroenterology. 2000 Mar-Apr;47(32):540-4
[
10791233.001
]
[Cites]
Br J Urol. 1966 Apr;38(2):133-7
[
5295908.001
]
[Cites]
Dig Dis Sci. 1991 Mar;36(3):376-8
[
1995276.001
]
[Cites]
Neth J Med. 2004 Jun;62(6):201-5
[
15460501.001
]
[Cites]
J Urol. 1987 Sep;138(3):611-3
[
3498049.001
]
[Cites]
Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60
[
9339931.001
]
[Cites]
Urology. 1992 May;39(5):461-3
[
1580040.001
]
[Cites]
Semin Oncol. 1983 Dec;10 (4):390-400
[
6665566.001
]
[Cites]
Can J Gastroenterol. 1998 Jan-Feb;12(1):75-8
[
9544417.001
]
[Cites]
Postgrad Med J. 1996 Mar;72(845):178-9
[
8731713.001
]
[Cites]
Kaohsiung J Med Sci. 2004 Mar;20(3):137-41
[
15124899.001
]
[Cites]
Surgery. 1996 Mar;119(3):349-51
[
8619191.001
]
(PMID = 18066632.001).
[ISSN]
1873-4626
[Journal-full-title]
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
[ISO-abbreviation]
J. Gastrointest. Surg.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
90.
Kim KY, Lee JW, Park MS, Jung MH, Jeon GA, Nam MJ:
Expression of a thioredoxin-related protein-1 is induced by prostaglandin E(2).
Int J Cancer
; 2006 Apr 1;118(7):1670-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Prostaglandin E(2) (PGE(2)) plays an important role in protection of the gastric mucosa against various damaging agents and growth-inhibitory activity on
tumor cells
.
However, the precise regulation mechanism of PGE(2) in gastric
cancer cells
is still unclear.
In this study, we isolated a gene, which is regulated by PGE(2) in SNU-1, human gastric
adenocarcinoma
cells
, using differential display RT-PCR (DD RT-PCR) and characterized the function of the gene induced by PGE(2).
The full-length cDNA of the gene was cloned by the
rapid
amplification of cDNA ends method.
TRP-1 was expressed in a lower extent in
renal
, gastric and colon
cancer
tissues and is translated into 33 kDa protein in nuclear and cytoplasmic fractions.
Finally, TRP-1 overexpression inhibits mammalian
cell
proliferation and specifically predispose to G0/G1 phase arrest.
[MeSH-major]
Adenocarcinoma
/ genetics.
Cell
Cycle / physiology. Stomach Neoplasms / genetics. Thioredoxins / biosynthesis
[MeSH-minor]
Amino Acid Sequence.
Cell
Cycle Proteins / metabolism.
Cell
Proliferation. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA, Complementary / analysis. DNA-Binding Proteins / metabolism. Dinoprostone / physiology. Gene Expression Profiling. Humans.
Kidney
Neoplasms / genetics.
Kidney
Neoplasms / pathology. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction. Tissue Distribution. Trans-Activators / metabolism
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Int J Cancer. 2006 Nov 15;119(10):2499-501; author reply 2498
[
16929493.001
]
(PMID = 16231315.001).
[ISSN]
0020-7136
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Cell Cycle Proteins; 0 / DNA, Complementary; 0 / DNA-Binding Proteins; 0 / MYBL2 protein, human; 0 / TXNL1 protein, human; 0 / Trans-Activators; 52500-60-4 / Thioredoxins; K7Q1JQR04M / Dinoprostone
91.
Taguchi E, Nishigami K, Kamio T, Honda T, Nakao K:
Free-floating thrombus in the right common carotid artery.
J Cardiol
; 2009 Oct;54(2):304-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Free-floating thrombus in the
right common carotid
artery.
We report the case with type A acute aortic dissection that vascular echo disclosed a free-floating thrombus in the
right common carotid
artery.
[MeSH-major]
Carotid
Artery Thrombosis /
diagnosis
.
Carotid
Artery,
Common
[MeSH-minor]
Acute
Disease
. Aged. Aneurysm, Dissecting / complications. Aneurysm, Dissecting /
diagnosis
. Aorta. Aortic Aneurysm / complications. Aortic Aneurysm /
diagnosis
. Autopsy. Cerebral Infarction /
diagnosis
. Cerebral Infarction / etiology. Diagnostic Imaging. Fatal Outcome. Female. Humans
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19782270.001).
[ISSN]
1876-4738
[Journal-full-title]
Journal of cardiology
[ISO-abbreviation]
J Cardiol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
92.
Altinoz MA, Santaguida C, Guiot MC, Del Maestro RF:
Spinal hemangioblastoma containing metastatic renal cell carcinoma in von Hippel-Lindau disease. Case report and review of the literature.
J Neurosurg Spine
; 2005 Dec;3(6):495-500
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Spinal hemangioblastoma containing metastatic
renal cell carcinoma
in von Hippel-Lindau
disease
. Case report and review of the literature.
The authors describe the case of a patient with von Hippel-Lindau (VHL)
disease
in which a spinal hemangioblastoma contained metastatic
renal cell carcinoma
(
RCC
).
The literature on
tumor
-to-
tumor
metastasis associated with VHL
disease
of the central nervous
system
(CNS) is reviewed.
Midthoracic back pain developed in this 43-year-old man with a left-sided radicular component 2 years after he underwent resection of a left
RCC
.
Radiological
findings demonstrated a T6-7 intradural intramedullary lesion.
Light and electron microscopic examination showed features of hemangioblastoma, which contained metastatic foci of
RCC
.
A review of the literature revealed that
RCC
-to-CNS hemangioblastoma is the second most
common
donor-recipient
tumor
association among the
tumor
-to-
tumor
metastases.
[MeSH-major]
Carcinoma
,
Renal Cell
/ secondary. Hemangioblastoma / pathology. Hemangioblastoma / secondary.
Kidney
Neoplasms / pathology. Spinal Cord Neoplasms / secondary
[MeSH-minor]
Adult. Back Pain / etiology. Humans. Laminectomy. Male. Thoracic Vertebrae. Von Hippel-Lindau
Tumor
Suppressor Protein / genetics. von Hippel-Lindau
Disease
Genetic Alliance.
consumer health - Hemangioblastoma
.
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16381215.001).
[ISSN]
1547-5654
[Journal-full-title]
Journal of neurosurgery. Spine
[ISO-abbreviation]
J Neurosurg Spine
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
93.
Meyners T, Heisterkamp C, Kueter JD, Veninga T, Stalpers LJ, Schild SE, Rades D:
Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis.
BMC Cancer
; 2010;10:582
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant
tumors
: a retrospective analysis.
BACKGROUND: This study investigated potential prognostic factors in patients treated with whole-brain irradiation (WBI) alone for brain metastases from relatively radioresistant
tumors
such as
malignant
melanoma,
renal cell carcinoma
, and colorectal
cancer
.
METHODS: Data from 220 patients were retrospectively analyzed for overall survival and local
control
.
Nine potential prognostic factors were evaluated:
tumor
type, WBI schedule, age, gender, Karnofsky performance score, number of brain metastases, extracerebral metastases, interval from
diagnosis
of
cancer
to WBI, and recursive partitioning analysis (RPA) class.
Local
control
rates at 6 and 12 months were 37% and 15%, respectively.
In the multivariate analyses, KPS ≥70 (p < 0.001), only 1-3 brain metastases (p < 0.001), and RPA class 1 (p < 0.001) were associated with improved local
control
.
[MeSH-minor]
Aged.
Carcinoma
,
Renal Cell
/ radiotherapy. Colorectal Neoplasms / radiotherapy. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Metastasis. Radiotherapy / methods. Retrospective Studies. Treatment Outcome
MedlinePlus Health Information.
consumer health - Brain Tumors
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47
[
10758303.001
]
[Cites]
J Neurooncol. 2010 Jan;96(1):17-32
[
19960231.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):253-8
[
14697446.001
]
[Cites]
Br J Cancer. 2004 Aug 31;91(5):829-33
[
15305201.001
]
[Cites]
Cancer. 1988 Nov 1;62(9):1912-7
[
2458823.001
]
[Cites]
Radiother Oncol. 1996 Feb;38(2):139-44
[
8966226.001
]
[Cites]
Cancer. 1996 Aug 15;78(4):711-6
[
8756361.001
]
[Cites]
Ann Surg Oncol. 1996 Sep;3(5):453-63
[
8876887.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
[
9128946.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):753-9
[
9128947.001
]
[Cites]
J Neurosurg. 1998 Jan;88(1):11-20
[
9420067.001
]
[Cites]
Cancer. 1998 Dec 15;83(12):2548-53
[
9874462.001
]
[Cites]
Clin Colorectal Cancer. 2005 Jul;5(2):108-13
[
16098251.001
]
[Cites]
Cancer. 2008 Jul 1;113(1):158-65
[
18459179.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1389-93
[
11121638.001
]
(PMID = 20977700.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2988027
94.